EP1432420A2 - Benzimidazolidinone derivatives as muscarinic agents - Google Patents

Benzimidazolidinone derivatives as muscarinic agents

Info

Publication number
EP1432420A2
EP1432420A2 EP02763824A EP02763824A EP1432420A2 EP 1432420 A2 EP1432420 A2 EP 1432420A2 EP 02763824 A EP02763824 A EP 02763824A EP 02763824 A EP02763824 A EP 02763824A EP 1432420 A2 EP1432420 A2 EP 1432420A2
Authority
EP
European Patent Office
Prior art keywords
optionally substituted
mmol
group
alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP02763824A
Other languages
German (de)
French (fr)
Other versions
EP1432420B1 (en
EP1432420A4 (en
Inventor
Nicholas Michael Kelly
Kristian Norup Koch
Bo-Ragnar Tolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acadia Pharmaceuticals Inc
Original Assignee
Acadia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharmaceuticals Inc filed Critical Acadia Pharmaceuticals Inc
Publication of EP1432420A2 publication Critical patent/EP1432420A2/en
Publication of EP1432420A4 publication Critical patent/EP1432420A4/en
Application granted granted Critical
Publication of EP1432420B1 publication Critical patent/EP1432420B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • Novel benzimidazolidinone derivatives have been prepared and identified as having high affinity for muscarinic Mi and M receptors. The treatment of mental disorders associated with increasing the activity of a cholinergic receptor using these novel compounds is anticipated. Moreover, these compounds also have dopamine D 2 antagonist activity, rendering them particularly interesting as anti-psychotic agents.
  • Muscarinic cholinergic receptors mediate the actions of the neurotransmitter acetylcholine in the central and peripheral nervous systems. Muscarinic receptors play a critical role in the central nervous system mediating higher cognitive functions, as well as in the peripheral parasympathetic nervous system where they mediate cardiac, respiratory, digestive, and endocrine and exocrine responses. Five distinct muscarinic receptor subtypes have been identified, M ⁇ -M 5 .
  • the muscarinic Mi receptor subtype is predominantly expressed in the cerebral cortex and is believed to be involved in the control of higher cognitive functions; the M 2 receptor is the predominant subtype found in heart and is involved in the control of heart rate; the M 3 receptor is widely expressed in many peripheral tissues and is believed to be involved in gastrointestinal and urinary tract stimulation as well as sweating and salivation; the ML* receptor is present in brain and may be involved in locomotion; the M 5 , receptor is present in the brain where its role is at present poorly defined. Mi and M have been particularly associated with the dopaminergic system.
  • Conditions associated with cognitive impairment are accompanied by a reduction of acetylcholine content in the brain. This is believed to be the result of degeneration of cholinergic neurons of the basal forebrain, which widely innervate multiple areas of the brain, including the association cortices and hippocampus, that are critically involved in higher processes.
  • acetylcholine levels have focused on increasing levels of choline, the precursor for acetylcholine synthesis, and on blocking acetylcholineesterase (AChE), the enzyme that metabolizes acetylcholine. Attempts to augment central cholinergic function through the administration of choline or phosphatidylcholine have not been successful.
  • AChE inhibitors have shown therapeutic efficacy, but have been found to have frequent cholinergic side effects due to peripheral acetylcholine stimulation, including abdominal cramps, nausea, vomiting, and diarrhoea. These gastrointestinal side effects have been observed in about a third of the patients treated.
  • AChE inhibitors such as tacrine
  • tacrine have also been found to cause significant hepatotoxicity with elevated liver transa ⁇ iinases observed in about 30% of patients.
  • the adverse effects of AChE inhibitors have severely limited their clinical utility.
  • the dopamine hypothesis of schizophrenia suggests that increased dopamine neurotransmission underlies the positive symptoms of the disease and is supported by the evidence that dopamine receptor blockade is effective in ameliorating such psychotic symptoms.
  • drugs that enhance dopamine neurotransmission in the brain cause psychotic-like episodes in man and exacerbate psychotic symptoms in schizophrenic patients.
  • drugs that increase dopamine neurotransmission cause behavioural effects such as increased locomotion, climbing and deficits in prepulse inhibition.
  • dopamine receptor antagonists can block these behavioural effects.
  • dopamine receptor antagonists also cause severe extrapyramidal side effects in patients as predicted by induction of catalepsy in animal models. These extrapyramidal side effects include tremor, bradykinesia, akithesias, and tardive dyskinesias.
  • Mi receptor agonist activity Due in part to these observations, the discovery of agents with Mi receptor agonist activity has been sought after for the treatment of dementia. However, existing agents lack specificity in their actions at the various muscarinic receptor subtypes. Known Mi muscarinic agonists such as arecoline have also been found to be weak agonists of M 2 as well as M 3 receptor subtypes and are ineffective in the treatment of cognitive impairment, due in large part to their dose-limiting M 2 and M 3 receptor mediated side effects.
  • Xanomeline (Shannon et al., J. Pharmacol. Exp. Ther. 1994, 269, 271; Shannon et al., Schizophrenia Res. 2000, 42, 249) is an M 1 /M 4 preferring muscarinic receptor agonist with little or no affinity for dopamine receptors despite inhibiting A10 but not A9 dopamine cells.
  • the thiadiazole derivative PTAC has been reported (Shannon et al., European Journal of Pharmacology , 1998, 356, 109) to have partial agonist effect at muscarinic M 2 and M 4 receptors and antagonist effect at muscarinic Mi, M 3 , and M 5 receptors as well as exhibiting functional dopamine antagonism.
  • muscarinic agonists including xanomeline have been shown to be active in animal models with similar profiles to known antipsychotic drugs, but without causing catalepsy (Bymaster et al., Eur. J. Pharmacol. 1998, 356, 109, Bymaster et al., Life Sci. 1999, 64, 527, Shannon et al., J. Pharmacol. Exp. Ther. 1999, 290, 901, Shannon et al., Schizophrenia Res. 2000, 42, 249). Further, xanomeline was shown to reduce psychotic behavioural symptoms such as delusions, suspiciousness, vocal outbursts, and hallucinations in Alzheimer's disease patients (Bodick et al., Arch. Neurol. 1997, 54, 465), however treatment induced side effects that severely limit the clinical utility of this compound.
  • the present investigators have focussed their efforts on the development of a molecule that simultaneously reduced the positive symptoms and improved the negative symptoms and the cognitive impairments associated with schizophrenia as a novel treatment of mental disorders. It is the intent of the present investigators to demonstrate that muscarinic Mi and/or M 4 agonists with combined D 2 antagonist activity may possess superior antipsychotic efficacy without the side effects associated with high dose D 2 antagonism alone. The D 2 antagonist properties of these molecules may contribute to a reduction in the positive symptoms of this disease.
  • the Mi and/or M 4 agonist properties of these compounds may reduce the cognitive dulling and perhaps ameliorate other negative symptoms associated with schizophrenia.
  • This unique combination of central nervous system activities in one molecule is unprecedented and may lead to the development of an entirely new class of antipsychotic drugs, ones with the superior clinical properties without the limiting side-effect profile.
  • WO 99/32481 discloses derivatives including 1-substituted benzimidazolones and derivatives thereof.
  • the compounds according to WO 99/32481 are intended for treatment of glaucoma, myopia, psychosis and various other conditions involving muscarinic receptors.
  • US 4,254,127 discloses l-(l-piperidinyl)alkyl-benzimidazolone derivatives wherein the piperidine is 4-substituted with aryl-alkyls, aryl-alkylcarbonyls, aryl-alkylcarbonyl derivatives, and aryl-alkoxides.
  • the compounds according to US 4,254,127 are reported to have psychotropic activity acting as serotonin antagonists.
  • US 5,789,425 and US 5,726,188 discloses 1-substituted imidazolidin-2-one derivatives with muscarinic Mi activity. Benzimidazolidinone derivatives are not disclosed therein.
  • WO 96/13262 disclose benzimidazolidin-2-one derivatives 1-subsituted with a
  • WO 97/16192, WO 97/16187 and US5,756,508 disclose novel l,3-dihydro[l- (l-heteroarylpiperidine-4-yl)piperidine-4-yl]-2H-benzimidazolones.
  • the compounds according to WO 97/16192, WO 97/16187 and US5,756,508 are reported to have antimuscarinic activity used for treatment and/or prevention of myopia.
  • WO 97/16186 and US 5,718,912 disclose l-[cycloalkylpiperidin-4-yl]-2H- benzimidazolones as selective muscarinic agonists of the M 2 subtype with low activity at the M 3 subtype, and when utilised for glaucoma therapy have fewer side effects than pilocarpine therapy.
  • Cakir, B et al. describes the synthesis and antinociceptive activity of some 1- (3-piperidinopropyl)benzothiazolone derivatives in Farmaco, 1999, 54, 846.
  • the present invention seeks to provide compounds which increase acetylcholine signalling or effect in the brain, and highly selective muscarinic agonists, particularly for the Mi and/or M 4 receptor subtypes as well as providing compounds aimed at the approach of treating psychosis using compounds which has a combined muscarinic agonist and dopamine antagonist profile.
  • the present invention relates to a compound of Formula I
  • X is selected from the group consisting of C, O, N and S
  • Z is selected from the group consisting of CH and N
  • SPU is a spacer unit providing a distance d between Z and N wherein
  • -SPU- is a biradical selected from the group consisting of -(CR 6 R 7 ) n -A- and -C 3 . 8 - cycloalkyl- wherein n is in the range 1 to 5, such as 1, 2, 3, 4, or 5 and A is absent or an optionally substituted -C 3 .g-cycloalkyl;
  • heterocyclic ring is selected from the group consisting of perhydroazocine, perhydroazepine, piperidine, pyrrolidine, azetidine, aziridine and 8-azabicyclo[3.2.1]octane and wherein the heterocyclic ring is substituted with one or more substituents R 4 selected from the group consisting of hydroxy, halogen, Ci-s-alkyL C 3 .8-cycloalkyl, C ⁇ g-alkoxy, C]_ 8 - alkylcarbonyl, d-s-alkylidene, C 2 . s -alkenyl, C 2 .
  • R 5 is selected from the group consisting of hydrogen, halogen, hydroxy, C ⁇ _g-alkyl- Ci-g- alkoxy, C 3 . 8 -cycloalkyl, C 3 . 8 -heterocyclyl, C ⁇ . 8 -alkylcarbonyl, C].g-alkylidene, C 2 -8-alkenyl and C 2 . 8 - alkynyl;
  • R 3 may be present 0-4 times and selected from the group consisting of halogen, hydroxy, optionally substituted Cj.g-alkyl, Cj-g-alkoxy, optionally substituted C ⁇ . 8 -alkylidene, optionally substituted C 2 - 8 -alkenyl, optionally substituted C 2 - 8 -alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C 3 . 8 -cycloalkyl, optionally substituted C 3 .
  • each R 6 and each R 7 is independently selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted C ⁇ _ 8 -alkyl, C ⁇ . 8 -alkoxy, optionally substituted C ⁇ _ 8 - alkylidene, optionally substituted C 2 . 8 -alkenyI, optionally substituted C 2 . 8 -alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C 3 .g-cycloalkyl, optionally substituted C3. 8 -heterocyclyl, and optionally substituted C ⁇ . s -alkylcarbonyl.
  • a second aspect of the invention relates to a method of increasing an activity of a cholinergic receptor comprising contacting the cholinergic receptor or a system containing the cholinergic receptor with an effective amount of at least one compound of Formula I.
  • an increase in activity of the cholinergic receptor and the cholinergic system is, as discussed supra, associated to the activity of anti-psychotics. Accordingly, further aspects of the present invention relate to a method of treating or preventing a mental disorder in a mammal, such as a human, comprising the administration of an effective amount of a compound of Formula I and to the use of a compound of Formula I, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the preparation of a medicament for the prophylactic or curative treatment of psychosis or alleviation of symptoms of psychosis.
  • a mammal may be selected from the group consisting of mice, rats, rabbits, guinea pigs, dogs, cats, sheep, goats, cows, primates, such as monkeys, chimpanzees, and apes, and humans. Most preferably, the mammal is a human.
  • aspects of the invention relate to compounds of Formula I for use as selective modulators of Mi and/or 4 muscarinic receptors for the treatment of disorders associated with muscarinic receptors and especially with said receptor subtypes.
  • compounds of Formula I have surprisingly been found to have selectivity for the Mi and M 4 muscarinic receptor subtypes. Therapeutic advantages may be derived from this selectivity. Further therapeutic advantages may be derived from the concomitant muscarinic Mi and M 4 agonist activity and dopaminergic D 2 antagonist activity.
  • Compounds of Formula I, by the modulation of muscarinic receptors may be implicated in the control of amyloid precursor processing, in particular by the activation of the Mi receptor.
  • a further aspect of the present invention relates to a method of modulating or preventing the progression or formation of amyloid plaques in an individual susceptible to or affected by Alzheimer's Disease by administering an effective amount of a compound of Formula I, said effective amount sufficient to modulate amyloid precursor protein processing.
  • Figure 1 is a graph depicting the reduction of spontaneous locomotor activity in mice with the administration of 10 mg/kg i.p. of 61KS19.
  • Figure 2 is a graph that shows the reduction of amphetamine-induced hyperactivity in mice with the administration of 3 and 10 mg/kg i.p. of 6 IKS 19
  • Figure 3 is a graph that shows the reduction of scopolamine-induced hyperactivity in mice with the administration of 1, 3 and 10 mg/kg i.p. of 6 IKS 19
  • Figure 4 is a graph that shows the reduction of MK-801 -induced hyperactivity in mice with the administration of 10 mg kg i.p. of 61KS19.
  • Figure 5 depicts the result of a comparison between haloperidol and 61KS19, and shows that unlike haloperidol, 61KS19 (10 mg/kg i.p.) failed to induce catalepsy.
  • the present invention relates to a compound of Formula I
  • X is selected from the group consisting of C, O, N and S
  • Z is selected from the group consisting of C and N
  • SPU is a spacer unit providing a distance d between Z and N wherein -SPU- is a biradical selected from the group consisting of -(CR 6 R 7 ) n -A- and -C 3 . 8 - cycloalkyl- wherein n is in the range 1 to 5, such as 1, 2, 3, 4, or 5 and A is absent or an optionally substituted -C 3 . 8 -cycloalkyl;
  • heterocyclic ring is selected from the group consisting of perhydroazocine, perhydroazepine, piperidine, pyrrolidine, azetidine, aziridine and 8-azabicyclo[3.2.1]octane and wherein the heterocyclic ring is substituted with one or more substituents R 4 selected from the group consisting of hydroxy, halogen, C ⁇ _ 8 -alkyl, C 3 . 8 -cycloalkyl, C ⁇ . 8 -alkoxy, C ⁇ . 8 - alkylcarbonyl, C ⁇ .g-alkylidene, C 2 .g-alkenyl, C 2 .
  • R 4 selected from the group consisting of C ⁇ .g-alkyl, C 3 .g-cycloalkyl, C ⁇ .g-alkoxy, C ⁇ _ 8 -alkylcarbonyl, C ⁇ . 8 -alkylidenec C ⁇ . 8 -alkyloxyimino, and C ⁇ _ 8 -alkyloxyamino each of which may be optionally substituted with a substituent R 5 ;
  • R 5 is selected from the group consisting of hydrogen, halogen, hydroxy, C ⁇ _ 8 -alkyl, C 3 . 8 - cycloalkyl, C 3 . 8 -heterocyclyl, C ⁇ _ 8 -alkylcarbonyl, C ⁇ . 8 -alkylidene, C 2 . 8 -alkenyl and C 2 . 8 -alkynyl;
  • R 3 may be present 0-4 times and selected from the group consisting of halogen, hydroxy, optionally substituted C ⁇ . 8 -alkyl, C ⁇ . 8 -alkoxy, optionally substituted C ⁇ . 8 -alkylidene, optionally substituted C 2 . 8 -alkenyl, optionally substituted C 2 . 8 -alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C 3 . 8 -cycloalkyl, optionally substituted C 3 . 8 - heterocyclyl, and optionally substituted C ⁇ .
  • each R 6 and each R 7 is independently selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted C ⁇ _ 8 -alkyl, Ci-g-alkoxy, optionally substituted C ⁇ _ 8 - alkylidene, optionally substituted C 2 . 8 -alkenyl, optionally substituted C 2 - 8 -alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C 3 . 8 -cycloalkyl, optionally substituted C 3 . 8 -heterocyclyl, and optionally substituted C ⁇ .g-alkylcarbonyl.
  • pharmaceutically acceptable salt refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound.
  • Pharmaceutical salts can be obtained by reacting a compound of the invention with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
  • Pharmaceutical salts can also be obtained by reacting a compound of the invention with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N- methyl-D-glucamine, tris(hydroxymethyl)methylamine, and salts with amino acids such as arginine, lysine, and the like.
  • a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N- methyl-D-glucamine, tris(hydroxymethyl)methylamine, and salts with amino acids such as arginine, lysine, and the like.
  • a “prodrug” refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug.
  • An example, without limitation, of a prodrug would be a compound of the present invention which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial.
  • a further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety.
  • the term "selective” or “selectivity” is intended to mean the ability of a compound to generate a desired response from a particular receptor type, subtype, class or subclass while generating less or little response from other receptor types.
  • "Selective” or “selectivity” of an Mi or M 4 muscarinic agonist compound is intended to mean the ability of a compound to increase the activity of the Mi or M , muscarinic receptor, respectively, while causing non-substantial, little or no increase in the activity of other subtypes including M 3 and M 5 subtypes, and preferably the M 2 subtype.
  • Compounds of the presents invention may also show selectivity toward both Mi and M 4 receptors, i.e. increase the activity of both the Mi and M 4 muscarinic receptors, while causing little or no increase in the activity of other subtypes including M 3 and M 5 subtypes, and preferably the M 2 subtype.
  • C ⁇ . 8 -alkyl is intended to mean a linear or branched saturated hydrocarbon chain wherein the longest chains has from one to eight carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl and octyl.
  • a branched hydrocarbon chain is intended to mean a C ⁇ . 8 -alkyl substituted at any carbon with a hydrocarbon chain.
  • C 2 . 8 -alkenyl is intended to mean a linear or branched hydrocarbon group having from two to eight carbon atoms and containing one or more double bonds.
  • Illustrative examples of C 2 - 8 -alkenyl groups include allyl, homo-allyl, vinyl, crotyl, butenyl, pentenyl, hexenyl, heptenyl and octenyl.
  • Illustrative examples of C 2 . ⁇ o-alkenyl groups with more than one double bond include butadienyl, pentadienyl, hexadienyl, heptadienyl, hexatrienyl.
  • C ⁇ . 8 -alkylidene is intended to mean a linear or branched hydrocarbon chain radical wherein the longest chain has from one to eight carbon atoms and an unsaturated bond at the radical position. Bonds further than the radical position may also be unsaturated.
  • C . 8 -alkyny ' is intended to mean linear or branched hydrocarbon groups containing from two to eight carbon atoms and containing one or more triple bonds.
  • Illustrative examples of C 2 . 8 -alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl and octynyl groups as well as branched forms of these.
  • the position of unsaturation (the triple bond) may be at any position along the carbon chain. More than one bond may be unsaturated such that the "C 2 - 8 -alkynyl" is a di-yne or enedi-yne as is known to the person skilled in the art.
  • C 3 . 8 -cycloalkyl is intended to cover three-, four-, five-, six- seven-, and eight-membered rings comprising carbon atoms only whereas the term “heterocyclyl” is intended to mean three-, four-, five-, six- seven-, and eight-membered rings wherein carbon atoms together with from 1 to 3 heteroatoms constitute said ring.
  • the heteroatoms are independently selected from oxygen, sulphur, and nitrogen.
  • C 3 . 8 -cycloalkyl and heterocyclyl rings may optionally contain one or more unsaturated bonds situated in such a way, however, that an aromatic ⁇ -electron system does not arise.
  • Illustrative examples of preferred "C 3 .g-cycloalkyr' are the carbocycles cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclopentadiene, cyclohexane, cyclohexene, 1,3-cyclohexadiene, 1,4-cyclohexadiene, cycloheptane, cycloheptene, 1,2- cycloheptadiene, 1,3-cycloheptadiene, 1,4-cycloheptadiene and 1,3,5 cycloheptatriene.
  • heterocyclyls are the heterocycles 2H-thipyran, 3H- thipyran, 4H-thipyran, tetrahydrothiopyran, 2H-pyran, 4H-pyran, tetrahydropyran, piperidine, 1,2- dithiin, 1,2-dithiane, 1,3-dithiin, 1,3-dithiane, 1,4-dithiin, 1,4-dithiane, 1,2-dioxin, 1,2-dioxane, 1,3- dioxin, 1,3-dioxane, 1,4-dioxin, 1,4-dioxane, piperazine, 1,2-oxathiin, 1,2-oxathiane, 4H-1,3- oxathiin, 1,3-oxathiane, 1,4-oxathiin, 1,4-oxathiane, 2H-l,2-thiazine, tetrahydro
  • aryl is intended to mean a carbocyclic aromatic ring or ring system. Moreover, the term “aryl” includes fused ring systems wherein at least two aryl rings, or at least one aryl and at least one C 3 . 8 -cycloalkyl, or at least one aryl and at least one heterocyclyl, share at least chemical bond.
  • aryl rings include optionally substituted phenyl, naphthalenyl, phenanthrenyl, anthracenyl, acenaphthylenyl, tetralinyl, fluorenyl, indenyl, indolyl, coumaranyl, coumarinyl, chromanyl, isochromanyl, and azulenyl.
  • a preferred aryl group is phenyl.
  • heteroaryl is intended to mean an aryl group where one or more carbon atoms in an aromatic ring have been replaced with one or more heteroatoms selected from the group comprising nitrogen, sulphur, phosphorous and oxygen.
  • heteroaryl comprises fused ring systems wherein at least one aryl ring and at least one heteroaryl ring, at least two heteroaryls, at least one heteroaryl and at least one heterocyclyl, or at least one heteroaryl and at least one C 3 . 8 - cycloalkyl share at least one chemical bond, such as one or two chemical bonds.
  • a heteroaryl may be selected from the group comprising furanyl, thienyl, pyrrolyl, phenoxazonyl, oxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, isoxazolyl, imidazolyl isothiazolyl, oxadiazolyl, furazanyl, triazolyl, thiadiazolyl, piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl and triazinyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, benzopyrazolyLindazolyl, benzimidazolyl, benzthiazolyl, purinyl, quinolizinyl, quinolinyl, isoquinolinyl,
  • C ⁇ . 8 -alkoxy is intended to mean C ⁇ _g-alkyl-oxy such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy. pentoxy, isopentoxy, neopentoxy and hexoxy
  • halogen includes fluorine, chlorine, bromine and iodine.
  • salts is intended to mean pharmaceutically acceptable acid addition salts obtainable by treating the base form of a functional group, such as an amine, with appropriate acids such as inorganic acids, for example hydrohalic acids; typically hydrochloric, hydrobromic, hydrofluoric, or hydroiodic acid; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example acetic, propionic, hydroacetic, 2-hydroxypropanoic acid, 2-oxopropanoic acid, ethandioic, propanedioic, butanedioic, (Z)-2-butenedioic, (E)-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutanedioic, 2-hydroxy-l,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic acid,
  • acids such as inorganic
  • the spacer unit SPU comprises a number of optionally substituted methylene groups CR 6 R 7 . It is understood by the phrase "each R 6 and each R 7 is optionally and independently selected" that not all R 6 groups may be identical and not all R 7 groups may be identical. Thus, each substituted methylene group may have an R 6 and an R 7 that is different than any other R 6 or R 7 substituents on other methylene groups. In some embodiments, some of R 6 or R 7 substituents may be identical in one or more methylene groups.
  • the present invention relates to a compound of Formula I, wherein
  • X is selected from the group consisting of O, N and S;
  • Y O or tautomers thereof
  • SPU is a spacer unit providing a distance d between Z and N wherein -SPU- is -(CR 6 R 7 ) n - A-, n is 3, and A is absent;
  • R 1 and R 2 form a piperidine ring substituted with one or more substituents R 4 selected from the group consisting of hydroxy, halogen, C ⁇ _ 8 -alkyl, C 3 . s -cycloalkyl, C ⁇ .g-alkoxy, C ⁇ .g-alkylcarbonyl, C ⁇ .g-alkylidene, C 2 - 8 -alkenyl, C 2 . 8 -alkynyl, C ⁇ . 6 -alkyloxyimino, and C ⁇ .
  • substituents R 4 selected from the group consisting of hydroxy, halogen, C ⁇ _ 8 -alkyl, C 3 . s -cycloalkyl, C ⁇ .g-alkoxy, C ⁇ .g-alkylcarbonyl, C ⁇ .g-alkylidene, C 2 - 8 -alkenyl, C 2 . 8 -alkynyl, C ⁇ . 6 -alkyloxyimino, and
  • R 4 is R 4 selected from the group consisting of C ⁇ _g-alkyl, C 3 .g-cycloalkyl, -g-alkoxy, Ci-g-alkylidenec, each of which may be optionally substituted with a substituent R 5 ;
  • R 5 is selected from the group consisting of hydrogen, halogen, hydroxy, C ⁇ _ 8 -alkyl, C]. 8 - alkoxy, C 3 . 8 -cycloalkyl, C 3 . 8 -heterocyclyl, C ⁇ . 8 -alkylcarbonyl, -g-alkylidene, C 2 . 8 -alkenyl and C 2 . 8 - alkynyl;
  • R x may be absent or selected from the group consisting of hydrogen, optionally substituted Ci-g-alkyl;
  • R 3 may be present 0-4 times and selected from the group consisting of halogen, hydroxy, optionally substituted C ⁇ . 8 -alkyl, Ci-g-alkoxy, optionally substituted C ⁇ . 8 -alkylidene, optionally substituted C 2 - 8 -alkenyl, optionally substituted C 2 . 8 -alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C 3 .g-cycloalkyl, optionally substituted C 3 .
  • each R 6 and each R 7 is optionally and independently selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted C ⁇ _ 8 -alkyl, C 3 . 8 -cycloalkyl,
  • Z is N (nitrogen).
  • the distance d relates to the distance between the ring nitrogen atom and the nitrogen atom of N(R*)R 2 .
  • X may be selected from the group consisting of N, S, and O, preferably N and O. In a preferred embodiment X and Z are both N.
  • Tautomers of the carbonyl and thiocarbonyl moiety are known to the person skilled in the art and are isomers involving migration of the pi system from the exo-cyclic to the endocyclic position.
  • the enolic or thio-enolic derivative may be O- or S-alkylated in a manner known to the person skilled in the art.
  • -Y O or its tautomer.
  • -Y O.
  • X is N
  • -Y 0
  • Z is N, resulting in a benzimidazolidinone ring system.
  • the moiety Z is substituted with a spacer unit (SPU).
  • SPU provides a distance d between Z and N.
  • the distance d is formed from a short, optionally substituted aliphatic chain, (CR 6 R 7 ) n , wherein n is in the range 1 to 5, such as 1, 2, 3, 4 or 5 or from said chain and a -C 3 . 8 - cycloalkyl- ring.
  • d may be defined in terms of through-bond distances between Z and N of N(R ! )R 2 or a combination of through-bond and through-space distances between Z and N of N(R')R 2 .
  • -SPU- is a biradical selected from the group consisting of -(CR 6 R 7 ) n -A- and -C 3 . 8 - cycloalkyl- wherein n is in the range 1 to 5 and
  • A is absent or an optionally substituted -C 3 . 8 -cycloalkyl.
  • n is in the range 2 to 5, most preferably 2 to 4, such as 2, 3, or 4.
  • the C 3 . 8 -cycloalkyl- ring of -SPU- is an optionally substituted cyclohexylene.
  • -SPU- may be selected from the group consisting of -(CR 4 R 5 ) n -A- and an optionally substituted cyclohexylene wherein n is in the range 1 to 5, preferably 2 to 5 and A is absent or an optionally substituted cyclohexylene.
  • -SPU- is an ethylene, propylene, butylene, or pentylene biradical, preferably ethylene, propylene or butylene, each of which may be optionally substituted.
  • -SPU- is a cylcohexylene biradical.
  • the cyclohexylene of -SPU- may be an optionally substituted 1,3- cyclohexylene or an optionally substituted 1,4-cyclohexylene, preferably an optionally substituted 1,4-cyclohexylene. That is to say that in the embodiment where SPU is or comprises of a cyclohexylene, said cyclohexylene is preferably bond to Z and N at positions 1 and 4 or 1 and 3 of said ring.
  • N together with R 1 and R 2 form a heterocyclic ring wherein said heterocyclic ring is selected from the group consisting of perhydroazocine, perhydroazepine, piperidine, pyrrolidine, azetidine, aziridine and 8-azabicyclo[3.2.1]octane.
  • N(R*)R 2 is selected from the group consisting of a piperidine, pyrrolidine, and azetidine, most preferably piperidine and pyrrolidine, particularly preferably piperidine.
  • the heterocyclic ring formed by N together with R 1 and R 2 is substituted with one or more substituents R 4 selected from the group consisting of hydroxy, halogen, C ⁇ _ 8 -alkyl, C 3 . 8 - cycloalkyl, C ⁇ 8 -alkoxy, C ⁇ _ 8 -alkylcarbonyl, C ⁇ _ 8 -alkylidene, C 2 .g-alkenyl, C 2 .g-alkynyl, C ._- alkyloxyimino, and C ⁇ _g-alkyloxyamino each of which may be optionally substituted with a substituent R 5 and at least one of said substituents R 4 is R 4 selected from the group consisting of C ⁇ _ 8 -alkyl, C 3 .g-cycloalkyl, C ⁇ _ 8 -alkoxy, C ⁇ .g-alkylcarbonyl, C ⁇ _g-alkylidene, C 2 .g-alkenyl
  • heterocyclic ring formed by N together with R 1 and R 2 may be substituted with one or more substituent R 4 wherein at least one R 4 is R 4 .
  • the heterocyclic ring formed by N together with R 1 and R 2 is substituted with one more substituent R 4 .
  • the heterocyclic ring is selected from the group comprising of a piperidine with at least one substituent R 4 in the 2-position, a piperidine with at least one substituent R 4 in the 3 -position, a piperidine with at least one substituent R 4 in the 4-position, a pyrrolidine with at least one substituent R 4 in the 3 -position, an azetidine with at least one substituent R 4 in the 3 -position and an aziridine with at least one substituent R 4' in the 2-position.
  • N(R X )R 2 is selected from the group consisting of a piperidine with at least one substituent R 4 in the 2-position, a piperidine with at least one substituent R 4 in the 3 -position, a piperidine with at least one substituent R 4 in the 4-position, most preferably consisting of a piperidine with at least one substituent R 4 in the 4-position.
  • N(R : )R 2 may be defined as wherein R 4 is selected from the group consisting of hydrogen, hydroxy, halogen, C ⁇ profession 8 -alkyl, C 3 .g- cycloalkyl, C ⁇ g-alkoxy, C ⁇ . 8 -alkylcarbonyl, C ⁇ . 8 -alkylidene, C 2 .g-alkenyl, and C 2 .g-alkynyl each of which may be optionally substituted with a substituent R 5 and wherein R 4 is selected from the group consisting of C ⁇ . 8 -alkyl, C 3 . 8 -cycloalkyl, C ⁇ g-alkylidene,
  • R 5 is selected from the group consisting of hydrogen, halogen, hydroxy, C ⁇ _g-alkyl, C 3 . 8 -cycloalkyl,
  • R 4 is selected from the group consisting of hydrogen, hydroxy and halogen most preferably hydrogen and hydroxy and R s substituted C ⁇ ._- alkyl.
  • the one or more substituent R 4 may be selected from the group consisting of C ⁇ .g-alkyl, C 3 .g-cycloalkyl, C ⁇ . 8 -alkylidene, each of which may be optionally substituted with a substituent R 5 .
  • the one or more substituent R 4 may be selected from the group consisting of a -g-alkyl, and C 3 . 8 -alkylidene, each of which may be optionally substituted with a substituent R 5 wherein R 5 is selected from the group consisting of hydrogen, halogen, hydroxy, C ⁇ .g-alkyl and C 3 .g-cycloalkyl.
  • R 5 is selected from the group consisting of hydrogen, halogen, hydroxy, C ⁇ . 8 -alkyl, C 3 . 8 -cycloalkyl, C 3 . 8 -heterocyclyl, C ⁇ _g-alkylcarbonyl, C ⁇ _ 8 -alkylidene, C 2 - 8 - alkenyl and C 2 . 8 -alkynyl. particularly hydrogen, hydroxy, halogen and -g-alkyl.
  • R 4 is selected from the group consisting of propyl, propylidene, butyl, butylidene, pentyl and pentylidene, each of which may be optionally substituted. In a most preferred embodiment, R 4 is selected from the group consisting of butyl, a pentyl and 3-(C ⁇ .g-alkyl)-butylidene, each of which may be optionally substituted.
  • embodiments of compound I may be chiral or comprised of one or more chiral centres. Where the compounds according to the invention have at least one chiral center, they may exist as a racemate, enantiomers or diastermeomers. It should be noted that all such isomers and mixtures thereof are included in the scope of the present invention. Furthermore, some of the crystalline forms for compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds of the present invention may form solvates with water (i.e. hydrates) or common organic solvents. Such solvates are also included in the scope of this invention.
  • the processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers
  • such isomers may be separated by conventional techniques such as preparative chiral cliromatography.
  • the compounds may be prepared in racemic form, or individual enantiomers may be prepared either by stereoselective synthesis or by resolution.
  • the compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di- ?-toluoyl-tf-tartaric acid and/or (+)-di- ?-toluoyl-/-tartaric acid followed by fractional crystallization and regeneration of the free base.
  • the compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.
  • any of the processes for preparation of the compounds of the present invention it may be necessary or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991.
  • the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
  • the nature of R x depends on X.
  • R x is a C ⁇ .g-alkyl such as methyl, ethyl, propyl, butyl, pentyl, or hexyl, typically methyl, ethyl or propyl.
  • the compounds according to Formula I are intended for use as a pharmaceutical.
  • a further aspect of the invention relates to a pharmaceutical composition comprising a compound as described herein, together with pharmaceutically acceptable carriers or excipients. Excipients and carriers will depend on, amongst other factors, the route of administration of the compound.
  • compositions comprising one or more compounds of Formula I together with a pharmaceutically acceptable diluent or excipient.
  • compositions are in unit dosage forms such as tablets, pills, capsules (including sustained-release or delayed-release formulations), powders, granules, elixirs, tinctures, syrups and emulsions, sterile parenteral solutions or suspensions, aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral (e.g., intravenous, intramuscular or subcutaneous), intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation, and may be formulated in an appropriate manner and in accordance with accepted practices such as those disclosed in Remington's Pharmaceutical Sciences, Gennaro, Ed., Mack Publishing Co., Easton PA, 1990.
  • compositions may be in sustained- release form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection.
  • an insoluble salt of the active compound such as the decanoate salt
  • the present invention also contemplates providing suitable topical formulations for administration to, e.g., eye or skin or mucosa.
  • the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • suitable binders, lubricants, disintegrating agents, flavoring agents and coloring agents can also be incorporated into the mixture.
  • suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
  • Lubricants used in these dosage forms include, without limitation, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
  • the active ingredient is mixed with a suitable pharmaceutical excipient, e.g., such as the ones described above, and other pharmaceutical diluents, e.g., water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof.
  • a suitable pharmaceutical excipient e.g., such as the ones described above
  • other pharmaceutical diluents e.g., water
  • the solid preformulation composition may then be subdivided into unit dosage forms of the type described above containing from 0.1 to about 50 mg of the active ingredient of the present invention.
  • the tablets or pills of the present composition may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner core containing the active compound and an outer layer as a coating surrounding the core.
  • the outer coating may be an enteric layer, which serves to resist disintegration in the stomach and permits the inner core to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with conventional materials such as shellac, cetyl alcohol and cellulose acetate.
  • the liquid forms in which the present compositions may be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical carriers.
  • Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, gelatin, methylcellulose or polyvinyl-pyrrolidone.
  • Other dispersing agents, which may be employed, include glycerin and the like.
  • compositions For parenteral administration, sterile suspensions and solutions are desired. Isotonic preparations, which generally contain suitable preservatives, are employed when intravenous administration is desired.
  • the compositions can also be formulated as an ophthalmic solution or suspension formation, i.e., hOeve drops, for ocular administration.
  • compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses two, three or four times daily.
  • compounds for the present invention may be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to persons skilled in the art.
  • the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
  • the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound employed.
  • a physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the disease or disorder, which is being treated.
  • the daily dosage of the products may be varied over a wide range from 0.01 to 100 mg per adult human per day.
  • the compositions are preferably provided in the form of tablets containing 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0 or 50.0 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • a unit dose typically contains from about 0.001 mg to about 50 mg of the active ingredient, preferably from about 1 mg to about 10 mg of active ingredient.
  • An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.0001 mg/kg to about 25 mg/kg of body weight per day.
  • the range is from about 0.001 to 10 mg/kg of body weight per day, and especially from about 0.001 mg/kg to 1 mg/kg of body weight per day.
  • the compounds may be administered on a regimen of 1 to 4 times per day.
  • Compounds according to the present invention may be used alone at appropriate dosages defined by routine testing in order to obtain optimal pharmacological effect on a muscarinic receptor, in particular the muscarinic Mi or M 4 receptor subtype, while minimizing any potential toxic or otherwise unwanted effects.
  • co-administration or sequential administration of other agents, which improve the effect of the compound may, in some cases, be desirable.
  • the pharmacological properties and the selectivity of the compounds of this invention for specific muscarinic receptor subtypes may be demonstrated by a number of different assay methods using recombinant receptor subtypes, preferably of the human receptors if these are available, e.g., conventional second messenger or binding assays.
  • a particularly convenient functional assay system is the receptor selection and amplification assay disclosed in US 5,707,798 describing a method of screening for bioactive compounds by utilizing the ability of cells transfected with receptor DNA, e.g., coding for the different muscarinic subtypes, to amplify in the presence of a ligand of the receptor. Cell amplification is detected as increased levels of a marker also expressed by the cells.
  • An important aspect of the present invention relates to a method of increasing an activity of a cholinergic receptor comprising contacting the cholinergic receptor or a system containing the cholinergic receptor with an effective amount of at least one compound of Formula I, as defined supra.
  • the present investigators have surprisingly found that the compounds of Formula I act as cholinergic agonists and, most remarkably, the compounds of Formula I are selective for the either the Mi or M t , or both the Mi and M 4 muscarinic receptor subtypes.
  • a further important aspect of the present invention relates to a method of treating or preventing a mental disorder in a mammal, such as a human, comprising the administration of an effective amount of a compound of Formula I.
  • disorders considered to be suitable for treatment by either Mi and/or M 4 agonism, or combined M 1 /M 4 agonism and dopaminergic D 2 antagonism are selected from the group consisting of cognitive impairment, forgetfulness, confusion, memory loss, attentional deficits, deficits in visual perception, depression, pain, sleep disorders, psychosis, and increased intraocular pressure.
  • suitable disorders considered to be suitable and particularly attractive may be selected from the group consisting of neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Down Syndrome, Pick disease, dementia, clinical depression, age-related cognitive decline, attention-deficit disorder, sudden infant death syndrome, and glaucoma.
  • the compounds of this invention are useful in the treatment of mania, bipolar disorder, unipolar disorder, schizoaffective disorder, schizophreniform disorder and anxiety. It should be noted that other non-schizophrenic causes of psychosis, including drug induced, those associated with dementia and other neurodegenerative disorders (such as Huntington's) are also anticipated to be suitable.
  • the Tic disorders also include a spectrum of disorders including Tourettes and
  • the affective disorder spectrum including unipolar, bipolar are also anticipated to be suitable for treatment using compounds of Formula I.
  • An important aspect of the invention therefore relates to the use of a compound according or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the preparation of a medicament for the prophylactic or curative treatment of psychosis or alleviation of symptoms associated with psychosis.
  • the medicament acts, at least in part, as an Mi agonist or as Mi and M 4 agonist.
  • the compound according to Formula I may further act as a D 2 antagonist.
  • an important aspect of the invention relates to a use of compounds of Formula I as Mi and M 4 agonist, as well as D 2 antagonists. Illustrative examples of compounds with this combined activity are tabulated in Example 1.
  • Compounds 61KS19, 45NK70, 45NK71, 45NK110, 61KS12 and 61KS13 have high binding efficacy for the Mi and M 4 receptor subtypes. Moreover, compounds of Formula I have high selectivity for the Mi and M 4 receptor subtypes over M 2 , M 3 , M 5 receptor subtypes. Further, compounds of Formula I have D 2 antagonistic activity.
  • muscarinic receptors may be implicated in the control of amyloid precursor processing, in particular by activation of the Mi receptor.
  • a further aspect of the present invention relates to a method of modulating or preventing the progression or formation of amyloid plaques in an individual susceptible to or affected by Alzheimer's Disease by administering an effective amount of a compound of Formula I, said effective amount sufficient to modulate amyloid precursor protein processing.
  • NIH-3T3 cells available from the American Type Culture Collection as ATCC CRL 1658 were transfected with plasmid DNA encoding the ml and m4 receptors and plasmid DNA encoding ⁇ -galactosidase.
  • Transfected cells were grown in the presence of between 1 nM and 40 ⁇ M of the test compound for 5 days. On day 5, the cells were lysed using 0.5% nonidet-P and ⁇ -galactosidase expression was quantified using the chromogenic substrate o-nitrophenyl- ⁇ -D-galactoside (ONGP).
  • UFP chromogenic substrate o-nitrophenyl- ⁇ -D-galactoside
  • Cell membranes expressing the D 2 receptor were prepared by transfecting tSA cells (Chahine, M., Bennet, P. B., George, A. L., Horn, R. (1994) Pfluegers Arch. 427, 136-142) with 10 ⁇ g plasmid DNA encoding the human dopamine D 2 receptor and 40 ⁇ l Superfect (Qiagen). The cells were harvested 48 hours and transfection and membranes were prepared by homogenizing the cells using a Polytron harvester in 20 mM Hepes, 10 mM EDTA, pH 7.4. The homogenate was centrifuged for 30 minutes at 37,000g.
  • the pellet was homogenized again in 60 ml 20 mM Hepes, 5 mM EDTA. The homogenate was centrifuged for 30 minutes at 37,000g. The supernatant was discarded. The pellet was homogenized again in 10 ml 20 mM Hepes, 1 mM EDTA. The resultant membranes were frozen at -80°C.
  • the membranes were combined with 150 pM [ 3 H]-Spiperone (Amersham- Pharmacia, 107 Ci/mmol) and ligand concentrations between 1 nM and 10 ⁇ M, or haloperidol concentrations between 0.1 nM and 1 ⁇ M in 460 ⁇ l 20 mM Hepes, 1 mM EDTA, 0.1% (w/v) bovine serum albumin.
  • Nonspecific binding was defined as binding in the presence of 1 ⁇ M haloperidol.
  • the membranes were incubated for 4 hours at 37°C, and then filtered onto Packard GFB Filterplates using a Packard harvester. The membranes were dried and 50 ⁇ l Microscint (Packard) was added to each well. The amount of bound radioligand was quantified using a Packard Topcount scintillation counter.
  • % inhibition minimum + (maximum - minimum)/(l + ([ligand]/[IC 5 o]))
  • mice Male Non-Swiss Albino mice (Harlan Sprague-Dawley) were housed (4 mice/cage) in rooms with temperature and humidity controlled and water and food (Harlan Teklad) freely available. Mice were kept on a 12-hr lightdark cycle. Procedure Locomotor Activity
  • Plastic 20x20x30cm activity cages were equipped with photocell beams (AccuScan Instruments).
  • 61KS19 (1, 3 and 10 mg/kg) was administered alone i.p. 30 min before the session.
  • mice were treated with 0.3 mg/kg dizocilpine, 3.0 mg/kg d-amphetamine or 3.0 mg/kg scopolamine i.p. 15 min before the session (15 min after 61KS19).
  • Preparative purification was performed on a Waters auto purification system ( 600 pumps, 2700 sample manager, 996 PDA detector, ZMD massspectrometer).
  • the columns used were YMC C18 J'sphere ODS H80.
  • Buffer A was 0.15% TFA in water
  • buffer B was 0.15% TFA in acetonitrile/water 95/5.
  • the columns were operated at 17 ml/min. Following an initial hold of 2.5 min at 30% buffer B, compounds were separated using a gradient af 30-100% buffer B in 8.5 min.
  • a dual column setup with two pumps was used to equilibrate one column, while running on the other.
  • LDA was generated by adding BuLi (20 mL, 1.68M, 32.6 mmol) to a solution of diisopropylamine (2.38 g, 32.6 mmol) in dry THF (lOmL) at -78°C under argon. The mixture was kept at that temperature for 30 min followed by the addition of a solution of N- Bocnortropinone (5.27 g, 23.4 mmol) in dry THF (20 mL). The mixture was then left stirring for lh while maintaining the temperature at 78°C.
  • Trifluorosulfonyl-8-tertButyloxycarbonyl-8-azabicyclo[3.2.1]-oct-2-ene (104KS22) (0.271 g, 0.758 mmol) were reacted according to GP2 to give the title compound (79KS61) (0.104 g, 52%).
  • Trifluorosulfonyl-8-tgrtButyloxycarbonyl-8-azabicyclo[3.2.1]-oct-2-ene (104KS22) (0.220 g, 0.616 mmol) were reacted according to GP2 to give the title compound (79KS79) (0.073 g, 40%).
  • Platinium dioxide 200 mg was added to 4-benzylpiperidine (1.75 g, 10 mmol) in EtOH (20 ml) and HC1 in dioxan (20 ml, 4 M). The flask was evacuated, flooded with hydrogen and this procedure was repeated twice. The reaction was stirred vigorously at r.t. for 72 h then platinium oxide (200 mg) was added and the reaction was stirred at r.t. for 18 h. The reaction mixture was filtered through Celite eluting with EtO Ac and the solute concentrated in vacuo. Ether (50 ml) was added and the reaction concentrated in vacuo.
  • Platinium dioxide (0.200 g) was added to 4-phenylpiperidine (1.55 g, 10 mmol) in EtOH (40 ml) and HC1 in dioxan (5 ml, 4 M). The flask was evacuated, flooded with hydrogen and this procedure was repeated twice. The reaction was stirred vigorously at r.t. for 72 h then filtered through Celite eluting with EtO Ac and the solute was concentrated in vacuo to give a white solid. Water (30 ml) was added followed by sodium hydroxide (20ml, 2 M) and the product was extracted into EtOAc (3x50 ml).
  • the product was purified by flash CC (SiO 2 ; EtOAc) and by prep. RP-HPLC [conditions: stationary phase, Luna 15um C18; column, 250x21.2 mm; mobile phase, 20 ml/min, H 0/MeCN, ammoniumacetate buffer (25nM)] to give the title compound (92LH60-1A) (0.135 g, 53%).
  • the crude product was purified by column chromatography (Si0 2 ; EtOAc/n- heptane 1:10) and prep. RP-HPLC (conditions: stationary phase, Luna 15um C18; column, 250x21.2 mm; mobile phase, 20 ml/min, H 2 0/CH 3 CN, ammoniumacetate buffer (25nM)) to give the title compound (85LM23) (0.002 g, 1%).
  • the oxalate salt was prepared by dissolving the product in Et 2 0 and a minimum of MeOH followed by the addition of a solution of oxalic acid (l.leq of obtained product) in Et 2 0. Filtration gave the title compound (61KS89-oxalate). NMR of the free base was recorded.
  • the oxalate salt was prepared by dissolving the product in Et 2 O and a minimum of MeOH followed by the addition of a solution of oxalic acid (l.leq of obtained product) in Et 2 0. Filtration gave the title compound (61KS91-3-oxalate). NMR of the free base was recorded.

Abstract

Benzimidazolidinone derivative compounds, which increase acetylcholine signalling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.

Description

BENZEVΠDAZOLΓDINONE DERIVATIVES AS MUSCARINIC AGENTS
FIELD OF THE INVENTION
[0001] Novel benzimidazolidinone derivatives have been prepared and identified as having high affinity for muscarinic Mi and M receptors. The treatment of mental disorders associated with increasing the activity of a cholinergic receptor using these novel compounds is anticipated. Moreover, these compounds also have dopamine D2 antagonist activity, rendering them particularly interesting as anti-psychotic agents.
BACKGROUND OF THE INVENTION
[0002] Muscarinic cholinergic receptors mediate the actions of the neurotransmitter acetylcholine in the central and peripheral nervous systems. Muscarinic receptors play a critical role in the central nervous system mediating higher cognitive functions, as well as in the peripheral parasympathetic nervous system where they mediate cardiac, respiratory, digestive, and endocrine and exocrine responses. Five distinct muscarinic receptor subtypes have been identified, Mι-M5. The muscarinic Mi receptor subtype is predominantly expressed in the cerebral cortex and is believed to be involved in the control of higher cognitive functions; the M2 receptor is the predominant subtype found in heart and is involved in the control of heart rate; the M3 receptor is widely expressed in many peripheral tissues and is believed to be involved in gastrointestinal and urinary tract stimulation as well as sweating and salivation; the ML* receptor is present in brain and may be involved in locomotion; the M5, receptor is present in the brain where its role is at present poorly defined. Mi and M have been particularly associated with the dopaminergic system.
[0003] Conditions associated with cognitive impairment, such as Alzheimer's disease, are accompanied by a reduction of acetylcholine content in the brain. This is believed to be the result of degeneration of cholinergic neurons of the basal forebrain, which widely innervate multiple areas of the brain, including the association cortices and hippocampus, that are critically involved in higher processes.
[0004] Efforts to increase acetylcholine levels have focused on increasing levels of choline, the precursor for acetylcholine synthesis, and on blocking acetylcholineesterase (AChE), the enzyme that metabolizes acetylcholine. Attempts to augment central cholinergic function through the administration of choline or phosphatidylcholine have not been successful. AChE inhibitors have shown therapeutic efficacy, but have been found to have frequent cholinergic side effects due to peripheral acetylcholine stimulation, including abdominal cramps, nausea, vomiting, and diarrhoea. These gastrointestinal side effects have been observed in about a third of the patients treated. In addition, some AChE inhibitors, such as tacrine, have also been found to cause significant hepatotoxicity with elevated liver transaπiinases observed in about 30% of patients. The adverse effects of AChE inhibitors have severely limited their clinical utility. [0005] The dopamine hypothesis of schizophrenia suggests that increased dopamine neurotransmission underlies the positive symptoms of the disease and is supported by the evidence that dopamine receptor blockade is effective in ameliorating such psychotic symptoms. Further, drugs that enhance dopamine neurotransmission in the brain cause psychotic-like episodes in man and exacerbate psychotic symptoms in schizophrenic patients. In animal studies, drugs that increase dopamine neurotransmission cause behavioural effects such as increased locomotion, climbing and deficits in prepulse inhibition. Known antipsychotics and dopamine receptor antagonists can block these behavioural effects. Unfortunately, dopamine receptor antagonists also cause severe extrapyramidal side effects in patients as predicted by induction of catalepsy in animal models. These extrapyramidal side effects include tremor, bradykinesia, akithesias, and tardive dyskinesias.
[0006] Due in part to these observations, the discovery of agents with Mi receptor agonist activity has been sought after for the treatment of dementia. However, existing agents lack specificity in their actions at the various muscarinic receptor subtypes. Known Mi muscarinic agonists such as arecoline have also been found to be weak agonists of M2 as well as M3 receptor subtypes and are ineffective in the treatment of cognitive impairment, due in large part to their dose-limiting M2 and M3 receptor mediated side effects.
[0007] Xanomeline (Shannon et al., J. Pharmacol. Exp. Ther. 1994, 269, 271; Shannon et al., Schizophrenia Res. 2000, 42, 249) is an M1/M4 preferring muscarinic receptor agonist with little or no affinity for dopamine receptors despite inhibiting A10 but not A9 dopamine cells. The thiadiazole derivative PTAC has been reported (Shannon et al., European Journal of Pharmacology , 1998, 356, 109) to have partial agonist effect at muscarinic M2 and M4 receptors and antagonist effect at muscarinic Mi, M3, and M5 receptors as well as exhibiting functional dopamine antagonism.
[0008] Recently, muscarinic agonists including xanomeline have been shown to be active in animal models with similar profiles to known antipsychotic drugs, but without causing catalepsy (Bymaster et al., Eur. J. Pharmacol. 1998, 356, 109, Bymaster et al., Life Sci. 1999, 64, 527, Shannon et al., J. Pharmacol. Exp. Ther. 1999, 290, 901, Shannon et al., Schizophrenia Res. 2000, 42, 249). Further, xanomeline was shown to reduce psychotic behavioural symptoms such as delusions, suspiciousness, vocal outbursts, and hallucinations in Alzheimer's disease patients (Bodick et al., Arch. Neurol. 1997, 54, 465), however treatment induced side effects that severely limit the clinical utility of this compound.
[0009] Analogues of 1,2,5-thiadiazole have been reported (Sauerberg et al., J. Med Chem. 1998, 41, 4378) to have high affinity and selectivity for central muscarinic receptors as well as exhibiting functional dopamine antagonism despite lack of affinity for dopamine receptors.
[0010] The present investigators have focussed their efforts on the development of a molecule that simultaneously reduced the positive symptoms and improved the negative symptoms and the cognitive impairments associated with schizophrenia as a novel treatment of mental disorders. It is the intent of the present investigators to demonstrate that muscarinic Mi and/or M4 agonists with combined D2 antagonist activity may possess superior antipsychotic efficacy without the side effects associated with high dose D2 antagonism alone. The D2 antagonist properties of these molecules may contribute to a reduction in the positive symptoms of this disease.
[0011] Based on distribution of Mi and M4 receptors in the cerebral cortex and hippocampus (the areas involved in higher order cognitive functions), the Mi and/or M4 agonist properties of these compounds may reduce the cognitive dulling and perhaps ameliorate other negative symptoms associated with schizophrenia. (Friedman, Biol. Psychiatry, 1999, 45, 1; Rowley, J. Med. Chem. 2001, 44, 477; Felder, J. Med. Chem. 2000, 43, 4333). This unique combination of central nervous system activities in one molecule is unprecedented and may lead to the development of an entirely new class of antipsychotic drugs, ones with the superior clinical properties without the limiting side-effect profile.
[0012] WO 99/32481 discloses derivatives including 1-substituted benzimidazolones and derivatives thereof. The compounds according to WO 99/32481are intended for treatment of glaucoma, myopia, psychosis and various other conditions involving muscarinic receptors.
[0013] US 4,254,127 discloses l-(l-piperidinyl)alkyl-benzimidazolone derivatives wherein the piperidine is 4-substituted with aryl-alkyls, aryl-alkylcarbonyls, aryl-alkylcarbonyl derivatives, and aryl-alkoxides. The compounds according to US 4,254,127 are reported to have psychotropic activity acting as serotonin antagonists.
[0014] US 5,789,425 and US 5,726,188 discloses 1-substituted imidazolidin-2-one derivatives with muscarinic Mi activity. Benzimidazolidinone derivatives are not disclosed therein.
[0015] WO 96/13262 disclose benzimidazolidin-2-one derivatives 1-subsituted with a
4-piperidinyl moiety which in turn is 1-substituted. The compounds according to WO 96/13262 are reported to have anti-muscarinic activity intended for the treatment of myopia. Benzimidazolidin-2- one derivatives 1-subsituted with moieties other than a 4-piperidinyl group is not disclosed.
[0016] WO 97/16192, WO 97/16187 and US5,756,508 disclose novel l,3-dihydro[l- (l-heteroarylpiperidine-4-yl)piperidine-4-yl]-2H-benzimidazolones. The compounds according to WO 97/16192, WO 97/16187 and US5,756,508 are reported to have antimuscarinic activity used for treatment and/or prevention of myopia.
[0017] WO 97/16186 and US 5,718,912 disclose l-[cycloalkylpiperidin-4-yl]-2H- benzimidazolones as selective muscarinic agonists of the M2 subtype with low activity at the M3 subtype, and when utilised for glaucoma therapy have fewer side effects than pilocarpine therapy.
[0018] Cakir, B et al. describes the synthesis and antinociceptive activity of some 1- (3-piperidinopropyl)benzothiazolone derivatives in Farmaco, 1999, 54, 846.
[0019] There is a need in the art to provide compounds that increase acetylcholine signalling or effect in the brain. Specifically there is a need for muscarinic agonists that are active at various muscarinic receptor subtypes in the central and peripheral nervous system. There is a further need to develop more highly selective muscarinic agonists, such as Mi and/or M» selective agents, both as pharmacological tools and as potential therapeutic agents. Moreover, there is a need for compounds aimed at the approach of treating psychosis using compounds which has a combined muscarinic agonist and dopamine antagonist profile.
SUMMARY OF THE INVENTION [0020] The present invention seeks to provide compounds which increase acetylcholine signalling or effect in the brain, and highly selective muscarinic agonists, particularly for the Mi and/or M4 receptor subtypes as well as providing compounds aimed at the approach of treating psychosis using compounds which has a combined muscarinic agonist and dopamine antagonist profile.
[0021] In a first aspect, the present invention relates to a compound of Formula I
or a pharmaceutically acceptable salt or prodrug thereof, wherein
X is selected from the group consisting of C, O, N and S
Z is selected from the group consisting of CH and N
Y is selected from the group consisting of =0, =N and =S or tautomers thereof, such as Y-alkylated tautomers;
SPU is a spacer unit providing a distance d between Z and N wherein
-SPU- is a biradical selected from the group consisting of -(CR6R7)n-A- and -C3.8- cycloalkyl- wherein n is in the range 1 to 5, such as 1, 2, 3, 4, or 5 and A is absent or an optionally substituted -C3.g-cycloalkyl;
N together with R1 and R2 form a heterocyclic ring wherein said heterocyclic ring is selected from the group consisting of perhydroazocine, perhydroazepine, piperidine, pyrrolidine, azetidine, aziridine and 8-azabicyclo[3.2.1]octane and wherein the heterocyclic ring is substituted with one or more substituents R4 selected from the group consisting of hydroxy, halogen, Ci-s-alkyL C3.8-cycloalkyl, Cμg-alkoxy, C]_8- alkylcarbonyl, d-s-alkylidene, C2.s-alkenyl, C2.8-alkynyl, Cι.6-alkyloxyimino, and C].6- alkyloxyamino each of which may be optionally substituted with a substituent R5 and wherein at least one of said substituents R4 is R4 selected from the group consisting of Ci-s-alkyl, C3.s-cycloalkyl, Ci-g-alkoxy, Cμg-alkylcarbonyl, -g-alkylidenec Cι.8-alkyloxyimino, and Ci-g-alkyloxyamino each of which may be optionally substituted with a substituent R5;
R5 is selected from the group consisting of hydrogen, halogen, hydroxy, Cι_g-alkyl- Ci-g- alkoxy, C3.8-cycloalkyl, C3.8-heterocyclyl, Cι.8-alkylcarbonyl, C].g-alkylidene, C2-8-alkenyl and C2.8- alkynyl;
Rxmay be absent or selected from the group consisting of hydrogen, optionally substituted Cι.g-alkyl, optionally substituted C .8-cycloalkyl, optionally substituted C2.8-alkenyl, optionally substituted C2-8-alkynyl, optionally substituted aryl, optionally substituted heteroaryl CH2- N(R5)(R5), CH2-OR5, CH2-SR5, CH2-0-C(=O)R5, CH2-0-C(=S)R5;
R3 may be present 0-4 times and selected from the group consisting of halogen, hydroxy, optionally substituted Cj.g-alkyl, Cj-g-alkoxy, optionally substituted Cι.8-alkylidene, optionally substituted C2-8-alkenyl, optionally substituted C2-8-alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3.8-cycloalkyl, optionally substituted C3.8- heterocyclyl, and optionally substituted -g-alkylcarbonyl; each R6 and each R7 is independently selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted Cι_8-alkyl, Cι.8-alkoxy, optionally substituted Cι_8- alkylidene, optionally substituted C2.8-alkenyI, optionally substituted C2.8-alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3.g-cycloalkyl, optionally substituted C3.8-heterocyclyl, and optionally substituted Cι.s-alkylcarbonyl.
[0022] A second aspect of the invention relates to a method of increasing an activity of a cholinergic receptor comprising contacting the cholinergic receptor or a system containing the cholinergic receptor with an effective amount of at least one compound of Formula I.
[0023] An increase in activity of the cholinergic receptor and the cholinergic system is, as discussed supra, associated to the activity of anti-psychotics. Accordingly, further aspects of the present invention relate to a method of treating or preventing a mental disorder in a mammal, such as a human, comprising the administration of an effective amount of a compound of Formula I and to the use of a compound of Formula I, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the preparation of a medicament for the prophylactic or curative treatment of psychosis or alleviation of symptoms of psychosis. In the context of the present invention a mammal may be selected from the group consisting of mice, rats, rabbits, guinea pigs, dogs, cats, sheep, goats, cows, primates, such as monkeys, chimpanzees, and apes, and humans. Most preferably, the mammal is a human.
[0024] Aspects of the invention relate to compounds of Formula I for use as selective modulators of Mi and/or 4 muscarinic receptors for the treatment of disorders associated with muscarinic receptors and especially with said receptor subtypes. [0025] As stated, compounds of Formula I have surprisingly been found to have selectivity for the Mi and M4 muscarinic receptor subtypes. Therapeutic advantages may be derived from this selectivity. Further therapeutic advantages may be derived from the concomitant muscarinic Mi and M4 agonist activity and dopaminergic D2 antagonist activity.
[0026] Compounds of Formula I, by the modulation of muscarinic receptors may be implicated in the control of amyloid precursor processing, in particular by the activation of the Mi receptor. Thus, a further aspect of the present invention relates to a method of modulating or preventing the progression or formation of amyloid plaques in an individual susceptible to or affected by Alzheimer's Disease by administering an effective amount of a compound of Formula I, said effective amount sufficient to modulate amyloid precursor protein processing.
BRIEF DESCRIPTION OF THE FIGURES
[0027] Figure 1 is a graph depicting the reduction of spontaneous locomotor activity in mice with the administration of 10 mg/kg i.p. of 61KS19.
[0028] Figure 2 is a graph that shows the reduction of amphetamine-induced hyperactivity in mice with the administration of 3 and 10 mg/kg i.p. of 6 IKS 19
[0029] Figure 3 is a graph that shows the reduction of scopolamine-induced hyperactivity in mice with the administration of 1, 3 and 10 mg/kg i.p. of 6 IKS 19
[0030] Figure 4 is a graph that shows the reduction of MK-801 -induced hyperactivity in mice with the administration of 10 mg kg i.p. of 61KS19.
[0031] Figure 5 depicts the result of a comparison between haloperidol and 61KS19, and shows that unlike haloperidol, 61KS19 (10 mg/kg i.p.) failed to induce catalepsy.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS [0032] In a first aspect, the present invention relates to a compound of Formula I
or a pharmaceutically acceptable salt or prodrug thereof, wherein
X is selected from the group consisting of C, O, N and S
Z is selected from the group consisting of C and N
Y is selected from the group consisting of =O, =N and =S or tautomers thereof, such as Y- alkylated tautomers;
SPU is a spacer unit providing a distance d between Z and N wherein -SPU- is a biradical selected from the group consisting of -(CR6R7)n-A- and -C3.8- cycloalkyl- wherein n is in the range 1 to 5, such as 1, 2, 3, 4, or 5 and A is absent or an optionally substituted -C3.8-cycloalkyl;
N together with R1 and R2 form a heterocyclic ring wherein said heterocyclic ring is selected from the group consisting of perhydroazocine, perhydroazepine, piperidine, pyrrolidine, azetidine, aziridine and 8-azabicyclo[3.2.1]octane and wherein the heterocyclic ring is substituted with one or more substituents R4 selected from the group consisting of hydroxy, halogen, Cι_8-alkyl, C3.8-cycloalkyl, Cι.8-alkoxy, Cι.8- alkylcarbonyl, Cι.g-alkylidene, C2.g-alkenyl, C2.8-alkynyl, Cι.6-alkyloxyimino, and Cι.6- alkyloxyamino each of which may be optionally substituted with a substituent R5 and wherein at least one of said substituents R4 is R4 selected from the group consisting of Cι.g-alkyl, C3.g-cycloalkyl, Cι.g-alkoxy, Cι_8-alkylcarbonyl, Cι.8-alkylidenec Cι.8-alkyloxyimino, and Cι_8-alkyloxyamino each of which may be optionally substituted with a substituent R5;
R5 is selected from the group consisting of hydrogen, halogen, hydroxy, Cι_8-alkyl, C3.8- cycloalkyl, C3.8-heterocyclyl, Cι_8-alkylcarbonyl, Cι.8-alkylidene, C2.8-alkenyl and C2.8-alkynyl;
Rx may be absent or selected from the group consisting of hydrogen, optionally substituted Ci-g-alkyl, optionally substituted C3.8-cycloalkyl, optionally substituted C2.8-alkenyl, optionally substituted C2.8-alkynyl, optionally substituted aryl, optionally substituted heteroaryl, CH2- N(R5)(R5), CH2-OR5, CH2-SR5, CH2-0-C(=0)R5, CH2-O-C(=S)R5;
R3 may be present 0-4 times and selected from the group consisting of halogen, hydroxy, optionally substituted Cι.8-alkyl, Cι.8-alkoxy, optionally substituted Cι.8-alkylidene, optionally substituted C2.8-alkenyl, optionally substituted C2.8-alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3.8-cycloalkyl, optionally substituted C3.8- heterocyclyl, and optionally substituted Cι.8-alkylcarbonyl; each R6 and each R7 is independently selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted Cι_8-alkyl, Ci-g-alkoxy, optionally substituted Cι_8- alkylidene, optionally substituted C2.8-alkenyl, optionally substituted C2-8-alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3.8-cycloalkyl, optionally substituted C3.8-heterocyclyl, and optionally substituted Cι.g-alkylcarbonyl.
[0033] The term "pharmaceutically acceptable salt" refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound. Pharmaceutical salts can be obtained by reacting a compound of the invention with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Pharmaceutical salts can also be obtained by reacting a compound of the invention with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N- methyl-D-glucamine, tris(hydroxymethyl)methylamine, and salts with amino acids such as arginine, lysine, and the like.
[0034] A "prodrug" refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. An example, without limitation, of a prodrug would be a compound of the present invention which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial. A further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety.
[0035] The term "selective" or "selectivity" is intended to mean the ability of a compound to generate a desired response from a particular receptor type, subtype, class or subclass while generating less or little response from other receptor types. "Selective" or "selectivity" of an Mi or M4 muscarinic agonist compound is intended to mean the ability of a compound to increase the activity of the Mi or M, muscarinic receptor, respectively, while causing non-substantial, little or no increase in the activity of other subtypes including M3 and M5 subtypes, and preferably the M2 subtype. Compounds of the presents invention may also show selectivity toward both Mi and M4 receptors, i.e. increase the activity of both the Mi and M4 muscarinic receptors, while causing little or no increase in the activity of other subtypes including M3 and M5 subtypes, and preferably the M2 subtype.
[0036] In the present context, the term "Cι.8-alkyl" is intended to mean a linear or branched saturated hydrocarbon chain wherein the longest chains has from one to eight carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl and octyl. A branched hydrocarbon chain is intended to mean a Cι.8-alkyl substituted at any carbon with a hydrocarbon chain.
[0037] In the present context, the term "C2.8-alkenyl" is intended to mean a linear or branched hydrocarbon group having from two to eight carbon atoms and containing one or more double bonds. Illustrative examples of C2-8-alkenyl groups include allyl, homo-allyl, vinyl, crotyl, butenyl, pentenyl, hexenyl, heptenyl and octenyl. Illustrative examples of C2.ιo-alkenyl groups with more than one double bond include butadienyl, pentadienyl, hexadienyl, heptadienyl, hexatrienyl. heptatrienyl and octatrienyl groups as well as branched forms of these. The position of the unsaturation (the double bond) may be at any position along the carbon chain. [0038] In the present context, the term "Cι.8-alkylidene" is intended to mean a linear or branched hydrocarbon chain radical wherein the longest chain has from one to eight carbon atoms and an unsaturated bond at the radical position. Bonds further than the radical position may also be unsaturated.
[0039] In the present context the term "C .8-alkyny ' is intended to mean linear or branched hydrocarbon groups containing from two to eight carbon atoms and containing one or more triple bonds. Illustrative examples of C2.8-alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl and octynyl groups as well as branched forms of these. The position of unsaturation (the triple bond) may be at any position along the carbon chain. More than one bond may be unsaturated such that the "C2-8-alkynyl" is a di-yne or enedi-yne as is known to the person skilled in the art.
[0040] In the present context the term "C3.8-cycloalkyl" is intended to cover three-, four-, five-, six- seven-, and eight-membered rings comprising carbon atoms only whereas the term "heterocyclyl" is intended to mean three-, four-, five-, six- seven-, and eight-membered rings wherein carbon atoms together with from 1 to 3 heteroatoms constitute said ring. The heteroatoms are independently selected from oxygen, sulphur, and nitrogen.
[0041] C3.8-cycloalkyl and heterocyclyl rings may optionally contain one or more unsaturated bonds situated in such a way, however, that an aromatic π-electron system does not arise.
[0042] Illustrative examples of preferred "C3.g-cycloalkyr' are the carbocycles cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclopentadiene, cyclohexane, cyclohexene, 1,3-cyclohexadiene, 1,4-cyclohexadiene, cycloheptane, cycloheptene, 1,2- cycloheptadiene, 1,3-cycloheptadiene, 1,4-cycloheptadiene and 1,3,5 cycloheptatriene.
[0043] Illustrative examples of "heterocyclyls" are the heterocycles 2H-thipyran, 3H- thipyran, 4H-thipyran, tetrahydrothiopyran, 2H-pyran, 4H-pyran, tetrahydropyran, piperidine, 1,2- dithiin, 1,2-dithiane, 1,3-dithiin, 1,3-dithiane, 1,4-dithiin, 1,4-dithiane, 1,2-dioxin, 1,2-dioxane, 1,3- dioxin, 1,3-dioxane, 1,4-dioxin, 1,4-dioxane, piperazine, 1,2-oxathiin, 1,2-oxathiane, 4H-1,3- oxathiin, 1,3-oxathiane, 1,4-oxathiin, 1,4-oxathiane, 2H-l,2-thiazine, tetrahydro-l,2-thiazine, 2H- 1,3-thiazine, 4H-l,3-thiazine, 5,6-dihydro-4H-thiazine, 4H-l,4-thiazine, tetrahydro-l,4-thiazine, 2H-l,2-oxazine, 4H-l,2-oxazine, 6H-l,2-oxazine, 2Hl,3-oxazine, 4H-l,3-oxazine, 4H-l,4-oxazine, maleimide, succinimide, dioxopiperazine, hydantoin, morpholine, trioxane, 4H-l,2,3-trithiin, 1,2,3- trithiane, 1,3,5-trithiane, hexahydro-l,3,5-triazine, tetrahydrothiophene, tetrahydrofuran, pyrroline, pyrrolidine, pyrrolidone, pyrrolidione, pyrazoline, pyrazolidine, imidazoline, imidazolidine, 1,2- dioxole, 1,2-dioxolane, 1,3-dioxole, 1,3-dioxolane, 3H-l,2-dithiole, 1,2-dithiolane, 1,3-dithiole, 1,3-dithiolane, isoxazoline, isoxazolidine, oxazoline, oxazolidine, thiazoline, thiozolidine, 3H-1,2- oxathiole, 1,2-oxathiolane, 5H-l,2-oxathiole, 1,3-oxathiole, 1,3-oxathiolane, 1,2,3-trithiole, 1,2,3- trithiolane, 1,2,4-trithiolane, 1,2,3-trioxole, 1,2,3-trioxolane, 1,2,4-trioxolane, 1,2,3-triazoline and 1,2,3-triazolidine. Binding to the heterocycle may be at the position of the heteroatom or via carbon atom of the heterocycle.
[0044] In the present context the term "aryl" is intended to mean a carbocyclic aromatic ring or ring system. Moreover, the term "aryl" includes fused ring systems wherein at least two aryl rings, or at least one aryl and at least one C3.8-cycloalkyl, or at least one aryl and at least one heterocyclyl, share at least chemical bond. Illustrative examples of "aryl" rings include optionally substituted phenyl, naphthalenyl, phenanthrenyl, anthracenyl, acenaphthylenyl, tetralinyl, fluorenyl, indenyl, indolyl, coumaranyl, coumarinyl, chromanyl, isochromanyl, and azulenyl. A preferred aryl group is phenyl.
[0045] In the present context, the term "heteroaryl" is intended to mean an aryl group where one or more carbon atoms in an aromatic ring have been replaced with one or more heteroatoms selected from the group comprising nitrogen, sulphur, phosphorous and oxygen.
[0046] Furthermore, in the present context, the term "heteroaryl" comprises fused ring systems wherein at least one aryl ring and at least one heteroaryl ring, at least two heteroaryls, at least one heteroaryl and at least one heterocyclyl, or at least one heteroaryl and at least one C3.8- cycloalkyl share at least one chemical bond, such as one or two chemical bonds.
[0047] Illustrative examples of a heteroaryl may be selected from the group comprising furanyl, thienyl, pyrrolyl, phenoxazonyl, oxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, isoxazolyl, imidazolyl isothiazolyl, oxadiazolyl, furazanyl, triazolyl, thiadiazolyl, piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl and triazinyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, benzopyrazolyLindazolyl, benzimidazolyl, benzthiazolyl, purinyl, quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinylthienofuranyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl and thianthrenyl.
[0048] When used herein the term "Cι.8-alkoxy" is intended to mean Cι_g-alkyl-oxy such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy. pentoxy, isopentoxy, neopentoxy and hexoxy
[0049] The term "halogen" includes fluorine, chlorine, bromine and iodine.
[0050] In the present context, i.e. in connection with the terms "aryl", "heteroaryl", "C3.g-cycloalkyl", "heterocyclyl", "Cι.8-alkyl", "Ci-g-alkoxy", "C2.8-alkenyr, and "C2.8-alkynyl", the term "optionally substituted" is intended to mean that the group in question may be substituted one or several times, such as 1 to 5 times, preferably 1 to 3 times, most preferably 1 to 2 times, with one or more groups selected from Cι.8-alkyl, Cι.8-alkoxy, oxo (which may be represented in the tautomeric enol form), carboxyl, amino, hydroxy (which when present in an enol system may be represented in the tautomeric keto form), nitro, sulphono, sulphanyl, Cμs-carboxyl, Cι.8- alkoxycarbonyl, Ci-g-alkylcarbonyl, formyl, aryl, aryloxy, aryloxycarbonyl, arylcarbonyl, heteroaryl, amino, mono- and di(Cι.8-alkyl)amino; carbamoyl, mono- and di(Cμg- alkyl)aminocarbonyl, amino-Cι.g-alkyl-aminocarbonyl, mono- and di(Cι.g-alkyl)amino-Cι.8-alkyl- aminocarbonyl, Cι.g-alkylcarbonylamino, cyano, guanidino, carbamido, Cι.8-alkanoyloxy, Cι_8- alkylsulphonyloxy, dihalogen-Cι.g-alkyl, trihalogen-Cι.g-alkyl, halogen, where aryl and heteroaryl representing substituents may be substituted 1-3 times with Cμg-alkyl, -g-alkoxy, nitro, cyano, hydroxy, amino or halogen. In general, the above substituents may be susceptible to further optional substitution.
[0051] The term "salts" is intended to mean pharmaceutically acceptable acid addition salts obtainable by treating the base form of a functional group, such as an amine, with appropriate acids such as inorganic acids, for example hydrohalic acids; typically hydrochloric, hydrobromic, hydrofluoric, or hydroiodic acid; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example acetic, propionic, hydroacetic, 2-hydroxypropanoic acid, 2-oxopropanoic acid, ethandioic, propanedioic, butanedioic, (Z)-2-butenedioic, (E)-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutanedioic, 2-hydroxy-l,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic acid, cyclohexanesulfamic, 2-hydoxybenzoic, 4-amino- 2-hydroxybenzoic, ethanedisulfonic, and other acids known to the skilled practitioner.
[0052] In certain embodiments of the present invention, the spacer unit SPU comprises a number of optionally substituted methylene groups CR6R7. It is understood by the phrase "each R6 and each R7 is optionally and independently selected" that not all R6 groups may be identical and not all R7 groups may be identical. Thus, each substituted methylene group may have an R6 and an R7 that is different than any other R6 or R7 substituents on other methylene groups. In some embodiments, some of R6 or R7 substituents may be identical in one or more methylene groups.
[0053] In one embodiment, the present invention relates to a compound of Formula I, wherein
X is selected from the group consisting of O, N and S;
Z is N
Y is =O or tautomers thereof;
SPU is a spacer unit providing a distance d between Z and N wherein -SPU- is -(CR6R7)n- A-, n is 3, and A is absent;
N together with R1 and R2 form a piperidine ring substituted with one or more substituents R4 selected from the group consisting of hydroxy, halogen, Cι_8-alkyl, C3.s-cycloalkyl, Cι.g-alkoxy, Cι.g-alkylcarbonyl, Cι.g-alkylidene, C2-8-alkenyl, C2.8-alkynyl, Cι.6-alkyloxyimino, and Cι.6- alkyloxyamino each of which may be optionally substituted with a substituent R5 and wherein at least one of said substituents R4 is R4 selected from the group consisting of Cι_g-alkyl, C3.g-cycloalkyl, -g-alkoxy, Ci-g-alkylidenec, each of which may be optionally substituted with a substituent R5; R5 is selected from the group consisting of hydrogen, halogen, hydroxy, Cι_8-alkyl, C].8- alkoxy, C3.8-cycloalkyl, C3.8-heterocyclyl, Cι.8-alkylcarbonyl, -g-alkylidene, C2.8-alkenyl and C2.8- alkynyl;
Rx may be absent or selected from the group consisting of hydrogen, optionally substituted Ci-g-alkyl;
R3 may be present 0-4 times and selected from the group consisting of halogen, hydroxy, optionally substituted Cι.8-alkyl, Ci-g-alkoxy, optionally substituted Cι.8-alkylidene, optionally substituted C2-8-alkenyl, optionally substituted C2.8-alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3.g-cycloalkyl, optionally substituted C3.8- heterocyclyl, and optionally substituted Cι_8-alkylcarbonyl; and each R6 and each R7 is optionally and independently selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted Cι_8-alkyl, C3.8-cycloalkyl,
[0054] In certain embodiments of compound of Formula I, Z is N (nitrogen). Thus, the distance d relates to the distance between the ring nitrogen atom and the nitrogen atom of N(R*)R2.
[0055] In compounds of Formula I, X may be selected from the group consisting of N, S, and O, preferably N and O. In a preferred embodiment X and Z are both N.
[0056] In a suitable embodiment of compounds of Formula I, -Y is selected from the group consisting of =0, =S and tautomers thereof. Tautomers of the carbonyl and thiocarbonyl moiety are known to the person skilled in the art and are isomers involving migration of the pi system from the exo-cyclic to the endocyclic position. The enolic or thio-enolic derivative may be O- or S-alkylated in a manner known to the person skilled in the art.
[0057] In a preferred embodiment however, -Y is =O or its tautomer. Preferably -Y is =O. Thus, in a combination of preferred embodiments, X is N, -Y is =0, and Z is N, resulting in a benzimidazolidinone ring system.
[0058] The moiety Z is substituted with a spacer unit (SPU). SPU provides a distance d between Z and N. The distance d is formed from a short, optionally substituted aliphatic chain, (CR6R7)n, wherein n is in the range 1 to 5, such as 1, 2, 3, 4 or 5 or from said chain and a -C3.8- cycloalkyl- ring. Thus, d may be defined in terms of through-bond distances between Z and N of N(R!)R2 or a combination of through-bond and through-space distances between Z and N of N(R')R2. Thus, -SPU- is a biradical selected from the group consisting of -(CR6R7)n-A- and -C3.8- cycloalkyl- wherein n is in the range 1 to 5 and
[0059] A is absent or an optionally substituted -C3.8-cycloalkyl. Preferably, n is in the range 2 to 5, most preferably 2 to 4, such as 2, 3, or 4.
[0060] In an interesting embodiment of the present invention, the C3.8-cycloalkyl- ring of -SPU- is an optionally substituted cyclohexylene. Thus, -SPU- may be selected from the group consisting of -(CR4R5)n-A- and an optionally substituted cyclohexylene wherein n is in the range 1 to 5, preferably 2 to 5 and A is absent or an optionally substituted cyclohexylene. [0061] In an interesting embodiment, -SPU- is an ethylene, propylene, butylene, or pentylene biradical, preferably ethylene, propylene or butylene, each of which may be optionally substituted. Alternatively, -SPU- is a cylcohexylene biradical.
[0062] The cyclohexylene of -SPU- may be an optionally substituted 1,3- cyclohexylene or an optionally substituted 1,4-cyclohexylene, preferably an optionally substituted 1,4-cyclohexylene. That is to say that in the embodiment where SPU is or comprises of a cyclohexylene, said cyclohexylene is preferably bond to Z and N at positions 1 and 4 or 1 and 3 of said ring.
[0063] As stated, N together with R1 and R2 form a heterocyclic ring wherein said heterocyclic ring is selected from the group consisting of perhydroazocine, perhydroazepine, piperidine, pyrrolidine, azetidine, aziridine and 8-azabicyclo[3.2.1]octane. In a preferred embodiment, N(R*)R2 is selected from the group consisting of a piperidine, pyrrolidine, and azetidine, most preferably piperidine and pyrrolidine, particularly preferably piperidine.
[0064] The heterocyclic ring formed by N together with R1 and R2 is substituted with one or more substituents R4 selected from the group consisting of hydroxy, halogen, Cι_8-alkyl, C3.8- cycloalkyl, Cμ8-alkoxy, Cι_8-alkylcarbonyl, Cι_8-alkylidene, C2.g-alkenyl, C2.g-alkynyl, C ._- alkyloxyimino, and Cι_g-alkyloxyamino each of which may be optionally substituted with a substituent R5 and at least one of said substituents R4 is R4 selected from the group consisting of Cι_ 8-alkyl, C3.g-cycloalkyl, Cι_8-alkoxy, Cι.g-alkylcarbonyl, Cι_g-alkylidene, C2.g-alkenyl, C2.g-alkynyl, Cι.8-alkyloxyimino, and Cι.8-alkyloxyamino each of which may be optionally substituted with a substituent R5.
[0065] Thus, the heterocyclic ring formed by N together with R1 and R2 may be substituted with one or more substituent R4 wherein at least one R4 is R4.
[0066] As stated, the heterocyclic ring formed by N together with R1 and R2 is substituted with one more substituent R4. In a preferred embodiment, the heterocyclic ring is selected from the group comprising of a piperidine with at least one substituent R4 in the 2-position, a piperidine with at least one substituent R4 in the 3 -position, a piperidine with at least one substituent R4 in the 4-position, a pyrrolidine with at least one substituent R4 in the 3 -position, an azetidine with at least one substituent R4 in the 3 -position and an aziridine with at least one substituent R4' in the 2-position.
[0067] In a particularly suitable embodiment, N(RX)R2 is selected from the group consisting of a piperidine with at least one substituent R4 in the 2-position, a piperidine with at least one substituent R4 in the 3 -position, a piperidine with at least one substituent R4 in the 4-position, most preferably consisting of a piperidine with at least one substituent R4 in the 4-position.
[0068] In the preferred embodiment wherein N together with R1 and R2 form a piperidine with at least one substituent R4 in the 4-position, N(R:)R2 may be defined as wherein R4 is selected from the group consisting of hydrogen, hydroxy, halogen, Cι„8-alkyl, C3.g- cycloalkyl, Cμg-alkoxy, Cι.8-alkylcarbonyl, Cι.8-alkylidene, C2.g-alkenyl, and C2.g-alkynyl each of which may be optionally substituted with a substituent R5 and wherein R4 is selected from the group consisting of Cι.8-alkyl, C3.8-cycloalkyl, Cμg-alkylidene,
C2.g-alkenyl, and C2-8-alkynyl each of which may be optionally substituted with a substituent R5; and
R5 is selected from the group consisting of hydrogen, halogen, hydroxy, Cι_g-alkyl, C3.8-cycloalkyl,
Cι.g-alkylidene, C2.g-alkenyl and C2-8-alkynyl.
[0069] In a preferred embodiment, R4 is selected from the group consisting of hydrogen, hydroxy and halogen most preferably hydrogen and hydroxy and Rs substituted C\._- alkyl.
[0070] The one or more substituent R4 may be selected from the group consisting of Cι.g-alkyl, C3.g-cycloalkyl, Cι.8-alkylidene, each of which may be optionally substituted with a substituent R5. In a combination of preferred embodiments, the one or more substituent R4 may be selected from the group consisting of a -g-alkyl, and C3.8-alkylidene, each of which may be optionally substituted with a substituent R5 wherein R5 is selected from the group consisting of hydrogen, halogen, hydroxy, Cι.g-alkyl and C3.g-cycloalkyl.
[0071] Most preferably, R5 is selected from the group consisting of hydrogen, halogen, hydroxy, Cι.8-alkyl, C3.8-cycloalkyl, C3.8-heterocyclyl, Cι_g-alkylcarbonyl, Cι_8-alkylidene, C2-8- alkenyl and C2.8-alkynyl. particularly hydrogen, hydroxy, halogen and -g-alkyl.
[0072] In a particularly preferred embodiment, R4 is selected from the group consisting of propyl, propylidene, butyl, butylidene, pentyl and pentylidene, each of which may be optionally substituted. In a most preferred embodiment, R4 is selected from the group consisting of butyl, a pentyl and 3-(Cι.g-alkyl)-butylidene, each of which may be optionally substituted.
[0073] As will be clear to the person skilled in the art, embodiments of compound I may be chiral or comprised of one or more chiral centres. Where the compounds according to the invention have at least one chiral center, they may exist as a racemate, enantiomers or diastermeomers. It should be noted that all such isomers and mixtures thereof are included in the scope of the present invention. Furthermore, some of the crystalline forms for compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds of the present invention may form solvates with water (i.e. hydrates) or common organic solvents. Such solvates are also included in the scope of this invention. [0074] Where the processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, such isomers may be separated by conventional techniques such as preparative chiral cliromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by stereoselective synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di- ?-toluoyl-tf-tartaric acid and/or (+)-di- ?-toluoyl-/-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.
[0075] During any of the processes for preparation of the compounds of the present invention, it may be necessary or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
[0076] The term Rx relates to a substituent of the term X and may be absent or selected from the group consisting of hydrogen, Cι_g-alkyl, C3.8-cycloalkyl, CH2-N(R5)(R5), CH2- OR5, CH2-SRS, CH2-0-C(=0)R5, CH2-O-C(=S)R5;wnerein R5 [_ selected from the group consisting of hydrogen, halogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3.8-cycloalkyl, optionally substituted C3.8-heterocyclyl, optionally substituted Cι_8- alkyl, optionally substituted Ci-g-alkylidene, optionally substituted C2.g-alkenyl, optionally substituted C2.8-alkynyl and optionally substituted Cι_8-alkylcarbonyl. In a preferred embodiment, Rx is selected from the group consisting of hydrogen, Cι.g-alkyl, CH2-N(R5)(R5), CH2-OR5, and CH2-O-C(=O)R5. The nature of Rx depends on X. It is intended to serve so as to make a prodrug of the molecule, to increase its bioavailability, or to lower the reactivity of the term X, such as in a protective group. In a suitable embodiment, Rx is a Cι.g-alkyl such as methyl, ethyl, propyl, butyl, pentyl, or hexyl, typically methyl, ethyl or propyl.
[0077] As can be derived from the Examples and from the disclosure herein, the compounds according to Formula I are intended for use as a pharmaceutical. Thus, a further aspect of the invention relates to a pharmaceutical composition comprising a compound as described herein, together with pharmaceutically acceptable carriers or excipients. Excipients and carriers will depend on, amongst other factors, the route of administration of the compound.
[0078] Compounds of the present invention may be administered in any of the foregoing compositions and according to dosage regimens established in the art whenever specific pharmacological modification of the activity of muscarinic receptors is required. [0079] The present invention also provides pharmaceutical compositions comprising one or more compounds of Formula I together with a pharmaceutically acceptable diluent or excipient. Preferably such compositions are in unit dosage forms such as tablets, pills, capsules (including sustained-release or delayed-release formulations), powders, granules, elixirs, tinctures, syrups and emulsions, sterile parenteral solutions or suspensions, aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral (e.g., intravenous, intramuscular or subcutaneous), intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation, and may be formulated in an appropriate manner and in accordance with accepted practices such as those disclosed in Remington's Pharmaceutical Sciences, Gennaro, Ed., Mack Publishing Co., Easton PA, 1990. Alternatively, the compositions may be in sustained- release form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. The present invention also contemplates providing suitable topical formulations for administration to, e.g., eye or skin or mucosa.
[0080] For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, flavoring agents and coloring agents can also be incorporated into the mixture. Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include, without limitation, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
[0081] For preparing solid compositions such as tablets, the active ingredient is mixed with a suitable pharmaceutical excipient, e.g., such as the ones described above, and other pharmaceutical diluents, e.g., water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. By the term "homogeneous" is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. The solid preformulation composition may then be subdivided into unit dosage forms of the type described above containing from 0.1 to about 50 mg of the active ingredient of the present invention. The tablets or pills of the present composition may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner core containing the active compound and an outer layer as a coating surrounding the core. The outer coating may be an enteric layer, which serves to resist disintegration in the stomach and permits the inner core to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with conventional materials such as shellac, cetyl alcohol and cellulose acetate.
[0082] The liquid forms in which the present compositions may be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical carriers. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, gelatin, methylcellulose or polyvinyl-pyrrolidone. Other dispersing agents, which may be employed, include glycerin and the like. For parenteral administration, sterile suspensions and solutions are desired. Isotonic preparations, which generally contain suitable preservatives, are employed when intravenous administration is desired. The compositions can also be formulated as an ophthalmic solution or suspension formation, i.e., hOeve drops, for ocular administration.
[0083] Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses two, three or four times daily. Furthermore, compounds for the present invention may be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to persons skilled in the art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
[0084] The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound employed. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the disease or disorder, which is being treated.
[0085] The daily dosage of the products may be varied over a wide range from 0.01 to 100 mg per adult human per day. For oral administration, the compositions are preferably provided in the form of tablets containing 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0 or 50.0 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. A unit dose typically contains from about 0.001 mg to about 50 mg of the active ingredient, preferably from about 1 mg to about 10 mg of active ingredient. An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.0001 mg/kg to about 25 mg/kg of body weight per day. Preferably, the range is from about 0.001 to 10 mg/kg of body weight per day, and especially from about 0.001 mg/kg to 1 mg/kg of body weight per day. The compounds may be administered on a regimen of 1 to 4 times per day.
[0086] Compounds according to the present invention may be used alone at appropriate dosages defined by routine testing in order to obtain optimal pharmacological effect on a muscarinic receptor, in particular the muscarinic Mi or M4 receptor subtype, while minimizing any potential toxic or otherwise unwanted effects. In addition, co-administration or sequential administration of other agents, which improve the effect of the compound, may, in some cases, be desirable.
[0087] The pharmacological properties and the selectivity of the compounds of this invention for specific muscarinic receptor subtypes may be demonstrated by a number of different assay methods using recombinant receptor subtypes, preferably of the human receptors if these are available, e.g., conventional second messenger or binding assays. A particularly convenient functional assay system is the receptor selection and amplification assay disclosed in US 5,707,798 describing a method of screening for bioactive compounds by utilizing the ability of cells transfected with receptor DNA, e.g., coding for the different muscarinic subtypes, to amplify in the presence of a ligand of the receptor. Cell amplification is detected as increased levels of a marker also expressed by the cells.
[0088] An important aspect of the present invention relates to a method of increasing an activity of a cholinergic receptor comprising contacting the cholinergic receptor or a system containing the cholinergic receptor with an effective amount of at least one compound of Formula I, as defined supra. The present investigators have surprisingly found that the compounds of Formula I act as cholinergic agonists and, most remarkably, the compounds of Formula I are selective for the either the Mi or Mt, or both the Mi and M4 muscarinic receptor subtypes.
[0089] Furthermore, beyond the remarkable selectivity of the compounds of the present invention for the Mi and M4 muscarinic receptor subtypes, the present investigators have surprisingly found that compounds of Formula I further act as dopaminergic D2 antagonists or D2 inverse agonists.
[0090] As was discussed earlier, this combined activity (Mi and M4 agonism, dopaminergic D2 antagonism) is an attractive method of treating an array of mental disorders. Consequently, a further important aspect of the present invention relates to a method of treating or preventing a mental disorder in a mammal, such as a human, comprising the administration of an effective amount of a compound of Formula I.
[0091] Disorders considered to be suitable for treatment by either Mi and/or M4 agonism, or combined M1/M4 agonism and dopaminergic D2 antagonism are selected from the group consisting of cognitive impairment, forgetfulness, confusion, memory loss, attentional deficits, deficits in visual perception, depression, pain, sleep disorders, psychosis, and increased intraocular pressure. [0092] Further, suitable disorders considered to be suitable and particularly attractive may be selected from the group consisting of neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Down Syndrome, Pick disease, dementia, clinical depression, age-related cognitive decline, attention-deficit disorder, sudden infant death syndrome, and glaucoma.
[0093] Furthermore the compounds of this invention are useful in the treatment of mania, bipolar disorder, unipolar disorder, schizoaffective disorder, schizophreniform disorder and anxiety. It should be noted that other non-schizophrenic causes of psychosis, including drug induced, those associated with dementia and other neurodegenerative disorders (such as Huntington's) are also anticipated to be suitable.
[0094] The Tic disorders also include a spectrum of disorders including Tourettes and
OCD.
[0095] The affective disorder spectrum, including unipolar, bipolar are also anticipated to be suitable for treatment using compounds of Formula I.
[0096] An important aspect of the invention therefore relates to the use of a compound according or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the preparation of a medicament for the prophylactic or curative treatment of psychosis or alleviation of symptoms associated with psychosis.
[0097] The medicament acts, at least in part, as an Mi agonist or as Mi and M4 agonist.
The compound according to Formula I may further act as a D2 antagonist. Thus, an important aspect of the invention relates to a use of compounds of Formula I as Mi and M4 agonist, as well as D2 antagonists. Illustrative examples of compounds with this combined activity are tabulated in Example 1.
[0098] Compounds 61KS19, 45NK70, 45NK71, 45NK110, 61KS12 and 61KS13 have high binding efficacy for the Mi and M4 receptor subtypes. Moreover, compounds of Formula I have high selectivity for the Mi and M4 receptor subtypes over M2, M3, M5 receptor subtypes. Further, compounds of Formula I have D2 antagonistic activity.
[0099] As discussed in Felder et al (J Med. Chem. 2000), muscarinic receptors may be implicated in the control of amyloid precursor processing, in particular by activation of the Mi receptor. Thus, a further aspect of the present invention relates to a method of modulating or preventing the progression or formation of amyloid plaques in an individual susceptible to or affected by Alzheimer's Disease by administering an effective amount of a compound of Formula I, said effective amount sufficient to modulate amyloid precursor protein processing.
EXAMPLES [0100] Embodiments of the present invention is disclosed in further detail in the following examples, which are not in any way intended to limit the scope of the invention as claimed.
Example 1 : Screening Assay
[0101] In the present example, methods for R-SAT and radioligand binding are described. In addition, screening of test compounds in assays using muscarinic receptor subtypes Mi and ML4 and dopamine receptor subtype D2 are described.
Methods
[0102] The Mi and M4 muscarinic receptor subtypes were cloned substantially as described by Bonner et al., (1987) Science 273 p. 527 and Bonner et al, (1988) Neuron 1, p. 403. R- SAT assays were carried out substantially as described in U.S. 5,707,798 and by Braϋner-Osborne, H.B. and Brann, M.R. (1995), Eur. J. Pharmacol 295:93-102. NIH-3T3 cells (available from the American Type Culture Collection as ATCC CRL 1658) were transfected with plasmid DNA encoding the ml and m4 receptors and plasmid DNA encoding β-galactosidase. Transfected cells were grown in the presence of between 1 nM and 40 μM of the test compound for 5 days. On day 5, the cells were lysed using 0.5% nonidet-P and β-galactosidase expression was quantified using the chromogenic substrate o-nitrophenyl-β-D-galactoside (ONGP).
[0103] Data were normalized relative to the maximum response of the cells to the muscarinic agonist carbachol, and the following equation was fitted to the data:
response = minimum + (maximum - minimum)/(l + ([ligand]/EC5o))
% Efficacy was defined as (maximum - minimum)/(maximum response of cells to carbachol). PEC50 = -log (EC50). Where data gave a bell-shaped curve, "maximum" was defined as the highest observed response.
[0104] The D2 dopamine receptor subtype was cloned substantially as described by
Stormann, Gdula, Weiner and Brann, 1990 [Mol Pharmacol 37, 1-6]. Cell membranes expressing the D2 receptor were prepared by transfecting tSA cells (Chahine, M., Bennet, P. B., George, A. L., Horn, R. (1994) Pfluegers Arch. 427, 136-142) with 10 μg plasmid DNA encoding the human dopamine D2 receptor and 40 μl Superfect (Qiagen). The cells were harvested 48 hours and transfection and membranes were prepared by homogenizing the cells using a Polytron harvester in 20 mM Hepes, 10 mM EDTA, pH 7.4. The homogenate was centrifuged for 30 minutes at 37,000g. The pellet was homogenized again in 60 ml 20 mM Hepes, 5 mM EDTA. The homogenate was centrifuged for 30 minutes at 37,000g. The supernatant was discarded. The pellet was homogenized again in 10 ml 20 mM Hepes, 1 mM EDTA. The resultant membranes were frozen at -80°C.
[0105] The membranes were combined with 150 pM [3H]-Spiperone (Amersham- Pharmacia, 107 Ci/mmol) and ligand concentrations between 1 nM and 10 μM, or haloperidol concentrations between 0.1 nM and 1 μM in 460 μl 20 mM Hepes, 1 mM EDTA, 0.1% (w/v) bovine serum albumin. Nonspecific binding was defined as binding in the presence of 1 μM haloperidol. The membranes were incubated for 4 hours at 37°C, and then filtered onto Packard GFB Filterplates using a Packard harvester. The membranes were dried and 50 μl Microscint (Packard) was added to each well. The amount of bound radioligand was quantified using a Packard Topcount scintillation counter.
[0106] Data were normalized relative to the maximum inhibition of [3H]-Spiperone binding by 1 μM haloperidol, and the following equation was fitted to the data:
% inhibition = minimum + (maximum - minimum)/(l + ([ligand]/[IC5o]))
% inhibition was defined as (maximum - minimum)/(maximum response of cells to haloperidol). PIC50 = -log (IC50). NT= not tested.
Results
Example 2: Behavioral Studies
Methods Animals
[0107] Male Non-Swiss Albino mice (Harlan Sprague-Dawley) were housed (4 mice/cage) in rooms with temperature and humidity controlled and water and food (Harlan Teklad) freely available. Mice were kept on a 12-hr lightdark cycle. Procedure Locomotor Activity
[0108] Plastic 20x20x30cm activity cages were equipped with photocell beams (AccuScan Instruments). For spontaneous activity, 61KS19 (1, 3 and 10 mg/kg) was administered alone i.p. 30 min before the session. For hyperactivity experiments, mice were treated with 0.3 mg/kg dizocilpine, 3.0 mg/kg d-amphetamine or 3.0 mg/kg scopolamine i.p. 15 min before the session (15 min after 61KS19). Locomotor data were collected during a 15 min session without habituation in a lit room. Each dose combination was tested in a separate group of animals (n=8). Distance traveled (cm) was calculated and averaged followed by ANOVA and post-hoc Dunnett's t-test comparisons.
Catalepsy
[0109] A custom-built 8-mm rod that is raised 3.5 cm from the lab benchtop was used. 61KS19 (10 mg/kg) or haloperidol (1 mg/kg) were administered i.p. 60 min before the start of the session. The forepaws of each animal is placed on the rod and the time to step down is measured. If the animal steps off immediately, another attempt is made until the animal stays on for more than 10 sec or 10 attempts have been made. A maximum of 2 min is allowed at which time the animal is taken away from the rod and returned to the homecage. Each dose or dose combination was tested in a separate group of animals (n=6). Averages and standard errors were calculated and compared using an ANOVA and post-hoc Dunnett's t-tests. Example 3 : Synthetic Procedures
3.1 General preparative LC-MS procedure
[0110] Preparative purification was performed on a Waters auto purification system ( 600 pumps, 2700 sample manager, 996 PDA detector, ZMD massspectrometer).
[0111] The columns used were YMC C18 J'sphere ODS H80. Buffer A was 0.15% TFA in water, buffer B was 0.15% TFA in acetonitrile/water 95/5. The columns were operated at 17 ml/min. Following an initial hold of 2.5 min at 30% buffer B, compounds were separated using a gradient af 30-100% buffer B in 8.5 min. A dual column setup with two pumps was used to equilibrate one column, while running on the other.
3.2 3-Trifluorosulfonyl-8-tgrtButyloxycarbonyl-8-azabicyclo[3.2.11-oct-2-ene (N-Boc- nortropanone enol triflate (104KS22 .
[0112] LDA was generated by adding BuLi (20 mL, 1.68M, 32.6 mmol) to a solution of diisopropylamine (2.38 g, 32.6 mmol) in dry THF (lOmL) at -78°C under argon. The mixture was kept at that temperature for 30 min followed by the addition of a solution of N- Bocnortropinone (5.27 g, 23.4 mmol) in dry THF (20 mL). The mixture was then left stirring for lh while maintaining the temperature at 78°C. Then a solution of 2-[N,N- Bis(trifluoromethylsulfonyl)amino]-5-chloropyridine (10.08 g, 25.7 mmol) in dry THF (20 mL) and the mixture was slowly allowed to reach room temperature overnight and subsequently concentrated and exposed to column chromatography (Si02; EtO Ac/heptane 1:6, Rf(producf) = 0.31) to give the title compound (104KS22) (6.68 g, 80%) which on prolonged standing crystallised into a white solid. !H NMR (CDC13) δ 1.43 (s, 9H, Boc-CHs), 1.72 (m, IH), 1.93-2.03 (m, 2H), 2.07 (d, J=16.6Hz, IH), 2.23 (broad m, IH), 3.05 (broad s, IH), 4.42 (broad m, 2H, H1+H5), 6.10 (broad s, IH, H2). 13C NMR (CDC13) δ 28.4 (Boc CH3), 30.1 and 29.2 (rotameric), 34.7 and 34.9 (rotameric), 36.5 and 37.1 (rotameric), 51.9, (broad s), 80.5 ((CH3)3C-), 118.7 (-CF3, q, J=300Hz), 124.0 (broad s, C2), 148.0 (broad s, C3), 153.9 (Boc C=0).
3.3 General Procedure 1 (GPP
[0113] To a mixture of 3-Trifluorosulfonyl-8-tertButyloxycarbonyl-8- azabicyclo[3.2.1]-oct-2-ene (104KS22) (0.107 g, 0.3 mmol, 1.0 equiv) , Cul (0.011 g, 0.05 moles, 0.20 equiv), dimethylethylamine (0.219 g, 3.0 mmol, 10 equiv) and the alkyne (2.0 equiv) in dry THF (3 mL) was added (PPh3)4Pd (0.10 equiv) at room temperature under argon. The mixture was shaken for 2 h followed by filtration and concentration. The residual syrup was taken up in DCM (2 mL) followed by careful addition of TFA (0.5 mL). The mixture was shaken for 10 min before it was concentrated, basified with NaOH (2M, 3 mL), extracted (EtO Ac), concentrated and put on an ionexchange column (Varian BondElut®-SCX, H+). Elution with 2.5 % NH4OH in MeOH and concentration gave the desired product.
3.4 3-Pent-l-vnyl-8-azabicvclor3.2.11oct-2-ene (79KS36-5)
[0114] 3-Trifluorosulfonyl-8-tgrtButyloxycarbonyl-8-azabicyclo[3.2.1]-oct-2-ene (104KS22) (0.107 g, 0.3 mmol) and Pent-1-yne (0.041 g, 0.6 mmol) were reacted according to GPl to give the title compound (79KS36-5) (0.033 g, 62%). HPLC-MS (ammonium acetate): [M+H]+= 176.23
3.5 3-Hex-l-vnyl-8-azabicvclor3.2.11oct-2-ene (79KS36-6)
[0115] 3-Trifluorosulfonyl-8-tertButyloxycarbonyl-8-azabicyclo[3.2.1]-oct-2-ene (104KS22) (0.107 g, 0.3 mmol) and Hex-1-yne (0.049 g, 0.6 mmol) were reacted according to GPl to give the title compound (79KS36-6) (0.049 g, 86 %). HPLC-MS (ammonium acetate): [M+H]+= 190.26
3.6 3-Hept-l-vnyl-8-azabicvclor3.2.11oct-2-ene (79KS36-7)
[0116] 3-Trifluorosulfonyl-8-tertButyloxycarbonyl-8-azabicyclo[3.2.1]-oct-2-ene (104KS22) (0.107 g, 0.3 mmol) and Hept-1-yne (0.058 g, 0.6 mmol) were reacted according to GPl to give the title compound (79KS36-7) (0.051 g, 84%). HPLC-MS (ammonium acetate): [M+H]+= 204.28
3.7 4-(8-Azabicvclof3.2. lloct-2-en-3 -yl)-but-3 -yn- 1 -ol (79KS36-2)
[0117] 3-Trifluorosulfonyl-8-tertButyloxycarbonyl-8-azabicyclo[3.2.1]-oct-2-ene (104KS22) (0.107 g, 0.3 mmol) and But-3-yn-l-ol (0.042 g, 0.6 mmol) were reacted according to GPl to give the title compound (79KS36-2) (0.018 g, 34%). HPLC-MS (ammonium acetate): [M+H]+= 178.21
3.8 5-(8-Azabicyclor3.2.11oct-2-en-3-ylVpent-4-vn-l-ol (79KS36-3)
[0118] 3-Trifluorosulfonyl-8-tertButyloxycarbonyl-8-azabicyclo[3.2. l]-oct-2-ene (104KS22) (0.107 g, 0.3 mmol) and Pent-3-yn-l-ol (0.050 g, 0.6 mmol) were reacted according to GPl to give the title compound (79KS36-3) (0.045 g, 79%). HPLC-MS (ammonium acetate): [M+H]+= 192.23
3.9 General Method 2 , GP2
[0119] To a slurry of Cul (2.0 equiv) in dry THF (5 mL) was added R-M (R=alkyl, M=Li or MgX) (4.0 equiv) at -25 °C and stirred at that temperature for 30 min before adding a solution of 3-Trifluorosulfonyl-8-tertButyloxycarbonyl-8-azabicyclo[3.2.1]-oct-2-ene (104KS22) (1.0 equiv) in dry THF (5 mL). The reaction mixture was kept stirring at -25°C for 2 h before the cooling was removed. The reaction was then quenched by firstly addition of water (20 mL) and secondly addition of a saturated aqeuous solution of NHL4CI (20 mL) before extraction with DCM. The combined organic phase was washed with a saturated aqeuous solution of NH4CI, dried (Na2SO4), filtered and concentrated in vacuo to give the crude product. This was then purified by column chromatography (Si02; EtO Ac/heptane 1:10 which gave the desired products
3.10 8-tertButyloxycarbonyl-3-propyl-8-aza-bicvclor3.2. l]oct-2-ene (79KS74).
[0120] Cul (0.234 g, 1.23 mmol), PrMgBr (1.3mL, 2.0M, 2.46 mmol) 3- Trifluorosulfonyl-8-tertButyloxycarbonyl-8-azabicyclo[3.2.1]-oct-2-ene (104KS22) (0.220 g, 0.616 mmol) were reacted according to GP2 to give the title compound (79KS74) (0.083 g, 54%). !H NMR (CDCI3) δ 0.84 (t 3H, J=7.1Hz, -CH2CH2CH3), 1.36 (sixt, 2H, J=7.1Hz, -CH2CH2CH3), 1.43 (s, 9H, Boc-CH3), 1.56 (dt, IH, J=7.0Hz, 13.2Hz), 1.64 (d, IH, J=17.0Hz), 1.76 - 1.96 (m, 4H),
2.11 (m, IH), 2.67 (d, IH, J=17.0Hz), 4.18 - 4.34 (m, 2H), 5.68 (d, IH, J=4.8Hz, H2); 13C NMR (CDC13) δ 13.7 (-CH2CH2CH3), 20.7 (-CH2CH2CH3), 28.6 (Boc-CH3), 30.0, 34.9, 37.4, 38.5 (- CH2CH2CH3)5 52.3, 53.3, 79.2 (-C(CH3)3), 126.6, 135.4 (C2, C3), 154.4 (CO).
3.11 8-tgrtButyloxycarbonyl-3-butyl-8-aza-bicvclo 3.2.11oct-2-ene (79KS61)
[0121] Cul (0.289 g, 1.52 mmol), BuLi (1.9mL, 1.6 M, 3.03 mmol) 3-
Trifluorosulfonyl-8-tertButyloxycarbonyl-8-azabicyclo[3.2.1]-oct-2-ene (104KS22) (0.271 g, 0.758 mmol) were reacted according to GP2 to give the title compound (79KS61) (0.104 g, 52%). *H NMR (CDC ) δ 0.82 (t, 3H, J=7.2Hz, -CH2CH2CH2CH3), 1.14 - 1.34 (m, 4H), 1.40 (s, 9H, Boc- CH3), 1.53 (dt, IH, J=7.6Hz, 13.3Hz), 1.61 (d, IH, J=17.1Hz), 1.72 - 1.92 (m, 4H), 2.07 (m, IH), 2.64 (d, IH, J=17.1Hz), 4.14 (m, 2H), 5.64 (d, IH, J=4.6H, H2); 13C NMR (CDC13) δ 14.1 (- CH2CH2CH2CH3) , 22.3 (-CH2CH2CH2CH3), 28.6 (Boc-CH3), 29.7 (-CH2CH2CH2CH3), 30.0, 34.8, 36.1 (-CH2CH2CH2CH3), 37.5, 52.3, 53.3, 79.1 (-C(CH3)3), 126.4, 135.6 (C2, C3), 154.4 (C=0).
3.12 8-tgrtButyloxycarbonyl-3-pentyl-8-aza-bicvclor3.2.11oct-2-ene (79KS94)
[0122] Cul (0.712 g, 3.74 mmol), pentyl-MgBr (3.8 mL, 2.0 M, 7.48 mmol) 3- Trifluorosulfonyl-8-tgrtButyloxycarbonyl-8-azabicyclo[3.2.1]-oct-2-ene (104KS22) (0.669 g, 1.87 mmol) were reacted according to GP2 to give the title compound (79KS94) (0.238 g, 46 %). *H NMR (CDC13) δ 0.87 (t, 3H, J=7.2Hz, -CH2CH2CH2CH2CH3), 1.15 - 1.38 (m, 6H), 1.44 (s, 9H, B0C-CH3), 1.57 (dt, IH, J=8.0Hz, J=12.0Hz), 1.65 (d, IH, J=17.1Hz), 1.76 - 1.96 (m. 4H), 2.06 - 2.17 (m, IH), 2.68 (d, IH, J=17.1Hz), 4.22 - 4.32 (m, 2H), 5.68 (d, IH, J=5.0Hz, H2); 13C NMR (CDCI3) δ 14.2 (-CH2CH2CH2CH2CH3), 22.7 (-CH2CH2CH2CH2CH3), 27.2 (- CH2CH2CH2CH2CH3), 28.6 (Boc-CH3), 30.0, 31.5 (-CH2CH2CH2CH2CH3), 34.9, 36.4 (- CH2CH2CH2CH2CH3), 37.5, 52.3, 53.3, 79.2 (-C(CH3)3), 126.4, 135.7 (C2, C3), 154.4 (C=0). 3.13 8-tgrtButyloxycarbonyl-3-hexyl-8-aza-bicyclo 3.2. l]oct-2-ene , 79KS79)
[0123] Cul (0.234 g, 1.23 mmol), hexyl-MgBr (1.23 mL, 2.0 M, 7.48 mmol) 3-
Trifluorosulfonyl-8-tgrtButyloxycarbonyl-8-azabicyclo[3.2.1]-oct-2-ene (104KS22) (0.220 g, 0.616 mmol) were reacted according to GP2 to give the title compound (79KS79) (0.073 g, 40%). H NMR (CDC13) δ 0.85 (t, 3H, J=6.7Hz, -CH2CH2CH2CH2CH2CH3), 1.14 - 1.38 (m, 8H), 1.42 (s, 9H, B0C-CH3), 1.50 - 1.60 (m, IH), 1.63 (d, IH, J=16.8Hz), 1.74 - 1.94 (m, 4H), 2.03 - 2.17 (m, IH), 2.65 (br s, IH), 4.25 (br s, 2H), 5.65 (br s, IH, H2); 13C NMR (CDC13) δ 14.2 (- CH2CH2CH2CH2CH2CH3), 22.8 (-CH2CH2CH2CH2CH2CH3), 27.5 (-CH2CH2CH2CH2CH2CH3), 28.6 (B0C-CH3) , 28.9 (-CH2CH2CH2CH2CH2CH3), 30.1, 31.9 (-CH2CH2CH2CH2CH2CH3), 34.8, 36.4 (-CH2CH2CH2CH2CH2CH3), 37.6, 52.3, 53.2, 79.2 (-C(CH3)3), 126.3, 135.9 (C2, C3), 154.4 (C=0).
3.14 General Procedure 3 (GP3)
[0124] The alkene (1.0 equiv) was dissolved in MeOH (3 mL) and Pd(l 0%)/C (tip of a spatula) was added. H2 (1 atm., balloon) was applied under stirring. The reaction mixture was left stirring for 2.5 h before it was filtered through a pad of celite and concentrated in vacuo to give the desired products which was pure enough for further reaction.
3.15 8-tβrtButyloxycarbonyl-3 -propyl-8-aza-bicyclo [3.2.1] octane (79KS75)
[0125] 8-tgrtButyloxycarbonyl-3-propyl-8-aza-bicyclo[3.2.1]oct-2-ene (79KS74)
(0.039 g, 0.155 mmol) was reacted according to GP3 to give the title compound (79KS75) (0.030 g, 76 %). XH MR (CDCI3) δ 0.86 (t, 3H, J=7.5Hz, -CH2CH2CH3), 1.08 - 1.17 (m, 2H), 1.20 - 1.36 (m, 4H), 1.44 (s, 9H, B0C-CH3), 1.52 (m, 2H, J=13.8Hz), 1.56 - 1.64 (m, 2H), 1.70 - 1.82 (m, IH), 1.86 - 1.94 (m, 2H), 4.05 (br s, 2H, H2); 13C NMR (CDCI3) δ 14.4 (-CH2CH2CH3) , 20.0 (- CH2CH2CH3), 28.2, 28.4, 28.7 (Boc-CH3), 38.0, 39.5, 53.8, 79.0 (-C(CH3)3), 153.7 (C=0).
3.16 8-tgrtButyloxycarbonyl-3-butyl-8-aza-bicvclor3.2.11octane (79KS92)
[0126] 8-tertButyloxycarbonyl-3-butyl-8-aza-bicyclo[3.2.1]oct-2-ene (79KS61) (0.047 g, 0.177 mmol) was reacted according to GP3 to give the title compound (79KS92) (0.045 g, 95%). 'HNMR (CDCI3) δ 0.86 (t, 3H, J=6.6Hz, -CH2CH2CH2CH3), 1.10 - 1.40 (m, 8H), 1.45 (s, 9H5 Boc- CHs), 1.47 - 1.56 (m, 2H, J=13.2), 1.56 - 1.64 (m, 2H), 1.68 - 1.82 (m, IH), 1.85 - 1.98 (m, 2H), 4.18 (m, 2H); 13C NMR (CDC13) δ 14.5 (-CH2CH2CH2CH3), 23.3 (-CH2CH2CH2CH3), 28.4, 28.7 (B0C-CH3), 29.0, 29.4 (-CH2CH2CH2CH3), 37.1 (-CH2CH2CH2CH3), 37.9, 38.7, 53.6, 54.4, 79.2 (- C(CH3)3), 153.9 (OO).
3.17 3-Pentyl-8-aza-bicvclor3.2.11octane (79KS95) [0127] 8-tert-Butyloxycarbonyl-3-pentyl-8-aza-bicyclo[3.2. l]oct-2-ene (79KS94)
(0.199 g, 0.712 mmol) was dissolved in CHC13 (3 mL) and TFA (1 mL) was added and the mixture was left stirring for 30 min. The mixture was then basified (2M NaOH), extracted (CHC13), dried (Na2S04), filtered and concentrated. The resultant syrup was reacted according to GP3 to give the title compound (79KS95) (0.126 g, 98 %). *H NMR (CDC13) δ 0.84 (t, 3H, J=7.1Hz, - CH2CH2CH2CH2CH3), 1.13 - 1.46 (m, 8H), 1.65 - 1.77 (m, 3H), 1.88 - 2.00 (m, 2H), 2.16 (ddd, 2H, J=5.3Hz, 8.3Hz, 13.5Hz), 3.62 (br s, 2H), 5.80 (br s, IH, NH); 13C NMR (CDC13) δ 14.2 (- CH2CH2CH2CH2CH3), 22.8 (-CH2CH2CH2CH2CH3), 28.0, 28.3, 28.7, 28.8, 32.0, 35.1, 37.6, 54.0 (C2+C5).
3.18 8-tgrt-Butyloxycarbonyl-3-hexyl-8-aza-bicvclor3.2. ηoctane (79KS81)
[0128] 8-tert-Butyloxycarbonyl-3-hexyl-8-aza-bicyclo[3.2. l]oct-2-ene (79KS79)
(0.035g, 0.119 mmol) was reacted according to GP3 to give the title compound (79KS81) (0.027 g, 77%). 'H NMR (CDC13) δ 0.85 (m, 3H, -CH2CH2CH2CH2CH2CH3). 1.10 - 1.40 (m, 11H), 1.45 (s, 9H, Boc-CHj), 1.51-1.55 (m, 2H), 1.58 - 1.63 (m, 2H), 1.69 - 1.82 (m, IH), 1.85 - 1.95 (m, 2H), 4.05 - 4.25 (m, 2H); 13C NMR (CDC13) δ 14.2 (-CH2CH2CH2CH2CH2CH3)5 22.8 (- CH2CH2CH2CH2CH2CH3), 26.9, 28.2, 28.5, 28.8 (Boc-CH3), 29.7, 32.1, 37.2, 37.7, 38.5, 53.5, 54.2, 79.0 (-C(CH3)3) , 153.7 (C=0).
3.19 General Method 4 (GP4)
[0129] NaH (55% in mineral oil, 5 equiv) was washed with heptane (2-10 mL) and covered with dry THF (5-20 mL). This was then stirred vigerously followed by the addition of a solution of l-tgrt-Butyloxycarbonylpiperidin-4-ol (1.0 equiv) in dry THF (5-20 mL) was carefully added. The stirring was continued for 30 min before adding an alkylhalide (1.2 equiv) in small portions. The stirring was continued for another 18h before quenching the reaction with water (10- 100 mL). Then the mixture was extracted (EtO Ac) followed by drying (Na2S0 ) of the combined organic phase. Filtration and concentration in vacuo gave a syrup which was purified by column chromatography (SiO2; EtOAc/heptane 1:6 which gave the desired products.
3.20 1 -tgrt-Butyloxycarbonyl-4-(prop-2-ene- 1 -oxyVpiperidine ( 104KS20)
[0130] NaH (16.4 g, 55% in mineral oil, 375 mmol), 1-tgrt- Butyloxycarbonylpiperidin-4-ol (15.1 g, 75.0 mmol) and allyl bromide (10.9 g, 90.0 mmol) were reacted according to GP4 to give the title compound (104KS20) (14.8 g, 82%). !H NMR (CDC13) δ 1.45 (s, 9H, B0C-CH3), 1.45 - 1.60 (m, 2H), 1.76 - 1.86 (m, 2H), 3.08 (ddd, 2H, J=4.1Hz, 9.5Hz, 13.4Hz), 3.45 - 3.54 (m, IH), 3.70 - 3.84 (m, 2H), 3.98 - 4.07 (m, 2H), 5.16 (m, 1H5 J=10.8Hz, - OCH2CH=CHcHt), 5.27 (m, IH, J=16.7Hz, -OCH2CH=CHcHt), 5.85 - 5.98 (m, IH, - OCH2CH=CHcHt); 13C NMR (CDC13) δ 28.7 (Boc-CH3) , 31.3, 41.6, 69.1, 74.2, 79.6 (-C(CH3)3) , 116.8 (-OCH2CH=CH2), 135.4 (-OCH2CH=CH2) , 155.1 (C=O).
3.21 l-tgrtButyloxycarbonyl-4-(cyclobutylmethoxy -piperidine (61KS51)
[0131] NaH (0.398 g, 55% in mineral oil, 9.94 mmol), 1- tgrtButyloxycarbonylpiperidin-4-ol (2.00 g, 9.94 mmol) and (Bromomethyl)cyclobutane (1.35 g, 9.04 mmol) were reacted according to GP4 to give the title compound (61KS51) (0.212 g, 9%). *H NMR (CDC13) δ 1.40 - 1.58 (m, 11H), 1.68 - 1.96 (m, 6H), 2.00 - 2.15 (m, 2H), 2.55 (m, IH), 3.10 (ddd, 2H, J=3.0Hz, 8.3Hz, 13.3Hz), 3.35 - 3.50 (m, 3H), 3.70 - 3.83 (m, 2H); 13C NMR (CDC13) δ 18.8, 25.3, 28.7 (Boc-CH3) , 31.4, 35.6, 41.5, 72.9, 74.7, 79.6 (-C(CH3)3) , 155.1 (C=0).
3.22 l-tgrtButyloxycarbonyl-4-hydroxymethyl-ρiperidine (61KS81)
[0132] 4-(Hydroxymethyl)piperidine (0.953 g, 8.27 mmol) was dissolved in dioxane/water (1:1, 50 mL) followed by the addition of Boc2O (2.17 g, 9.92 mmol) and NaHC03 (8.77 g, 82.7 mmol). The mixture was stirred at room temperature for 24 h before extraction with DCM was performed. The combined organic phase was washed consecutively with citric acid (5% sol.) and aqueous NaHC03 followed by drying (Na2S04), filtration and evaporation of the solvent to give the title compound (61KS81) (1.75 g, 98%). :H NMR (CDC13) δ 1.15 (dq, 2H, J=4.8Hz, 12.4Hz), 1.45 (s, 9H, Boc-CH3), 1.58 - 1.75 (m, 3H), 2.70 (t, 2H, J=12.0Hz), 3.49 (d, 2H, J=6.0Hz, -CΪ OH), 4.00 - 4.23 (m, 2H); 13C NMR (CDC13) δ 28.7 (Boc-CH3), 30.3, 39.0, 43.7, 67.3, 67.8, 79.5 (-C(CH3)3) , 155.1 (C=0).
3.23 1 -tgrtButyloxycarbonyl-4-methoxymethyl-piperidine (61 KS 83 )
[0133] Mel (0.094 g, 0.659 mmol, l.leq), l-tgrtButyloxycarbonyl-4-hydroxymethyl- piperidine (61KS81) (0.129 g, 0.599 mmol, l.Oeq) and NaH (0.029 g, 55% in mineral oil, 0.719 mmol, 1.2eq) were reacted according to GP4 to give the title compound (61KS83) (0.076 g, 56%). NMR (CDCI3) δ 1.10 (dq, 2H, J=4.7Hz, 12.2Hz), 1.40 (s, 9H, B0C-CH3), 1.60 - 1.75 (m, 3H), 2.63 (t, 2H, J=12.7Hz), 3.18 (d, 2H, J=6.0Hz, -CH^OC^). 3.29 (s, 3H, -CHzOCHj), 3.94 - 4.15 (m, 2H); 13C NMR (CDC13) δ 28.6 (Boc-CH3), 29.2, 36.7, 43.9, 59.0, 77.8, 79.4 (-C(CH3)3), 155.0 (C=0).
3.24 l-tgrtButyloxycarbonyl-4-ethoxymethyl-piperidine (61KS90)
[0134] l-tgrtButyloxycarbonyl-4-hydroxymethyl-piperidine (61KS81) (0.100 g, 0.464 mmol), NaH (0.093 g, 55% in mineral oil, 2.32 mmol) and EtOMs ( 0.345 g, 2.78 mmol) were reacted according to GP4 to give the title compound (61KS90) (0.071 g, 63%). !H NMR (CDC13) δ 1.08 (dq, 2H, J=4.1Hz, 12.9Hz), 1.14 (t, 3H, 6.8Hz, -CH2OCH2CH3), 1.42 (s, 9H, B0C-CH3), 1-63 - 1.75 (m, 3H), 2.65 (t, 2H, 12.8Hz), 3.21 (d, 2H, J==6.1Hz, -CH2OCH2CH3), 3.42 (q, 2H, J=6.8Hz, - CH2OCH2CH3), 3.96 - 4.14 (m, 2H); 13C NMR (CDC13) δ 15.3 (-CH2OCH2CH3), 28.6 (Boc-CH3), 29.3, 36.8, 66.6, 75.6, 79.4 (-C(CH3)3), 155.1 (C=0).
3.25 l-tgrtButyloxycarbonyl-4-hydroxyethyl-piperidine (61KS82)
[0135] 4-Piperidineethanol (1.05 g, 8.13 mmol) was dissolved in dioxane/water (1:1, 50 mL) followed by the addition of Boc20 (2.13 g, 9.76 mmol) and NaHC03 (8.62 g, 81.3 mmol). The mixture was stirred at room temperature for 24 h before extraction with DCM was performed. The combined organic phase was washed consequetively with citric acid (5% sol.) and aqeueous NaHC03 followed by drying (Na2SU4), filtration and evaporation of the solvent to give the title compound (61KS82) (1.77 g, 95%). ]H NMR (CDC13) δ 1.12 (dq, 2H, J=4.6Hz, 11.8Hz), 1.35 - 1.55 (m, 14H), 2.70 (t, 2H, J=12.8Hz), 3.70 (t, 2H, J=6.3Hz, -CH2CH2OH), 3.95 - 4.20 (m, 2H); 13C NMR (CDCI3) δ 28.7 (Boc-CH3), 32.8, 39.5, 44.2, 60.5, 67.3, 79.4 (-C(CH3)3), 155.1 (C=0).
3.26 l-tertButyloxycarbonyl-4-(2-methoxyethyl)-piperidine (61KS86)
[0136] Mel (3.72 g, 2.62 mmol), l-tgrtButyloxycarbonyl-4-hydroxyethyl-piperidine
(61KS82) (1.00 g, 4.36 mmol) and NaH (0.872 g, 55% in mineral oil, 21.8 mmol) were reacted according to GP4 to give the title compound (61KS86) (0.447 g, 42%). JH NMR (CDC13) δ 1.10 (dq, 2H, J=4.2Hz, 12.2Hz), 1.38 - 1.70 (m, 14H), 2.68 (t, 2H, 12.6Hz), 3.32 (s, 3H, - CH2CH2OCH3), 3.40 (t, 2H, J=6.0Hz, -CHzCI OC^), 4.00 - 4.15 (m, 2H); 13C NMR (CDC13) δ 28.7 (B0C-CH3), 32.4, 33.1, 36.4, 44.1, 58.8 (-CH2CH2OCH3), 70.4 (-CH2CH2OCH3), 79.4 (- C(CH3)3), 155.1 (C=0).
3.27 General Procedure 5 (GP5)
[0137] The alkene (1.0 equiv) was dissolved in MeOH (10-50 mL) and ammonium formate (10 equiv) was added. The reaction flask was then flushed with argon before adding Pd(10%)/C (30-700mg). The reaction mixture was stirred for 4h before the catalyst was filtered off using celite as filter aid. After concentration the product was taken up in DCM (5-30 mL) and filtered through cotton wool and concentrated to give the desired products.
3.28 l-tgrtButyloxycarbonyl-4-propoxy-piperidine (104KS21
[0138] l-tgrtButyloxycarbonyl-4-(prop-2-ene-l-oxy)-piperidine (104KS20) (7.60 g,
31.5 mmol), ammonium formate (20 g, 315 mmol) and Pd(10%)/C (0.500 g) were reacted according to GP5 to give the title compound (104KS21) (5.61 g, 73 %). XH NMR (CDC13) δ 0.90 (m, 3H), 1.42 (s, 9H, B0C-CH3), 1.35 - 1.60 (m, 4H), 1.70 - 1.85 (m, 2H), 3.00 - 3.15 (m, 2H), 3.30 - 3.44 (m, 3H), 3.65 - 3.70 (2H); 13C NMR (CDC13) δ 10.8 (-OCH2CH2CH3), 23.5 (-OCH2CH2CH3),
28.6 (B0C-CH3), 31.3, 41.5 (C2 and C3), 69.9, 74.5 (C4 and -OCH2CH2CH3) , 79.5 (-C(CH3)3) , 155.0 (C=0). 3.29 l-tgrtButyloxycarbonyl-4-(isobutoxy)-piperidine (61KS66)
[0139] 3-Bromo-2-methylpropen (0.578 g, 4.28 mmol), NaH (0.189 g, 55% in mineral oil, 4.71 mmol), l-tgrtButyloxycarbonylpiperidin-4-ol (0.948 g, 4.71 mmol), Pd(10%)/C (0.700 g), ammonium fonnate (1.84 g, 2.91 mmol) were reacted according to GP4 and GP5 to give the title compound (61KS66) (0.740 g, 67% over 2 steps). 1H NMR (CDC13) δ 0.90 (d, 6H, J=6.7Hz, - OCH2CH(CH3)2), 1.44 (s, 9H, Boc-CH3), 1.46 - 1.56 (m, 2H), 1.73 - 1.87 (m, 3H), 3.15 (ddd, 2H, J=3.2Hz, 8.5Hz, 13.1Hz), 3.19 (d, 2H, J=6.7Hz, -OCH2CH(CH3)2), 3.39 (tt, IH, J=3.2Hz, 8.0Hz), 3.65 - 3.76 (m, 2H); 13C NMR (CDC13) δ 19.6, 28.6, 28.7 (Boc-CH3), 31.2, 41.4, 74.6 (C4), 75.2 (- OCH2CH(CH3)2) , 79.5 (-C(CH3)3), 155.1 (C=0).
3.30 4-Propyloxypiperidine (79KS66)
[0140] To solution of the Boc-protected piperidine l-t-butyloxycarbonyl-4- propyloxypiperidine (104KS21) (12.6g, 51.8 mmol) in DCM (30mL) was carefully added TFA (25mL) under stirring. The mixture was left stirring for 18 h and concentrated in vacuo. To the remaining syrup was added 2M NaOH (20mL) and this mixture was extracted with DCM. The combined organic phase was dried (Na2SU ), filtered and concentrated to give the title compound (79KS66) (7.4 g, quant.) as a yellow oil. The material was used for the next reaction step without further purification. XHNMR (CDC13): δ 0.89 (t, 3H, J=7.4Hz, -OCH2CH2CH3), 1.40 -1.50 (m, 2H),
1.55 (sixt, 2H, J=7.4Hz, -OCH2CH__CH_), 1.84 - 1.94 (m, 2H), 2.64 (ddd, 2H, J=3.0Hz, 9.8Hz, 12.7Hz), 3.35 (dt, 2H, J=1.5Hz, 12.7Hz), 3.21 (br s, IH, NH), 3.30 - 3.37 (m, IH, H4), 3.35 (td, 2H, J=1.2Hz, 7.4Hz, -OCH2CH2CH3); 13C NMR (CDC13): δ 10.8 (-OCH2CH2CH3), 23.5 (- OCH2CH2CH3), 32.5, 44.1 (C2 and C3), 69.7 (-OCH2CH2CH3), 74.8 (C4).
3.31 4-Cvclohexylmethyl-piperidine (56NK128
[0141] Platinium dioxide (200 mg) was added to 4-benzylpiperidine (1.75 g, 10 mmol) in EtOH (20 ml) and HC1 in dioxan (20 ml, 4 M). The flask was evacuated, flooded with hydrogen and this procedure was repeated twice. The reaction was stirred vigorously at r.t. for 72 h then platinium oxide (200 mg) was added and the reaction was stirred at r.t. for 18 h. The reaction mixture was filtered through Celite eluting with EtO Ac and the solute concentrated in vacuo. Ether (50 ml) was added and the reaction concentrated in vacuo. Water (50 ml) and ether (50 ml) were added then sodium hydroxide (2 M) was added until pH 12. The phases were separated and the aqueous phase was extracted with ether (2x50 ml). The organic phases were combined, washed with brine (20 ml), dried (K2CO3), filtered and carefully concentrated in vacuo to give the crude title compound (56NK128) as a pale yellow oil (1.42 g, 78%). 'H NMR (CDC13) δ 3.04 (m, 2H),
2.56 (m, 2H), 1.72-1.55 (m, 9H), 1.45 (m, IH), 1.32 (m, IH), 1.18 (m, 2H), 1.05 (m, 4H), 0.83 (m, 2H); HPLC-MS (ammonium acetate) [M+H]+=182.3 (calc. 182.2). 3.32 4-.2-Ethoxyethvnpiperidine C56NK129')
[0142] 4-(2-Ethoxyethyl)pyridine (0.151 g, 1.0 mmol) was dissolved in EtOH (4 ml) and acetic acid (0.5 ml) and the flask was evacuated, flooded with hydrogen and this proceedure was repeated twice. Platinium oxide (0.040 g) was added and the reaction was stirred vigorously at r.t. for 18 h. The reaction mixture was filtered through Celite eluting with EtO Ac and the solute concentrated in vacuo. Ether (20 ml) was added and the reaction concentrated in vacuo. Sodium hydroxide (2 ml, 2 M) was added and the product was extracted into ether (2x20 ml). The organic phases were dried (K2C03), filtered and carefully concentrated in vacuo to give the crude title compound (56NK129) as a yellow oil (0.154 g, 98%). JH NMR (CDC13) δ 3.45 (m, 4H), 3.03 (m, 2H), 2.58 (m, 2H), 1.76 (br. S, IH), 1.66 (m, 2H), 1.51 (m, 3H), 1.18 (t, J=7.5 Hz, 3H), 1.11 (m, 2H); HPLC-MS (ammonium acetate) [M+H]+=158.2 (calc. 158.2).
3.33 4-Cvclohexylpiperidine (75NK45)
[0143] Platinium dioxide (0.200 g) was added to 4-phenylpiperidine (1.55 g, 10 mmol) in EtOH (40 ml) and HC1 in dioxan (5 ml, 4 M). The flask was evacuated, flooded with hydrogen and this procedure was repeated twice. The reaction was stirred vigorously at r.t. for 72 h then filtered through Celite eluting with EtO Ac and the solute was concentrated in vacuo to give a white solid. Water (30 ml) was added followed by sodium hydroxide (20ml, 2 M) and the product was extracted into EtOAc (3x50 ml). The organic phase was washed with brine (20 ml), dried (K2CO3), filtered and carefully concentrated in vacuo to give the crude title compound (75NK45) as a pale yellow oil (1.38 g, 82%). 'HNMR ^DCla) δ 3.07 (m, 2H), 2.58 (m, 2H), 1.93 (br. s, IH), 1.71 (m, 4H), 1.64 (m, 4H), 1.16 (m, 6H), 0.95 (m, 2H); HPLC-MS (ammonium acetate) [M+H]+=168.2 (calc. 168.3).
3.35 General procedure 6 (GP6)
[0144] A 4 ml vial was charged with Aniline (1 equiv) and carbonyldiimidazole (1.3 equiv) in DMF (1 ml) and shaken at 60° for 4 h. The reaction was cooled to r.t. and 4 M HC1 added (1 ml). The product was extracted into ethyl acetate (2 x 1 ml) and the combined org. layer filtered through a WHATMAM FT 5.0 μm PTFE column. The solute was concentrated in vacuo and used without further purification.
3.36 4-Methyl-3H-benzooxazol-2-one (86KK20a
[0145] 2-Hydroxy-6-methylanilin (0.154g, 1.25 mmol) and carbonyldiimidazole (0.250 g, 1.54 mmol) were reacted according to GP6 to give the crude title compound (86KK20a). 3.37 5.7-Dimethyl-3H-benzooxazol-2-one ,86KK20fr)
[0146] 2-Hydroxy-3,5-dimethylanilin (0.66 g, 1.21 mmol) and carbonyldiimidazole (0.250 g, 1.54 mmol) were reacted according to GP6 to give the crude title compound (86KK20b).
3.38 6-Methyl-3H-benzooxazol-2-one (86KK20c)
[0147] 2-Ηydroxy-4-methylanilin (0.145 g, 1.17 mmol) and carbonyldiimidazole (0.250 g, 1.54 mmol) were reacted according to GP6 to give the crude title compound (86KK20d).
3.39 5-Methyl-3H-benzooxazol-2-one (86KK20d)
[0148] 2-Hydroxy-5-methylanilin (0.147 g, 1.19 mmol) and carbonyldiimidazole (0.250 g, 1.54 mmol) were reacted according to GP6 to give the crude title compound (86KK20d).
3.40 5-t-Butyl-3H-benzooxazol-2-one (86KK20e)
[0149] 2-Ηydroxy-5-t-butylanilin (0.203 g, 1.23 mmol) and carbonyldiimidazole
(0.250 g, 1.54 mmol) were reacted according to GP6 to give the crude title compound (86KK20e).
3.41 6-Chloro-3H-benzooxazol-2-one (86KK20f)
[0150] 4-Chloro-2-hydroxyanilin (0.179 g, 1.25 mmol) and carbonyldiimidazole
(0.250 g, 1.54 mmol) were reacted according to GP6 to give the crude title compound (86KK20f).
3.42 5-Methoxy-3H-benzooxazol-2-one (86KK20r>
[0151] 2-Ηydroxy-5-methoxyanilin (0.175 g, 1.26 mmol) and carbonyldiimidazole
(0.250 g, 1.54 mmol) were reacted according to GP6 to give the crude title compound (86KK20i).
3.43 6-Fluoro-3H-benzooxazol-2-one (86KK20J)
[0152] 4-Fluoro-2-hydroxyanilin (0.154 g, 1.21 mmol) and carbonyldiimidazole
(0.250 g, 1.54 mmol) were reacted according to GP6 to give the crude title compound (86KK20J).
3.44 5-Fluoro-3H-benzooxazol-2-one (86KK20k)
[0153] 5-Fluoro-2-hydroxyanilin (0.117 g, 0.92 mmol) and carbonyldiimidazole (0.250 g, 1.54 mmol) were reacted according to GP6 to give the crude title compound (86KK20k).
3.45 General procedure 7 (GPl)
[0154] A 4 ml vial was charged with hydroxybenzoic acid (1 equiv) and carbonyldiimidazole (1.2 equiv) in TΗF (1 ml) and shaken at 60° for 20 h. The reaction was cooled to r.t., 4 M ΗC1 added (1 ml), and the product was extracted into EtOAc (2 x 1 ml). The combined org. layer was dried over Na2S04 and concentrated in vacuo before being purified by flash column chromatography (CC) give of the product.
3.46 5.7-Dichloro-6-ethyl-3H-benzooxazol-2-one (97KK10)
[0155] 3,5-Dichloro-4-ethyl-2-hydroxybenzoic acid (0.288 g, 1.40 mmol) and carbonyldiimidazole (0.275 g, 1.70 mmol) were reacted according to GP7. Purified by flash CC (SiO2; DCM/MeOΗ 40:1) to give the title compound (97KK10) (0.269 g, 83%). !Η-NMR (MeOH) δ 1.14 (t, J = 7.4 Hz, CH3), 2.92 (q, J = 7.4 Hz, CH2), 7.04 (s, 1 H); 13C (MeOH) δ 13.2, 24.9, 110.4, 116.4, 130.2, 130.9, 134.4, 141.2, 155.8.
3.47 7-Fluoro-3H-benzooxazol-2-one (97KK09a)
[0156] 3-Fluoro-2-hydroxybenzoic acid (0.265 g, 2.08 mmol) and carbonyldiimidazole (0.352 g, 2.17 mmol) were reacted according to GP7. Purified by flash CC (Si02; DCM/MeOH 20:1) to give the title compound (97KK09a) (0.189 g, 59%). XH-NMR (CDC13) δ 6.90 - 6.85 (m, 1 H), 7.38 - 7.33 (m, 1 H), 7.86 - 7.83 (m, 1 H), 10.38 (br. s, 1 H).
3.48 5-Bromo-7-fluoro-3H-benzooxazol-2-one (97KK09b)
[0157] 5-Bromo-3-fluoro-2-hydroxybenzoic acid (0.080 g, 0.39 mmol) and carbonyldiimidazole (0.075 g, 0.46 mmol) was reacted according to GP7. Purified by flash CC (Si02; DCM/MeOH 20:1) to give the title compound (97KK09b) (0.055 g, 61%). !H-NMR (MeOD) δ 6.90 - 6.85 (m, 1 H), 7.10 - 7.03 (m, 1 H).
3.49 5.7-Dichloro-6-methyl-3H-benzooxazol-2-one (97KK09c)
[0158] 3,5-Dichloro-2-hydroxy-4-methylbenzoic acid (0.331 g, 1.72 mmol) and carbonyldiimidazole (0.285 g, 1.76 mmol) were reacted according to GP7. Purified by flash CC (Si02; DCM/MeOH 20:1) to give the title compound (97KK09c) (0.240 g, 64%). Η-NMR (MeOD) δ 2.43 (s, CH3), 7.05 (s, 1 H).
3.50 6.7-Difluoro-3H-benzooxazol-2-one C97KK11)
[0159] 3,4-Difluoro-2-hydroxybenzoic acid (0.329 g, 2.27 mmol) and carbonyldiimidazole (0.390 g, 2.41 mmol) were reacted according to GP7. Purified by flash CC (Si02; DCM/MeOH 40:1) to give the title compound (97KK11) (0.139 g, 36%). JH-NMR (MeOD) δ 6.83 - 6.80 (m, 1 H), 7.08 - 7.01 (m, 1 H); 13C-NMR (MeOD) δ 105.6 (J = 4.5 Hz, J = 7.8 Hz), 112.6 (J = 20.3 Hz), 129.6, 133.1 (J = 4.5 Hz, J = 10.3 Hz), 136.7 (J = 17.8 Hz, J = 250.3 Hz), 148.1 (J = 10.0 Hz, J = 240.0 Hz), 156.3. 3.51 General procedure 8 (GP8^)
[0160] A 4 ml vial was charged with carboxylic acid (1 equiv), diphenylphosphoryl azide (1 equiv), triethylamine (1 equiv), and toluene (4 ml). The mixture was shaken at 110° under an Argon atmosphere for 20 h. The reaction mixture was cooled to r.t., water added (1 ml), and the product was extracted into ethyl acetate (2 x 1 ml). The combined org. layer was concentrated in vacuo before being purified by using an Isco CombiFlasch Sq 16x to give the product.
3.52 7-Methyl-3H-benzooxazol-2-one (86KK37a)
[0161] 2-Hydroxy-3-methylbenzoic acid (0.303 g, 1.99 mmol), diphenylphosphoryl azide (0.548 g, 1.99 mmol), and Et3N (0.201 g, 1.99 mmol) were reacted according to GP8. Purified by using an Isco CombiFlash Sq 16x [10 g silica column, eluting 0-50% EtOAc in n-heptane (31 min) then 50% EtOAc in n-heptane (20 min)] to give the title compound (86KK37a) (0.204 g, 69%). Η-NMR (CDC13) δ 2.39 (s, CH3), 7.08 - 7.04 (m, 1 H), 6.94 - 6.92 (m, 2 H), 9.29 (br. s, 1 H); 13C-NMR (CDC13) δ 14.7, 107.7, 121.0, 124.1, 124.5, 129.1, 142.9, 156.2.
3.53 7-Isopropyl-3H-benzooxazol-2-one (86KK37b)
[0162] 2-Hydroxy-3-isopropylbenzoic acid (0.342 g, 1.90 mmol), diphenylphosphoryl azide (0.523 g, 1.90 mmol), and Et3N (0.192 g, 1.90 mmol) were reacted according to GP8. Purified by using an Isco CombiFlash Sq 16x [10 g silica column, eluting 0-50% EtOAc in n-heptane (31 min) then 50% EtOAc in n-heptane (20 min)] to give the title compound (97KK37b) (0.263 g, 78%). Η-NMR (CDCI3) δ 1.33 (d, J = 7.0, 2 CH3), 3.24 (p, J = 7.0, CH), 7.00 - 6.94 (m, 2 H), 7.12 - 7.10 (m, 1 H), 9.58 (br. S, 1 H); 13C-NMR (CDC13) δ 22.5, 28.9, 107.8, 120.6, 124.4, 129.3, 131.9, 141.8, 156.5.
3.54 5 -Diisopropyl-3H-benzooxazol-2-one (86KK39a)
[0163] 2-Hydroxy-3,5-diisopropylbenzoic acid (0.378 g, 1.70 mmol), diphenylphosphoryl azide (0.468 g, 1.70 mmol), and Et3N (0.172 g, 1.70 mmol) were reacted according to GP8. Purified by using an Isco CombiFlash Sq 16x [10 g silica column, eluting 0-50% EtOAc in n-heptane (41 min) then 50%o EtOAc in n-heptane (10 min)] to give the title compound (86KK39a) (0.234 g, 63%). !H-NMR (CDC13) δ 1.25 (d, J = 7.0, CH3), 1.25, (d, J = 6.8, CH3), 1.34 (d, J = 6.8, CH3), 1.34 (d, J = 7.0, CH3), 2.94 - 2.87 (m, CH), 3.24 - 3.17 (m, CH), 6.89 - 6.83 (m, 2 H), 10.23 (br. S, 1 H); 13C-NMR (CDC13) δ 22.6, 24.5, 29.4, 34.6, 105.9, 118.9, 129.6, 131.2, 140.1, 145.7, 157.3.
3.55 5-7-Dibromo-3H-benzooxazol-2-one (86KK39c) [0164] 3,5-Dibromo-2-hydroxybenzoic acid (0.477 g, 1.61 mmol), diphenylphosphoryl azide (0.443 g, 1.61 mmol), and Et3N (0.163 g, 1.61 mmol) were reacted according to GP8. Purified by using an Isco CombiFlash Sq 16x [(10 g silica column, eluting 0- 50%) EtOAc in n-heptane (31 min) then 50% EtOAc in n-heptane (20 min)] to give the title compound (86KK39d) (0.345 g, 73%). !H-NMR (MeOD + CDC13) δ 7.17 (s, 1 H), 7.38 (s, 1 H); 13C-NMR (MeOD + CDCl3) δ 103.2, 113.0, 117.4, 128.3, 133.3, 142.4, 155.2.
3.56 6-Methoxy-3H-benzooxazol-2-one (86KK39d)
[0165] 2-Hydroxy-4-methoxybenzoic acid (0.433 g, 2.58 mmol), diphenylphosphoryl azide (0.548 g, 2.58 mmol), and Et3N (0.261 g, 2.58 mmol) were reacted according to GP8. Purified by using an Isco CombiFlash Sq 16x [(10 g silica column, eluting 0-50% EtOAc in n-heptane (31 min) then 50% EtOAc in n-heptane (20 min)] to give the title compound (86KK39d) (0.216 g, 50%). Η-NMR (DMSO) δ 3.70 (s, OCH3), 6.70 - 6.68 (m, 1 H), 6.97 - 6.94 (m, 2 H), 11.36 (br. s, 1 H); 13C-NMR (DMSO) δ 56.5, 97.7, 109.9, 110.6, 124.3, 144.7, 155.5, 155.9.
3.57 4.6-Dimethoxy-3H-benzooxazol-2-one (86KK39e)
[0166] 2-Hydroxy-4,6-dimethoxybenzoic acid (0.456 g, 2.30 mmol), diphenylphosphoryl azide (0.633 g, 2.30 mmol), and Et3N (0.233 g, 2.30 mmol) were reacted according to GP8. Purified by using an Isco CombiFlash Sq 16x [10 g silica column, eluting 0-50% EtOAc in n-heptane (31 min) then 50% EtOAc in n-heptane (20 min)] to give the title compound (86KK39e) (0.050 g, 11%). !H-NMR (DMSO) δ 3.71 (s, OCH3), 3.81 (s, OCH3), 6.41 (d, J = 2.2, 1 H), 6.56 (d, J = 2.2 Hz, 1 H), 11.50 (br. s, IH); 13C-NMR (DMSO) δ 56.5, 56.6, 89.8, 95.6, 113.0, 144.9, 145.0, 155.4, 156.7.
3.58 4.5.7-Trichloro-3H-benxooxazol-2-one (97KK26)
[0167] 3,5,6-Trichloro-2-hydroxybenzoic acid (0.498 g, 2.06 mmol), diphenylphosphoryl azide (0.567 g, 2.06 mmol), and Et3N (0.208 g, 2.06 mmol) were reacted according GP8. Purified by using an Isco CombiFlash Sq 16x [10 g silica column, eluting 0-30%> EtOAc in n-heptane (43 min) then 30% EtOAc in n-heptane (10 min)] to give the title compound (97KK26) (0.344 g, 70%). 'H-NMR (MeOD) δ 7.24 (s, 1 H); 13C-NMR (MeOD) δ 113.3, 114.8, 123.8, 128.8, 132.3, 140.4, 155.0.
3.59 5.7-Diiodo-3H-benzooxazol-2one (92LΗ49)
[0168] A 4 ml vial was charged with 2-hydroxy-3,5-diiodobenzoic acid (0.780 g, 2.00 mmol), diphenylphosphoryl azide (0.202 g, 1.99 mmol), triethylamine (0.550 g, 2.00 mmol), and toluene (4 ml). The mixture was shaken at 110° under an Argon atmosphere for 20 h. The reaction mixture was cooled to r.t., water added (1 ml), and the product was extracted into ethyl acetate (2 x 1 ml). The combined org. layer was concentrated in vacuo before being purified twice by flash CC (SiO2; DCM MeOH 9:1 and then n-heptan/EtOAc 1:1) to give the title compound (92LH49) (0.205 g, 26%). !-NMR (DMSO) δ 7.34 - 7.32 (m, 1 H), 7.71 -7.70 (m, 1 H), 11.96 (br. s, 1 H); 13C-NMR (DMSO) δ 75.3, 88.0, 117.7, 131.6, 136.8, 144.9, 152.6.
3.60 4-methoxy-3H-benzooxazol-2-one (92LH58)
[0169] A 4 ml vial was charged with 2-hydroxy-6-methoxybenzoic acid (0.336 g, 2.00 mmol), diphenylphosphoryl azide (0.202 g, 1.99 mmol), triethylamine (0.550 g, 2.00 mmol), and toluene (4 ml). The mixture was shaken at 110° under an Argon atmosphere for 20 h. The reaction mixture was cooled to r.t., water added (1 ml), and the product was extracted into ethyl acetate (2 x 1 ml). The combined org. layer was concentrated in vacuo give the crude title compound (92LH58) (0.345 g)
3.61 7-Nitro-3H-benzooxazol-2-one (92LH59)
[0170] A 4 ml vial was charged with 2-hydroxy-3-nitrobenzoic acid (0.66 g, 2.00 mmol), diphenylphosphoryl azide (0.202 g, 1.99 mmol), triethylamine (0.550 g, 2.00 mmol), and toluene (4 ml). The mixture was shaken at 110° under an Argon atmosphere for 20 h. The reaction mixture was cooled to r.t., water added (1 ml), and was extracted with ethyl acetate (2 1 ml). The water phase was added SiO2 and concentrated in vacuo. The product was purified by flash CC (SiO2; EtOAc) to give the title compound (92LH59) (0.230 g, 64%). 'H-NMR (DMSO) δ 7.42 7.30 (m, 2 H), 7.86 - 7.84 (m, 1 H).
3.62 4-Methyl-7-isopropyl-3H-benzooxazol-2-one f92LH7D
[0171] A 4 ml vial was charged with 2-hydroxy-3-isopropyl-6-methylbenzoic acid (0.389 g, 2.00 mmol), diphenylphosphoryl azide (0.202 g, 1.99 mmol), triethylamine (0.550 g, 2.00 mmol), and toluene (4 ml). The mixture was shaken at 110° under an Argon atmosphere for 20 h. The reaction mixture was cooled to r.t., water added (1 ml), and the product was extracted into ethyl acetate (2 x 1 ml). The combined org. layer was concentrated in vacuo before being purified by prep. RP-HPLC [conditions: stationary phase, Luna 15um C18; column, 250x21.2 mm; mobile phase, 20 ml/min, H20/CH3CN, ammoniumacetate buffer (25nM)] to give the title compound (92LH71) (0.100 g, 26%). Η-NMR (CDCfe) δ 1.34 - 1.29 (m, 6 H), 2.37 - 2.35 (m, 3 H), 3.22 - 3.17 (m, l H), 6.94 - 6.87 (m, 2 H9, 10.70 (br. s, 1 H); 13C-NMR (CDC13) δ 15.8, 22.5, 28.8, 118.0, 120.2, 125.4, 128.6, 129.0, 141.4, 157.4.
3.63 7-Methyl-4-isopropyl-3H-benzooxazol-2-one C92LH76) [0172] A 4 ml vial was charged with 2-hydroxy-3-methyl-6-isopropylbenzoic acid (0.389 g, 2.00 mmol), diphenylphosphoryl azide (0.202 g, 1.99 mmol), triethylamine (0.550 g, 2.00 mmol), and toluene (4 ml). The mixture was shaken at 110° under an Argon atmosphere for 20 h. The reaction mixture was cooled to r.t., water added (1 ml), and the product was extracted into ethyl acetate (2 x 1 ml). The combined org. layer was concentrated in vacuo before being purified by prep. RP-HPLC [conditions: stationary phase, Luna 15um C18; column, 250x21.2 mm; mobile phase, 20 ml/min, H20/CH3CN, ammoniumacetate buffer (25nM)] to give the title compound (92LH76) (0.066 g, 17%). *H-NMR (MeOD) δ 1.25 (d, J 6.9 Hz, CH3), 1.26 (d, J = 7.0 Hz, CH3), 2.30 (s, CH3), 3.01 (quint, J = 6.9 Hz, CH), 6.95 - 6.86 (m, 2 H); 13C-NMR (CDC13) δ 14.2, 22.9, 30.1, 118.5, 121.4, 124.8, 128.6, 129.9, 143.6, 157.6.
3.64 General procedure 9 (GP9
[0173] A reaction flask was charged with benzothiazol-2-one (1 equiv), chloroiodoalkane (1 equiv), and base (1.5 equiv) in MeCH (3 ml) and stirred at r.t. for 24 h. The reaction mixture was added water and the product extracted into CH2C12. The combined org. layer was dried over Na2S0 and concentrated in vacuo before being purified by flash column chromatography (CC).
3.65 3-f 2-Chloroethvn-3H-benzothiazol-2-one (62KK38
[0174] 2-Ηydroxybenzothiazol (0.508 g, 3.29 mmol), 2-chloro-l-iodoethane (0.499 g, 2.52 mmol), and K2C03 (0.547 g, 3.96 mmol) in MeCN (10 ml) were reacted according to GP9. Purified by CC (A1203; DCM/n.heptane 1:2) to give the title compound (62KK38) (0.292 g, 54%).
3.66 3-.3-Chloropropyl>3H-benzothiazol-2-one (62KK21)
[0175] 2-Hydroxybenzothiazol (1.003 g, 6.50 mmol), 3-chloro-l-iodopropane (1.361 g, 6.66 mmol), and K2C03 (1.021 g, 7.39 mmol) in MeCN (20 ml) were reacted according to GP9. Purified by CC (Si02; DCM/n.heptane 1:1) to give the title compound (62KK21) (0.847 g, 57%).
3.67 3-r4-ChlorobutylV3H-benzothiazol-2-one .62KK29)
[0176] 2-Hydroxybenzothiazol (0.496 g, 3.22 mmol), 4-chloro-l-iodobutane (0.722 g, 3.24 mmol), and K2C03 (0.576 g, 4.17 mmol) in MeCN (13 ml) were reacted according to GP9. Purified by CC (Si02; DCM/n.heptane 1:1) to give the title compound (62KK30) (0.487 g, 63%).
3.68 3-f2-Chloroethyl)-3H-benzooxazol-2-one (62KK39)
[0177] 3H-benzooxazol-2-one (0.425 g, 3.05 mmol), 2-chloro-l-iodoethane (0.563 g, 2.84 mmol), and K2C03 (0.647 g, 4.68 mmol) in MeCN (10 ml) were reacted according to GP9. Purified by CC (A1203; DCM/n-heptane 1:2) to give the title compound (62KK39) (0.158 g, 28%). 3.69 3-f3-ChloropropylV3H-benzooxazol-2-one f62KK30^
[0178] 3H-benzooxazol-2-one (0.580 g, 4.16 mmol), 3-chloro-l-iodopropane (0.854 g, 4.18 mmol), and K2C03 (0.691g, 5.00 mmol) in MeCN (10 ml) were reacted according to GP9. Purified by CC (Si02; DCM/n-heptane 1:1, DCM) to give the title compound (62KK30) (0.133 g, 14%).
3.70 3-C4-Chlorobutyl)-3H-benzooxazol-2-one (62KK2&)
[0179] 3H-benzooxazol-2-one (0.419 g, 3.01 mmol), 4-chloro-l-iodobutane (0.677 g, 3.04 mmol), and K2C03 (0.500 g, 3.62 mmol) in MeCN (12 ml) were reacted according to GP9. Purified by CC (Si02; DCM/n-heptane 1:1, DCM) to give the title compound (62KK28) (0.309 g, 45%).
3.71 3-(5-Chloropentvn-3H-benzothiazol-2-one (107LH0n
[0180] 2-Hydroxybenzothiazol (0.302 g, 2.0 mmol), 5-chloro-l-iodopentane (0.370 g,
2.0 mmol), and Cs2C03 (0.977 g, 3.0 mmol) were reacted according to GP9. Purified by flash CC (Si02; DCM) to give the title compound (107LH01) (0.461 g, 90%). *H NMR (CDC13) δ 1.59 - 1.53 (m, 2 H), 1.87 - 1.75 (m, 4 H), 3.53 (t, J = 6.6 Hz, CH2), 3.96 (t, J = 7.2 Hz, CH2), 7.44 - 7.03 (m, 4 H); 13C NMR (CDC13) δ 24.2, 27.0, 32.2, 42.6, 44.7, 110.6, 122.8, 123.0, 123.2, 126.4, 137.2, 170.0.
3.72 3-(6-ChlorohexylV3H-benzothiazol-2-one .107LH02)
[0181] 2-Hydroxybenzothiazol (0.302 g, 2.0 mmol), 6-chloro-l-iodohexane (0.398 g,
2.0 mmol), and Cs2C03 (0.977 g, 3.0 mmol) were reacted according to GP9. Purified by flash CC (Si02; DCM) to give the title compound (107LH02) (0.491 g, 91%). *H NMR (CDC13) δ 1.53 - 1.40 (m, 4 H), 1.80 - 1.73 (m, 4 H), 3.52 (t, J = 6.6 Hz, CH2), 3.95 (t, J = 7.2 Hz, CH2), 7.44 - 7.03 (m, 4 H); 13C NMR (CDC13) δ 26.2, 26.6, 27.6, 32.5, 42.7, 45.0, 110.6, 122.8, 123.0, 123.1, 126.4, 137.2, 170.0.
3.73 General procedure 10 . GP 10)
[0182] A 4 ml vial was charged with benzooxazol-2-one (1 equiv), 3-chloro-l- iodopropane (1.2 equiv), and Cs2C03 (1.2 equiv) in CH3CN (1 ml) and shaken at r.t. for 20 h. The reaction mixture was added water (1 ml) and the product extracted into EtOAc (2 1 ml). The combined organic layer filtered through a WHATMAM FT 5.0 μm PTFE column and concentrated in vacuo before being purified by using an Isco CombiFlasch Sq 16x to give the product. 3.74 3-f 3 -Chloropropyl>4-methyl-3H-benzooxazol-2-one (86KK21 a)
[0183] Crude 4-methyl-3H-benzooxazol-2-one (86KK20a) DMF solution, 3-chloro-l- iodopropane (0.480 g, 1.47 mmol), and Cs2C03 (0.299 g, 1.46 mmol) were reacted according to GP10. Purified by using an Isco CombiFlash Sq 16x [10 g silica column, eluting 0-25% EtOAc in n-heptane (33 min) then 25% EtOAc in n-heptane (10 min)] to give the title compound (86KK21a) (0.111 g). Η-NMR (CDCI3) δ 2.37-2.21 (m, CH2), 2.55 (s, CH3), 3.65 (t, J = 6.1 Hz, CH2), 4.14 (t, J = 6.8 Hz, CH2), 7.03-6.90 (m, 3 H); 13C-NMR (CDC13) δ 17.7, 32.6, 41.6, 41.9, 108.3, 120.0, 122.6, 127.2, 128.9, 143.1, 155.2.
3.75 3-,3-Chloropropyl)-5.7-dimethyl-3H-benzooxazol-2-one (86KK21b)
[0184] Crude 5,7-dimethyl-3H-benzooxazol-2-one (86KK20b) DMF solution, 3- chloro-1-iodopropane (0.480 g, 1.47 mmol), and Cs2C03 (0.299 g, 1.46 mmol) were reacted according to GP10. Purified by using an Isco CombiFlash Sq 16x [10 g silica column, eluting 0- 25% EtOAc in n-heptane (33 min) then 25% EtOAc in n-heptane (10 min)] to give the title compound (86KK21b) (0.094 g). !H-NMR (CDC13) δ 2.28-2.21 (m, CH2), 2.32 (s, CH3), 2.35 (s, CH3), 3.59 (t, J = 5.9 Hz, CH2), 3.94 (t, J = 6.7 Hz, CH2), 6.68 (s, 1 H), 6.73 (s, 1 H); 13C-NMR (CDCI3) δ 14.6, 21.7, 30.9, 39.7, 42.0, 106.4, 120.4, 124.9, 130.9, 133.9, 139.5, 155.1.
3.76 3-(3-Chloropropyl)-6-methyl-3H-benzooxazol-2-one (86KK21c)
[0185] Crude 6-methyl-3H-benzooxazol-2-one (86KK20c) DMF solution, 3-chloro-l- iodopropane (0.480 g, 1.47 mmol), and Cs2C03 (0.299 g, 1.46 mmol) were reacted according to GPIO. Purified by using an Isco CombiFlash Sq 16x [10 g silica column, eluting 0-25% EtOAc in n-heptane (33 min) then 25% EtOAc in n-heptane (3 min)] to give the title compound (86KK21c) (0.092 g). !H-NMR (CDC13) δ 2.28-2.21 (m, CH2), 2.38 (s, CH3), 3.58 (t, J = 6.5 Hz, CH2), 3.97 (t, J = 6.7 Hz, CH2), 7.01-6.92 (m, 3 H); 13C-NMR (CDCI3) δ 21.6, 30.9, 39.7, 41.9, 108.0, 111.0, 124.5, 129.0, 133.0, 143.0, 154.8.
3.77 3-(3-ChlorpropylV5-methyl-3H-benzooxazol-2-one (86KK21d)
[0186] Crude 5-methyl-3H-benzooxazol-2-one (86KK20d) DMF solution, 3-chloro-l- iodopropane (0.480 g, 1.47 mmol), and CS2CO3 (0.299 g, 1.46 mmol) were reacted according to GP10. Purified by using an Isco CombiFlash Sq 16x [10 g silica column, eluting 0-25% EtOAc in n-heptane (33 min) then 25% EtOAc in n-heptane (3 min)] to give the title compound (86KK21d) (0.062 g). !H-NMR (CDC13) δ 2.29-2.22 (m, CH2), 2.40 (s, CH3), 3.60 (t, J = 5.9 Hz, CH2), 3.97 (t, J = 6.7 Hz, CH2), 6.91-6.87 (m, 2 H), 7.07-7.05 (m, 1 H); 13C-NMR (CDC13) δ 21.7, 30.9, 39.7, 41.9, 109.0, 109.9, 123.1, 131.3, 134.2, 140.9, 155.0. 3.78 5-t-Butyl-3-('3-ChloropropylV3H-benzooxazol-2-one (86KK21e
[0187] Crude 5-t-butyl-3H-benzooxazol-2-one (86KK20e) DMF solution, 3-chloro-l- iodopropane (0.480 g, 1.47 mmol), and CS2CO3 (0.299 g, 1.46 mmol) were reacted according to GP10. Purified by using an Isco CombiFlash Sq 16x [10 g silica column, eluting 0-25% EtOAc in n-heptane (33 min) then 25% EtOAc in n-heptane (3 min)] to give the title compound (86KK21e) (0.102 g). 1H-NMR (CDCI3) δ 1.35 (br. s, C(CH3)3), 2.31-2.25 (m, CH2), 3.61 (t, J - 5.9 Hz, CH2), 4.02 (t, J = 6.7, CH2), 7.14-7.10 (m, 3 H). 13C-NMR (CDC13) δ 31.1, 31.9, 35.2, 39.4, 42.0, 105.7, 109.6, 119.6, 131.2, 140.8, 148.0, 155.1.
3.79 3-(3-ChloropropylV6-chloro-3H-benzooxazol-2-one (86KK21f)
[0188] Crude 6-Chloro-3H-benzooxazol-2-one (86KK20f) DMF solution, 3-chloro-l- iodopropane (0.480 g, 1.47 mmol), and Cs2C03 (0.299 g, 1.46 mmol) were reacted according to GP10. Purified by using an Isco CombiFlash Sq 16x [10 g silica column, eluting 0-20% EtOAc in n-heptane (33 min) then 20% EtOAc in n-heptane (3 min)] to give the title compound (86KK21f) (0.200 g). 1H-NMR (CDCI3) δ 2.22-2.16 (m, CΗ2). 3.52 (t, J = 5.9 Hz, CH2), 3.93 (t, J = 6.6 HZ, CH2), 6.94-6.92 (m, 1 H), 7.19-7.11 (m, 2 H); 13C-NMR (CDC13) δ 30.2, 39.3, 41.2, 108.4, 110.8, 123.8, 127.8, 129.6, 142.6, 153.8.
3.80 3-(3-Chloropropyl)-5-methoxy-3H-benzooxazol-2-one (86KK21J)
[0189] Crude 5-methoxy-3H-benzooxazol-2-one (86KK20i) DMF solution, 3-chloro- l-iodopropane (0.480 g, 1.47 mmol), and Cs2C03 (0.299 g, 1.46 mmol) were reacted according to GP10. Purified by using an Isco CombiFlash Sq 16x [10 g silica column, eluting 0-20% EtOAc in n-heptane (33 min) then 20% EtOAc in n-heptane (3 min)] to give the title compound (86KK2H) (0.079 g). 1H-NMR (CDCI3) δ 2.25 - 2.22 (m, CH2), 3.60 - 3.57 (m, CH2), 3.97 - 3.93 (m, CH2),
3.80 (s, OCH3), 6.65 - 6.58 (m, 2 H), 7.07 - 7.04 (m, 1 H); 13C-NMR (CDC13) δ 30.7, 39.5, 41.8, 56.1, 95.6, 107.1, 110.4, 132.0, 136.7, 155.1, 156.9.
3.81 3-(3-Chloropropyl)-6-fluoro-3H-benzooxazol-2-one (86KK21J)
[0190] Crude 6-fluoro-3H-benzooxazol-2-one (86KK20J) DMF solution, 3-chloro-l- iodopropane (0.480 g, 1.47 mmol), and Cs2C03 (0.299 g, 1.46 mmol) were reacted according to GP10. Purified by using an Isco CombiFlash Sq 16x [10 g silica column, eluting 0-20% EtOAc in n-heptane (33 min) then 20% EtOAc in n-heptane (3 min)] to give the title compound (86KK21J) (0.157 g). 'Η-NMR (CDC13) δ 2.22 - 2.15 (m, CH2), 3.53 (t, J = 6.1 Hz, CH2), 3.92 (t, J = 6.6 Hz, CH2), 6.95 - 6.82 (m, 3 H); 13C (CDC13) δ 30.6, 39.7, 41.7, 99.5 (J = 28.7 Hz), 108.3 (J = 9.4 Hz), 110.5 (J = 24.2 Hz), 127.5 (J = 1.9 Hz), 142.7 (J = 13.6 Hz), 154.5, 158.8 (J = 241.6). 3.82 3-G-ChloropropylV5-fluoro-3H-benzooxazol-2-one .86KK21k)
[0191] Crude 5-fluoro-3H-benzooxazol-2-one (86KK20k) DMF solution, 3-chloro-l- iodopropane (0.480 g, 1.47 mmol), and Cs2C03 (0.299 g, 1.46 mmol) were reacted according to GP10. Purified by using an Isco CombiFlash Sq 16x [10 g silica column, eluting 0-20% EtOAc in n-heptane (35 min) then 20% EtOAc in n-heptane (3 min)] to give the title compound (86KK21k) (0.078 g). Η-NMR (CDC13) δ 2.28 (quint, J = 6.3 Hz, CH2), 3.62 (t, J = 6.1 Hz, CH2), 4.00 (t, J = 6.7 Hz, CH2), 6.87 - 6.80 (m, 2 H), 7.16 - 7.13 (m, 1 H); 13C-NMR (CDC13) δ 30.6, 39.9, 41.7, 97.0 (J = 29.7), 108.8 (J = 24.8), 110.8 (J = 9.7), 132.1 (J = 12.6), 138.6, 154.8, 159.7 (J = 242.0 Hz).
3.83 General procedure 11 (GPl 1)
[0192] A 4 ml vial was charged with 3-H-benzooxazol-2-one (1 equiv), 3- bromopropanol (1.2 equiv), diethyl azodicarboxylate (1.2 equiv), and triphenylphosphine (1.2 equiv) in TΗF (2 ml). The mixture was stirred at r.t under an Argon atmosphere for 20 h. The reaction mixture was concentrated in vacuo before being purified by using an Isco CombiFlasch Sq 16x to give the product.
3.84 3-(3-Bromopropyl)-6-methoxy-3H-benzooxazol-2-one (97KK01a)
[0193] 6-Methoxy-3H-benzooxazol-2-one (86KK39d) (0.093 g, 0.56 mmol), 3- bromopropan-1-ol (0.093 g, 0.67 mmol), diethyl azodicarboxylate (0.117 g, 0.67 mmol), and PPh3 (0.176 g, 0.67 mmol) in TΗF (4 ml) were reacted according to GPU. Purified by using an Isco CombiFlash Sq 16x [4 g silica column, eluting 0-80% DCM in n-heptane (37 min) then 80% DCM in n-heptane (10 min)] to give the title compound (97KK01a) (0.114 g, 71%>). Η-NMR (MeOD + CDCI3) δ 2.30 (m, CΗ2), 3.44 (t, J = 6.5, CH2), 3.95 (t, J = 6.9, CH2), 6.78 - 6.75 (m, 1 H), 6.85 -
6.84 (m, 1 H), 7.05 - 7.03 (m, 1 H); 13C-NMR (MeOD + CDCI3) δ 30.2, 31.5, 41.4, 56.4, 98.3, 109.5, 110.3, 125.3, 144.1, 156.1, 157.3.
3.85 3-(3-Bromopropyl)-5.7-dibromo-3H-benzooxazol-2-one (97KK01b)
[0194] 5,7-Dibromo-3H-benzooxazol-2-one (86KK39c) (0.138 g, 0.47 mmol), 3- bromopropan-1-ol (0.078 g, 0.56 mmol), diethyl azodicarboxylate (0.098 g, 0.56 mmol), and PPh3 (0.148 g, 0.56 mmol) in THF (4 ml) was reacted according to GPU. Purified by using an Isco CombiFlash Sq 16x [4 g silica column, eluting 0-60% DCM in n-heptane (36 min) then 60% DCM in n-heptane (15 min)] to give the title compound (97KK09b) (0.152 g, 87%). 'H-NMR (MeOD + CDCI3) δ 2.35 - 2.30 (m, CH2), 3.44 (t, J = 6.3, CH2), 3.96 (t, J = 6.8 Hz, CH2), 7.25 (s, 1 H), 7.41 (s, 1 H); 13C-NMR (MeOD + CDC13) δ 29.7, 30.8, 41.8, 103.6, 111.4, 117.4, 128.5, 133.3, 140.4, 153.9. 3.86 3-G-BromopropylV7-methyl-3H-benzooxazol-2-one (97KK03a
[0195] 7-Methyl-3H-benzooxazol-2-one (86KK37a) (0.100 g, 0.67 mmol), 3- bromopropan-1-ol (0.112 g, 0.80 mmol), diethyl azodicarboxylate (0.140 g, 0.80 mmol), and PPh3 (0.211 g, 0.80 mmol) in THF (4 ml) was reacted according to GPll. Purified by using an Isco CombiFlash Sq 16x [4 g silica column, eluting 0-60%> DCM in n-heptane (36 min) then 60%> DCM in n-heptane (15 min)] to give the crude title compound (97KK03a) (0.072 g). Η-NMR (MeOD) δ 2.31 - 2.26 (m, CH2), 3.46 (t, J = 6.5 Hz, CH2), 3.94 (t, J = 6.6, CH2), 7.10 - 6.91 (m, 3 H).
3.87 3-(3-Bromopropyl)-7-isopropyl-3H-benzooxazol-2-one (97KK03b)
[0196] 7-Isopropyl-3H-benzooxazol-2-one (86KK37b) (0.131 g, 0.74 mmol), 3- bromopropan-1-ol (0.123 g, 0.89 mmol), diethyl azodicarboxylate (0.155 g, 0.89 mmol), and PPh3 (0.233 g, 0.89 mmol) in THF (4 ml) was reacted according to GPll. Purified by using an Isco CombiFlash Sq 16x [4 g silica column, eluting 0-60% DCM in n-heptane (35 min) then 60% DCM in n-heptane (15 min)] to give the crude title compound (97KK03b) (0.089 g). H-NMR ( MeOD) δ
1.29 (d, J = 7.0, 2 CH3), 2.29 (quint, J = 6.7 Hz, CH2), 3.18 (sept, J = 6.9 Hz, CH), 3.47 (t, J = 6.5 Hz, CH2), 3.97 (t, J = 6.9, CH2), 7.04 - 7.00 (m, 2 H), 7.17 - 7.13 (m, 1 H).
3.88 3-(3-Bromopropyl)-5.7-diisopropyl-3H-benzooxazol-2-one (97KK03c)
[0197] 5,7-Diisopropyl-3H-benzooxazol-2-one (86KK39a) (0.110 g, 0.50 mmol), 3- bromopropan-1-ol (0.083 g, 0.60 mmol), diethyl azodicarboxylate (0.104 g, 0.60 mmol), and PPh (0.157 g, 0.60 mmol) in THF (4 ml) was reacted according to GPll. Purified by using an Isco CombiFlash Sq 16x [4 g silica column, eluting 0-60% DCM in n-heptane (35 min) then 60% DCM in n-heptane (15 min)] to give the crude title compound (97KK03c) (0.078 g). 'H-NMR (MeOD) δ 1.25 (d, J = 6.8 Hz, 2 CH3), 1.30 (d, J = 7.0 Hz, 2 CH3), 2.30 (quint, 6.7 Hz, CH2), 2.93 (sept, J = 6.8 Hz, CH), 3.15 (sept, J = 6.9 Hz, CH), 3.49 (t, J = 6.5 Hz, CH2), 3.98 (t, J = 6.7 Hz, CH2), 6.88 (s, 1 H), 6.96 (s, 1 H).
3.89 3-(3-Bromopropyl)-4,6-dimethoxy-3H-benzooxazol-2-one (97KK05b)
[0198] 4,6-Dimethoxy-3H-benzooxazol-2-one (86KK39e) (0.050 g, 0.26 mmol), 3- bromopropan-1-ol (0.043 g, 0.31 mmol), diethyl azodicarboxylate (0.54 g, 0.31 mmol), and PPh3 (0.82 g, 0.31 mmol) in THF (4 ml) was reacted according to GPll. Purified by using an Isco CombiFlash Sq 16x [4 g silica column, eluting 0-60% DCM in n-heptane (35 min) then 60%» DCM in n-heptane (15 min)] to give the title compound (97KK05b) (0.035 g, 43%). !H-NMR (MeOD) δ
2.30 (quint, J = 6.7 Hz, CH2), 3.43 (t, J = 6.6 Hz, CH2), 3.77 (s, OCH3), 3.88 (s, OCH3), 4.07 (t, J = 6.8 Hz, CH2), 6.47 - 6.37 (m, 2 H). 3.90 3-.3-BromopropylV7-fluoro-3H-benzooxazol-2-one .97KK12a)
[0199] 7-Fluoro-3H-benzooxazol-2-one (97KK09a) (0.186 g g, 1.21 mmol), 3- bromopropan-1-ol (0.202 g, 1.45 mmol), diethyl azodicarboxylate (0.253 g, 1.45 mmol), and PPh3 (0.381 g, 1.45 mmol) in THF (4 ml) was reacted according to GPl l. Purified by using an Isco CombiFlash Sq 16x [4 g silica column, eluting 0-50%> DCM in n-heptane (46 min) then 50%> DCM in n-heptane (10 min)] to give the title compound (97KK12a) (0.100 g, 30%). Η-NMR (CDC13) δ 2.32 - 2.26 (m, CH2), 3.38 (t, J = 6.1 Hz, CH2), 3.94 (t, J = 6.9 Hz, CH2), 6.87 - 6.82 (m, 1 H), 7.10 - 7.05 (m, 2 H); 13C-NMR (CDC13) δ 29.8, 30.8, 41.4, 104.4 (J = 3.9 Hz), 110.8 (J = 16.8 Hz), 124.8 (J = 7.1 Hz), 139.8 (J = 14.5 Hz), 133.8 (J = 4.8 Hz), 146.2 (J = 250.3 Hz), 154.0
3.91 3-(3-Bromopropyl)-5.7-dichloro-6-methyl-3H-benzooxazol-2-one (97KK12b)
[0200] 5,7-Dichloro-6-methyl-3H-benzooxazol-2-one (97KK09c) (0.239 g g, 1.10 mmol), 3-bromopropan-l-ol (0.183 g, 1.32 mmol), diethyl azodicarboxylate (0.230 g, 1.32 mmol), and PPh3 (0.346 g, 1.32 mmol) in THF (4 ml) was reacted according to GPl l. Purified by using an Isco CombiFlash Sq 16x [4 g silica column, eluting 0-50%> DCM in n-heptane (46 min) then 50%) DCM in n-heptane (10 min)] to give the crude title compound (97KK12b) (0.051 g).
3.92 General Procedure 12 (GP 12)
[0201] The heterocycle (1 equiv) and Nal (2 equiv) in acetone (1 ml per mmol) were heated to 50°C for 72 h then cooled to r.t.. Aqueous sodium thiosulphate solution (10-20 ml) was added and the product was extracted into EtOAc (2x20-100 ml). The organic layer was dried (K2C03), filtered and concentrated in vacuo before being purified.
3.93 l-(2-Iodoethyl)- -dihvdrobenzoimidazol-2-one (56NK93~)
[0202] l-(2-Chloroethyl)-l,3-dihydrobenzoimidazol-2-one (178 mg, 0.905 mmol) was used according to GP12. The crude product was purified using an Isco CombiFlash Sq 16x [4.1 g silica column, eluting heptane (5 min), 0-40% EtOAc in heptane (20 min), 40% EtOAc in heptane (10 min)] to give the title compound (56NK93) as a pale yellow oil (204 mg, 78%). !H NMR (CDC13) δ 9.26 (br. s, IH), 7.10 (m, 3H), 7.04 (m, IH), 4.28 (t, J=7.6Hz, 2H), 3.44 (t, J=7.6Hz, 2H); HPLC-MS (ammonium acetate) [M+H]+=289.0.
3.94 l-.4-Iodobutyl)-l,3-dihvdrobenzoimidazol-2-one f56NK94)
[0203] l-(4-Chlorobutyl)-l,3-dihydrobenzoimidazol-2-one (456 mg, 2.03 mmol) was used according to GP12. The crude product was purified using an Isco CombiFlash Sq 16x [10 g silica column, eluting heptane (2 min), 0-40% EtOAc in heptane (31 min), 40% EtOAc in heptane (15 min)] to give the title compound (56NK94) as a pale yellow oil (491 mg, 77%). !H NMR (CDCI3) δ 9.28 (br. s, IH), 7.10 (m, 3H), 7.02 (m, IH), 3.92 (m, 2H), 3.25 (m, 2H), 1.92 (m, 4H); HPLC-MS (ammonium acetate) [M+H]+=317.0.
3.95 l-(3-Iodopropyl)-1.3-dihydrobenzoimidazol-2-one (56NK36)
[0204] l-(3-Chloropropyl)-l,3-dihydrobenzoimidazol-2-one (10.5 g, 50 mmol) was used according to GP12. The crude product was recrystallised from EtOAc to give the title compound (56NK36) as a while powder (12.15 g, 80 %). XH NMR (CDC13) δ 9.93 (br. s, IH), 7.11 (m, IH), 4.00 (t, J=6.2Hz , 2H), 3.22 (t, J=6.8Hz , 2H), 2.34 (pent, J=6.8 Hz, 2H); HPLC-MS (ammonium acetate) [M+H]+=302.1.
3.96 l-(3-Iodopropyl)-3-methyl-1.3-dihydrobenzoimidazol-2-one (56NK85)
[0205] l-(3-Chloropropyl)-3-methyl-l,3-dihydrobenzoimidazol-2-one (852 mg, 3.79 mmol) was used according to GP12. The crude product was purified using an Isco CombiFlash Sq 16x [10 g silica column, eluting heptane (1 min), 0-40% EtOAc in heptane (25 min), 40% EtOAc in heptane (10 min)] to give the title compound (56NK85) as a pale yellow oil (1.02 g, 86%). H NMR (CDCI3) δ 7.10 (m, 3H), 6.98 (m, IH), 3.98 (t, J=6.8Hz, 2H), 3.42 (s, 3H), 3.20 (t, J=6.8Hz, 2H), 2.31 (pent, J=6.8 Hz, 2H); 13C NMR (CDC13) δl54.30, 130.01, 129.23, 121.28, 107.48, 107.47, 41.59, 32.40, 27.06, 2.17; HPLC-MS (ammonium acetate) [M+H]+=317.0.
3.97 l-(2-ChloroethylV1.3-dihvdrobenzoimidazol-2-one (56NK9D
[0206] Sodium hydride (400 mg, 10 mmol, 60% in oil) was washed with dry DMF (10 ml) under an argon atmosphere then DMF (10 ml) was added. The slurry of NaH in DMF was added slowly to 2-hydroxybenzimidazole (1.34 g, 10 mmol) in DMF (10 ml) at 0°C under argon. The reaction was stirred at 0°C for 20 min then l-chloro-2-iodoethane (1.90 g, 10 mmol) in DMF (5 ml) was added slowly. The reaction was stirred at r.t. for 1.5 h then water (10 ml) was added and the reaction acidified with HC1 (2M, few drops) then made basic with aqueous sodium hydrogen carbonate solution. The product was extracted with EtOAc (3x30 ml) and the organic layer was washed with aqueous sodium thiosulphate solution (10 ml), aqueous magnesium sulphate solution (4%, 2x10 ml), brine (10 ml), dried (K2C03), filtered and concentrated in vacuo before being purified by using an Isco CombiFlash Sq 16x [10 g silica column, eluting heptane (5 min), 0-40%> EtOAc in heptane (35 min), 40% EtOAc in heptane (20 min)] to give the title compound (56NK91) as a pale yellow oil (162 mg, 8%). 'H NMR (CDC13) δ 8.70 (br. s, IH), 7.09 (m, 4H), 4.22 (t, J=6.5Hz, 2H), 3.84 (t, J=6.5Hz, 2H); 13C NMR (CDC13) δ 155.11, 130.28, 127.74, 121.91, 121.60, 109.63, 108.45, 42.75, 41.16.
3.98 l-(4-Chlorobutyl)-1.3-dihvdrobenzoimidazol-2-one f56NK92) [0207] Sodium hydride (400 mg, 10 mmol, 60% in oil) was washed with dry DMF (10 ml) under an argon atmosphere then DMF (10 ml) was added. The slurry of NaH in DMF was added slowly to 2-hydroxybenzimidazole (1.34 g, 10 mmol) in DMF (10 ml) at 0°C under argon. The reaction was stirred at 0°C for 20 min then l-chloro-4-iodobutane (2.18 g, 10 mmol) in DMF (5 ml) was added slowly. The reaction was stirred at r.t. for 1.5 h then water (10 ml) was added and the reaction acidified with HC1 (2M, few drops) then made basic with aqueous sodium hydrogen carbonate solution. The product was extracted with EtOAc (3x30 ml) and the organic layer was washed with aqueous sodium thiosulphate solution (10 ml), aqueous magnesium sulphate solution (4%, 2x10 ml), brine (10 ml), dried (K2C03), filtered and concentrated in vacuo before being purified by using an Isco CombiFlash Sq 16x [10 g silica column, eluting heptane (5 min), 0-40% EtOAc in heptane (35 min), 40% EtOAc in heptane (20 min)] to give the title compound (56NK92) as a pale yellow oil (416 mg, 19%). !H NMR (CDC13) δ 10.48 (br. s, IH), 7.26-7.00 (m, 4H), 3.95 (t, J=6.8Hz, 2H), 3.59 (t, J=6.3Hz, 2H), 1.97 (m, 2H), 1.87 (m, 2H); 13C NMR (CDC13) δ 158.88, 130.08, 128.14, 121.56, 121.25, 109.82, 107.74, 44.32, 39.88, 29.53, 25.66; HPLC-MS (ammonium acetate) [M+H]+=225.2.
3.99 1 -.3 -Chloropropyl)-3 -methyl- 1.3 -dihydrobenzoimidazol-2-one (56NK01 )
[0208] l-(3-Chloropropyl)-l,3-dihydrobenzoimidazol-2-one (2.10 g, 10 mmol), methyl iodide (1.5 ml, 25 mmol), sodium hydroxide (2 M, 5 ml, 10 mmol) and MeCN (10 ml) were stirred at r.t. 18 h. Water (10 ml) was added and the product was extracted into EtOAc (2x30 ml). The organic layer was washed with aqueous sodium thiosulphate solution (5 ml), brine (10 ml), dried (K2Cθ3), filtered and concentrated in vacuo before being purified by using an Isco CombiFlash Sq 16x [35 g silica column, eluting heptane (1 min), 0-50%> EtOAc in heptane (40 min), 50% EtOAc in heptane (40 min)] to give the title compound (56NK01) as a pale yellow oil (1.93 g, 86%). *H NMR (CDC13) δ 7.10 (m, 3H), 6.98 (m, IH), 4.06 (t, J=6.6Hz, 2H), 3.85 (t, J=6.6Hz, 2H), 3.42 (s, 3H), 2.25 (pent, J=6.6 Hz, 2H); HPLC-MS (ammonium acetate) [M+H]+=225.1.
3.100 3-.4-Chlorobutyl)-3H-benzooxazole-2-thione C56NK132)
[0209] Iodine (127 mg, 0.5 mmol) in DMF (2 ml) was added to 2-(4- chlorobutylsulfanyl)-benzooxazole (697 mg, 2.88 mmol) and the reaction was heated to 125°C for 24 h then cooled to r.t. Aqueous sodium thiosulplate solution (5 ml) was added and the product was extracted with ether (3x30 ml). The organic phase was washed with aqueous magnesium sulphate solution (4%, 2x10 ml), brine (10 ml), dried (K2C03), filtered and concentrated in vacuo. The crude product was purified using an Isco CombiFlash Sq 16x [4.1 g silica column, eluting heptane (3 min), 0-10% EtOAc in heptane (25 min), 10% EtOAc in heptane (2 min)] to give the title compound (56NK132) as a white powder (68 mg, 10%). *H NMR (CDC13) δ 7.36 (m, IH), 7.28 (m, 2H), 7.13 (m, IH), 4.25 (t, J=7.2Hz, 2H), 3.62 (t, J=6.2Hz, 2H), 2.06 (m, 2H), 1.92 (m, 2H).
3.101 l-f3-ChloropropylVlH-indol-2.3-dione (85LM02).
[0210] A 500 ml flask was charged with lH-indol-2,3-dione (isatin) (3.62 g, 25 mmol), l-chloro-3-iodopropan (2.8 ml, 27 mmol) and Cs2C03 (18 g, 55 mmol) in MeCN (200 ml). The mixture was stirred 40°C for 48 hours. Water (50 ml) and EtOAc (50 ml) were added and the phases were separated. The aqueous phase was re-extracted with EtOAc (50ml). The combined org. layer were dried (Na2Sθ4) and evaporated to dryness. The crude product was purified by to column chromatography (Si02; EtOAc/n-heptane 1:4) to give the title compound (85LM02) (4.2 g, 80%). *H NMR (CDC13) δ 2.20 (qv, 2H), 3.60 (t, 2H), 3.90 (t, 2H), 7.00 (d, IH), 7.15 (t, IH), 7.55-7.65 (m, 2H); HPLC-MS (ammonium acetate) [M+H]+=224.2.
3.102 l-(3-Iodopropyl)-lH-indol-2.3-dione (85LM05).
[0211] A 50 ml flask, charged with compound l-(3-chloropropyl)-lH-indol-2,3-dione (85LM02) (0.232 g, 1 mmol) and Nal (0.327 g, 2.2 mmol) in acetone (10 ml), was stirred at 50°C for 24 hours. Water (10 ml) was added and the phases were separated. The aqueous phase was re- extracted with acetone (10ml). The combined organic phases were dried (Na2S04) and evaporated to dryness to give the crude title compound (85LM05) (0.294 g). Η NMR (CDC13) δ 2.20 (qv, 2H), 3.20 (t, 2H), 3.80 (t, 2H), 7.0 (d, IH), 7.15 (t, IH), 7.55-7.65 (m, 2H).
3.103 3-αH-Indol-3-yl)propan-l-ol (85LM16B).
[0212] A suspension of L1AIH4 (2.48g, 65mmol) in dry THF (140 ml) was stirred in a 500 ml flask. 3-(lH-indol-3-yl)propionic acid (5.38g, 28 mmol) was dissolved in dry THF (20 ml) and added slowly. The mixture was heated to 35°C. Stirring was continued for 2 hours at 35°C and overnight at room temperature. Water (20 ml) was added drop wise and very slowly, followed by addition of H2O/H2SO4 (1:1) (50 ml). To the resulting mixture NaOH was added (until pH 7) and the two phases were separated. The organic phase was dried (Na2S04) and evaporated to dryness to give the crude title compound (85LM16B) (5.0 g). The material was used for the next reaction step without further purification. 1H NMR (CD3OD) δ 1.92 (qv, 2H), 2.80 (t, 2H), 3.61 (t, 2H), 7.00 (t, IH), 7.05 (t, IH), 7.33 (d, IH), 7.55 (d, IH).
3.104 Toluene-4-sulfonic acid 3-(TH-indol-3-vDpropyl ester C85LM17).
[0213] Crude 3-(lH-indol-3-yl)propan-l-ol (85LM16B) (5.0 g, 29 mmol) and pyridine (10 ml, 160 mmol) was dissolved in dry TΗF (140 ml) in a 100 ml flask. The mixture was cooled to -78°C and p-toluenesulfonyl chloride (10.9 g, 57 mmol) dissolved in dry TΗF (10 ml) was slowly added followed by stirring at -78°C for 1 hour and then heating to room temperature over a period of 20 minutes. The solution was washed with H2S04 (10 ml, IM) then saturated aqueous sodium bicarbonate (10 ml) and finally water (10 ml). The organic phase was dried (Na2S04) and evaporated to dryness to give the crude title compound (85LM17) (4.0 g). The material was used for the next reaction step without further purification.
3.105 3-(3-Bromo-2-hvdroxypropyl)-3H-benzothiazol-2-one (85LM04).
[0214] A 50 ml flask, charged with 2-hydroxybenzothiazol (0.650 g, 4.3 mmol), 1,3- dibromo-2-propanol (0.22 ml, 2.2 mmol) and Cs2C03 (3.0 g, 9.2 mmol) in MeCN (20 ml), was stirred at 40°C for 24 hours. Water (10 ml) and EtOAc (10 ml) were added and the phases were separated. The aqueous phase was re-extracted with EtOAc (10ml). The combined organic phases were dried (Na2S04) and evaporated to dryness to give the crude title compound (85LM04) (0.308 g). The material was used for the next reaction step without further purification.
3.106 3-(3-Chloro-2-methyl-propylV3H-benzothiazol-2-one (85LM13).
[0215] A 50 ml flask, charged with 2-hydroxybenzothiazol (0.603 g, 4.0 mmol), 1- bromo-3-chloro-2-methylpropan (0.56 ml, 4.8 mmol) and Cs2C03 (2.86 g, 8.8 mmol) in CΗ3CN (20 ml), was stirred at 40°C for 24 hours. Water (10 ml) and EtOAc (10 ml) were added and the phases were separated. The aqueous phase was re-extracted with EtOAc (10ml). The combined organic phases were dried (Na2Sθ4) and evaporated to dryness. The crude product was subjected to column chromatography (Si02; EtOAc/n-heptane 1:8) to give the title compound (85LM13) (0.769 g, 80%). 1HNMR (CDC13) δ 1.10 (d, 3H), 2.45 (octet, IH), 3.55 (d, 2H), 3.90 (dd, IH), 4.05 (dd, IH), 7.10- 7.20 (m, 2H), 7.35 (t, IH), 7.40 (d, IH); HPLC-MS (ammonium acetate) [M+H]+=242.1.
3.107 General Procedure 13 (GP 13)
[0216] A 100 ml flask, charged with either (R)- or (S)-3-bromo-2-methyl-propanol (1 equiv), 2-hydroxybenzothiazol (1 equiv) mmol) ,and Cs2C03 (1 equiv) in MeCN (30 ml), was stirred at 50°C for 48 hours. Water (20 ml) and EtOAc (20 ml) were added and the phases were separated. The aqueous phase was re-extracted with EtOAc (20ml). The combined org. layer was dried (Na2SO4) and concentrated in vacuo to give the crude product. The material was used for the next reaction step without further purification.
3.108 3-(( R)-3-Hvdroxy-2-methylpropylV3H-benzothiazol-2-one (85LM72-60\ (S)-3-Bromo-2-methylpropanol (0.760 g, 5.0 mmol), 2-hydroxybenzothiazol (0.751 g, 5.0 mmol), and Cs2C03 (1.6 g, 5.0 mmol) in MeCN (30 ml) were reacted according to GP13 to give the title crude compound (85LM72-60) (1.3 g). 3.109 3-(fSV3-Hvdroxy-2-methylpropyl)-3H-benzothiazol-2-one , 85LM89-76V (R)-3-Bromo-2-methylpropanol (0.760 g, 5.0 mmol), 2-hydroxybenzothiazol (0.751 g, 5.0 mmol), and Cs2C0 (1.6 g, 5.0 mmol) in MeCN (30 ml) were reacted according to GP13 to give the title crude compound (85LM89-76) (1.3 g).
3.110 General Procedure 14 (GP14)
[0217] 3-Hydroxyalkyl-3H-benzothiazol-2-one (1 equiv) and pyridine (4 equiv) was dissolved in dry DCM (50 ml) in a 100 ml flask. The mixture was stirred and cooled to -78°C followed by slow addition of p-toluenesulfonyl chloride (5 equiv) dissolved in dry DCM (10 ml). Stirring was continued at -78°C for 1 hour and at room temperature for 2 hours. The solution was washed with hydrochloric acid (10 ml, IM) then saturated aqueous sodium bicarbonate (10 ml) and finally water (10 ml). The organic phase was dried (Na2S04) and evaporated to dryness. The crude product was purified by column chromatography (Si02; DCM).
3.111 Toluene-4-sulfonic acid (R)-2-methyl-3-C2-oxobenzothiazol-3-yl>propyl ester .85LM73-
6TJ
[0218] 3-((R)-3-Hydroxy-2-methylpropyl)-3H-benzothiazol-2-one (85LM72-60) (1.3 g, 2.8 mmol), pyridine (0.900 g, 11.4 mmol), and p-toluenesulfonyl chloride (2.7 g, 14.2 mmol) were reacted according to GP14 to give the title compound (85LM73-61) (0.90 g, 48%) - 2 steps). Η NMR (CDC13) δ 1.0 (d, 3H), 2.45 (m, 4H), 3.80-3.90 (m, 2H), 3.90-4.00 (m, 2H), 7.0 (d, IH), 7.15 (t, IH), 7.25-7.35 (m, 3H), 7.40 (d, IH), 7.75 (d, 2H).
3.112 Toluene-4-sulfonic acid (S)-2-methyl-3-(2-oxo-benzothiazol-3-yl)-propyl ester (85LM90- 77).
[0219] 3-((S)-3-Hydroxy-2-methylpropyl)-3H-benzothiazol-2-one (85LM89-76) (1.3 g, 2.8 mmol), pyridine (0.900 g, 11.4 mmol), and p-toluenesulfonyl chloride (2.7 g, 14.2 mmol) were reacted according to GP14 to give the title compound (85LM90-77) (0.90 g, 46%> - 2 steps). *H NMR (CDC13) δ 1.0 (d, 3H), 2.45 (m. 4H), 3.80-3.90 (m, 2H), 3.90-4.00 (m, 2H), 7.0 (d5 IH), 7.15 (t, IH), 7.25-7.35 (m, 3H), 7.40 (d, IH), 7.75 (d, 2H).
3.113 3-G-IodopropylV3H-benzothiazol-2-one ( 61KS80Y
[0220] 3-(3-Chloropropyl)-3H-benzothiazol-2-one (62KK21) (1.58 g, 6.94 mmol) was dissolved in acetone (10 mL) and Nal (2.08 g, 13.9 mmol) was added. The mixture was heated to 50 °C under stirring for 18 h. A saturated aq. solution of Na2S203 (5mL) was added followed by extraction (EtOAc). The combined organic phase was dried (Na2Sθ4), filtered and concentrated in vacuo which gave the title compound (61KS80) (2.17 g, 98%) as a colourless oil which on prolonged standing crystallised to a white powder. This was sufficiently pure for further reaction. !H NMR (CDCI3) 2.25 (q, 2H, J=7.0Hz, -CHzCH^CHJ), 3.22 (t, 2h, J=7.0Hz, -CK2CH.2CR_I), 4.04 (t, 2H, J=7.0Hz, -CR_CK2CR_I), 7.13 - 7.46 (m, 4H, Ar); 13C NMR (CDCI3) 0.0 (- CH2CH2CH2I), 29.8 (-CH2CH2CH2I), 41.7 (-CH2CH2CH2I), 108.8, 121.1, 121.1, 121.6, 124.8, 135.2 (Ar), 168.3 (CO).
3.114 General procedure 15 (GP 15)
[0221] A 4 ml vial was charged with 3-chloroalkyl-3H-benzooxazol-2-one (1 equiv),
4-butylpiperidine (1 equiv), Nal (0.100 g, 0.67 mmol), and K2C03 (0.075 g, 0.54 mmol) in MeCN (1 ml) and shaken at 50 °C for 20 h. The reaction mixture was cooled to r.t. and DCM was added (2 ml). Isocyanate resin (ca. 3 equiv, 1.1 mmol/g) was added and the mixture left at r.t. for 24 h. The mixture was filtered through cotton onto an acidic ion-exchange column. The column was washed with MeOH (2 column volumes) then the product was eluded of the column using 10% ammonium hydroxide in MeOH (2 column volumes) and concentrated m vacuo.
3.115 3 -[2-(4-Butylpineridin- 1 -yl)ethyll-3H-benzothiazol-2-one (67KK20a
[0222] 3-(2-Chloroethyl)-3H-benzothiazol-2-one (62KK38) (0.043 g, 0.2 mmol) and
4-butylpiperidine (0.028 g, 0.2 mmol) were reacted according to GP15 to give the title compound (67KK20a) (0.008 g, 13%). HPLC-MS (ammonium acetate) [M+H]+ = 319.4.
3.116 3-[2-f2-Ethylpiperidin-l-yl)ethyll-3H-benzothiazol-2-one (67KK17f)
[0223] 3-(2-Chloroethyl)-3H-benzothiazol-2-one (62KK38) (0.032 g, 0.15 mmol) and
2-ethylpiperidine (0.017 g, 0.15 mmol) were reacted according to GP15 to give the title compound (67KK17f) (0.003 g, 7%). HPLC-MS (ammonium acetate) [M+H]+ = 291.3.
3.117 3-r2-(4-Methylpiperidin-l-vnethyll-3H-benzothiazol-2-one (67KK20c)
[0224] 3-(2-Chloroethyl)-3H-benzothiazol-2-one (62KK38) (0.043 g, 0.2 mmol) and 4-methylpiperidine (0.020 g, 0.2 mmol) were reacted according to GP15 to give the title compound (67KK20c) (0.008 g, 14%). HPLC-MS (ammonium acetate) [M+H]+ = 277.3.
3.118 3-r3-(4-Butylpiperidin-l-yl)propyn-3H-benzothiazol-2-one (62KK40d)
[0225] 3-(3-Chloropropyl)-3H-benzothiazol-2-one (62KK21) (0.046 g, 0.2 mmol) and 4-butylpiperidine (0.028 g, 0.2 mmol) were reacted according to GPl 5 to give the title compound (62KK40d) (0.042 g, 63%). HPLC-MS (ammonium acetate) [M+H]+ = 333.1.
3.119 3-r3-(2-Ethylpiperidin-l-vnpropyll-3H-benzothiazol-2-one .67KK01f) [0226] 3-(3-Chloropropyl)-3H-benzothiazol-2-one (62KK21) (0.048 g, 0.21 mmol) and 2-ethylpiperidine (0.022 g, 0.19 mmol) were reacted according to GP15 to give the title compound (67KK01f) (0.015 g, 26%). HPLC-MS (ammonium acetate) [M+H]+ = 305.1.
3.120 3-r3-(4-Methylpiperidin-l-yl)propyll-3H-benzothiazol-2-one (67KK01g)
[0227] 3-(3-Chloropropyl)-3H-benzothiazol-2-one (62KK21) (0.048 g, 0.21 mmol) and 4-methylpiperidine (0.020 g, 0.20 mmol) were reacted according to GP15 to give the title compound (67KK01g) (0.024 g, 41%). HPLC-MS (ammonium acetate) [M+H]+ = 291.0.
3.121 3-r4-.4-Butylpiperidin-l-vnbutyll-3ff-benzothiazol-2-one (62KK40e
[0228] 3-(4-Chlorobutyl)-3H-benzothiazol-2-one (62KK29) (0.049 g, 0.20 mmol) and 4-butylpiperidine (0.028 g, 0.20 mmol) were reacted according to GPl 5 to give the title compound (62KK40e) (0.032 g, 46%). HPLC-MS (ammonium acetate) [M+H]+ = 347.1.
3.122 3-r4-( 2-Ethylpiperidin- 1 -vnbutyll-3H-benzothiazol-2-one (67KK04f)
[0229] 3-(4-Chlorobutyl)-3H-benzothiazol-2-one (62KK29) (0.025 g, 0.10 mmol) and 2-ethylpiperidine (0.011 g, 0.10 mmol) were reacted according to GPl 5 to give the title compound (67KK04f) (0.015 g, 47%). HPLC-MS (ammonium acetate) [M+H]+ = 319.1.
3.123 3-[4-(4-Methylpiperidin-l-yl)butyll-3H-benzothiazol-2-one (67KK40g)
[0230] 3-(4-Chlorobutyl)-3H-benzothiazol-2-one (62KK29) (0.025 g, 0.10 mmol) and 4-methylpiperidine (0.010 g, 0.10 mmol) were reacted according to GP15 to give the title compound (67KK04g) (0.019 g, 62%). HPLC-MS (ammonium acetate) [M+H]+ = 305.1.
3.124 3-r2-(4-Butylpiperidin-l-yl)ethyll-3H-benzooxazol-2-one (62KK40f)
[0231] 3-(2-Chloroethyl)-3H-benzooxazol-2-one (62KK39) (0.039 g, 0.20 mmol) and 4-butylpiperidine (0.028 g, 0.20 mmol) were reacted according to GP15 to give the title compound (62KK40f) (0.014 g, 23%). HPLC-MS (ammonium acetate) [M+H]+ = 303.1.
3.125 3-r2-(2-Ethylpiperidin-l-yl)ethyll-3H-benzooxazol-2-one (67KK16-f)
[0232] 3-(2-Chloroethyl)-3H-benzooxazol-2-one (62KK39) (0.032 g, 0.16 mmol) and 2-ethylpiperidine (0.017 g, 0.15 mmol) were reacted according to GP15 to give the title compound (67KK16-f) (0.006 g, 15%). HPLC-MS (ammonium acetate) [M+H]+ = 275.4.
3.126 3-r2-(4-Methylpiperidin-l-yl)ethyll-3H-benzooxazol-2-one (67KK16-g) [0233] 3-(2-Chloroethyl)-3H-benzooxazol-2-one (62KK39) (0.032 g, 0.16 mmol) and 4-methylpiperidine (0.015 g, 0.15 mmol) were reacted according to GP15 to give the title compound (67KK16-g) (0.015 g, 38%). HPLC-MS (ammonium acetate) [M+H]+ = 261.3.
3.127 3-[3-('4-Butylpiperidin-l-yl)propyll-3H-benzooxazol-2-one (62KK40g)
[0234] 3-(3-Chloroρropyl)-3H-benzooxazol-2-one (62KK30) (0.042 g, 0.20 mmol) and 4-butylpiperidine (0.028 g, 0.20 mmol) were reacted according to GPl 5 to give the title compound (62KK40g) (0.033 g, 52%). HPLC-MS (ammonium acetate) [M+H]+ = 317.3.
3.128 3-r3-(2-Ethylpiperidin-l-yl)propyl1-3H-benzooxazol-2-one (67KK07-f)
[0235] 3-(3-Chloropropyl)-3H-benzooxazol-2-one (62KK30) (0.021 g, 0.10 mmol) and 2-ethylpiperidine (0.011 g, 0.10 mmol) were reacted according to GPl 5 to give the title compound (67KK07-f) (0.013 g, 45%). HPLC-MS (ammonium acetate) [M+H]+ = 289.1.
3.129 3-r3-(4-Methylpiperidin-l-yl)propyn-3H-benzooxazol-2-one (67KK07-g)
[0236] 3-(3-Chloropropyl)-3H-benzooxazol-2-one (62KK30) (0.021 g, 0.10 mmol) and 4-methylpiperidine (0.010 g, 0.10 mmol) were reacted according to GP15 to give the title compound (67KK07-g) (0.016 g, 58%). HPLC-MS (ammonium acetate) [M+H]+ = 275.1.
3.130 3-r4-.4-Butylpiperidin-l-ynbutyll-3H-benzooxazol-2-one .62KK40h')
[0237] 3-(4-Chlorobutyl)-3H-benzooxazol-2-one (62KK28) (0.045 g, 0.20 mmol) and 4-butylpiperidine (0.028 g, 0.20 mmol) were reacted according to GP15 to give the title compound (62KK40h) (0.031 g, 47%). HPLC-MS (ammonium acetate) [M+H]+ = 331.2.
3.131 3-r4-(2-Ethylpiperidin-l-ynbutyll-3H-benzooxazol-2-one (67KK06-f)
[0238] 3-(4-Chlorobutyl)-3H-benzooxazol-2-one (62KK28) (0.023 g, 0.10 mmol) and 2-ethylpiperidine (0.011 g, 0.10 mmol) were reacted according to GP15 to give the title compound (67KK06-f) (0.007 g, 23%). HPLC-MS (ammonium acetate) [M+H]+ = 303.1.
3.132 3-[4-r4-Methylpiperidin-l-vnbutyl]-3H-benzooxazol-2-one (67KK016-g')
[0239] 3-(4-Chlorobutyl)-3H-benzooxazol-2-one (62KK28) (0.023 g, 0.10 mmol) and 4-methylpiperidine (0.010 g, 0.10 mmol) were reacted according to GP15 to give the title compound (67KK06-g) (0.009 g, 31%). HPLC-MS (ammonium acetate) [M+H]+ = 289.1.
3.133 General procedure 16 (GPl 6)
[0240] A 4 ml vial was charged with 3-(3-chloropropyl)-3H-benzooxazol-2-one (1 equiv), 4-butylpiperidine (1.2 equiv), Nal (0.100 g, 0.67 mmol), and K2C03 (0.075 g, 0.54 mmol) in MeCN (1 ml) and shaken at 50 °C for 20 h. The reaction mixture was cooled to r.t., water added (1 ml), and the product was extracted into EtOAc (2 x 1 ml). The combined org. layer was added an acidic ion-exchange column. The column was washed with MeOH (2 column volumes) then the product was eluded of the column using 10% ammonium hydroxide in MeOH (2 column volumes) and concentrated in vacuo. The product was purified by flash CC and/or by prep. RP-HPLC [conditions: stationary phase, Luna 15um C18; column, 250x21.2 mm; mobile phase, 20 ml/min, H20/MeCN, ammoniumacetate buffer (25nM)].
3.134 3-[3-f4-butylpiperidin-l-yllpropyl)-4-methyl-3H-benzooxazol-2-one .86KK25a')
[0241] 3-(3-Chloropropyl)-4-methyl-3H-benzooxazol-2-one (86KK21a) (0.063 g, 0.28 mmol) and 4-butylpiperidine (0.044 g, 0.31 mmol) were reacted according to GP16. Purified by prep. RP-HPLC to give the title compound (86KK25a) (0.039 g, 42%). !H NMR (CD3OD + CDC13) δ 0.87 (t, J = 6.7 Hz, CH3), 1.30 - 1.08 (m, 9 H), 1.62 (d, J = 11.9 Hz, 2 H), 1.97 - 1.87 (m, 4 H), 2.42 (t. J = 7.2 Hz, CH2), 2.55 (s, CH3), 2.86 (d, J = 11.7 Hz, 2 H), 4.03 (t J = 7.0, CH2), 7.05 - 6.94 (m, 3 H); 13C NMR (CD3OD + CDC13) δ 14.4, 17.6, 23.8, 27.8, 30.0, 33.0, 36.7, 37.2, 43.0, 55.0,
56.8, 108.7, 121.5, 123.4, 128.1, 129.9, 144.1, 156.8; HPLC-MS (ammonium acetate) [M+Η\+=33l.3 (MH¥).
3.135 3 -[3 -(4-butylpiperidin- l-yl]propyl)-5,7-dimethyl-3H-benzooxazol-2-one (86KK25b) [0242] 3-(3-Chloropropyl)-5,7-dimethyl-3H-benzooxazol-2-one (86KK21b) (0.043 g,
0.18 mmol) and 4-butylpiperidine (0.028 g, 0.20 mmol) were reacted according to GP16. Purified by prep. RP-HPLC to give the title compound (86KK25b) (0.032 g, 52%). !H NMR (CD3OD + CDCI3) δ 0.88 (t, J = 6.5 Hz, CH3), 1.27 - 1.11 (m, 9 H), 1.64 (d, J = 12,1 Hz, 2 H), 1.98 - 1.87 (m, 4 H), 2.30 (s, CH3), 2.35 (s, CH3), 2.39 - 2.35 (m, 2 H), 2.84 (d, J = 11.7 Hz, 2 H), 3.84 (t, J = 6.7 Hz, CH2), 6.75 (s, 1 H), 6.81 (s, 1 H); 13C NMR (CD3OD + CDC13) δ 14.4, 14.4, 21.6, 23.8, 25.6,
29.9, 33.0, 36.6, 37.2, 41.5, 54.9, 56.7, 107.9, 120.8, 125.5, 131.8, 134.9, 140.3, 156.6; HPLC-MS (ammonium acetate) [M+H]+=345.3.
3.136 3-r3-(4-butylpiperidin-l-yllpropylV6-methyl-3H-benzooxazol-2-one (86KK25c^)
[0243] 3-(3-chlorpropyl)-6-methyl-3H-benzooxazol-2-one (86KK21c) (0.052 g, 0.23 mmol) and 4-butylpiperidine (0.035 g, 0.25 mmol) were reacted according to GP16. Purified by prep. RP-HPCL to give the title compound (86KK25c) (0.014 g, 18%). *H NMR (CD3OD + CDC13) δ 0.88 (t, J = 7.0, CH3), 1.29 - 1.12 (m, 9 H), 1.65 (d, J = 11.1 Hz, 2 H), 2.00 - 1.89 (m, 4 H), 2.38 (s, CH3), 2.41 - 2.38 (m, 2 H), 2.86 (d, J = 11.9 Hz, 2 H), 3.87 (t, J = 6.8, CH2), 7.06 - 7.04 (m, 3 H); 13C NMR (CD3OD + CDC13) δ 14.4, 21.4, 23.7, 25.6, 29.9, 32.9, 36.6, 37.1, 41.5, 54.8, 56.7, 109.5, 111.3, 125.4, 129.9, 133.9, 143.9, 156.4; HPLC-MS (ammonium acetate) 3.137 3-13-(4-butylpiperidin-l-yllpropylV5-methyl-3H-benzooxazol-2-one r86KK25d)
[0244] 3-(3-chloropropyl)-5-methyl-3H-benzooxazol-2-one (86KK21d) (0.032 g, 0.14 mmol) and 4-butylpiperidine (0.021 g, 0.15 mmol) were reacted according to GP16. Purified by prep. RP-HPLC to give the title compound (86KK25d) (0.022 g, 48%). lU NMR (CD3OD + CDC13) δ 0.89 (t, J = 7.0, CH3), 1.29 - 1.15 (m, 9 H), 1.64 (d, J = 10.6, 2 H), 1.98 - 1.67 (m, 4 H), 2.37 - 2.41 (m, 2 H), 2.39 (s, CH3), 2.86 (d, J = 11.9 Hz, 2 H), 3.87 (t, J = 6.9, CH2), 6.92 - 7.09 (m, 3 H); 13C NMR (CD3OD + CDCI3) δ 14.4, 21.6, 23.8, 25.7, 29.9, 33.0, 36.6, 37.2, 41.4, 54.9, 56.6, 110.3, 110.4, 123.9, 132.3, 135.2, 141.9, 156.6; HPLC-MS (ammonium acetate) [M+H]+=331.3.
3.138 5-t-Butyl-3-r3-(4-butylpiperidin-l -yl)propyl]-3H-benzooxazol-2-one (86KK25e)
[0245] 5-t-butyl-3-(3-chloropropyl)-3H-benzooxazol-2-one (86KK21e) (0.056 g, 0.21 mmol) and 4-butylpiperidine (0.032 g, 0.23 mmol) were reacted according to GP16. Purified by prep. RP-HPLC to give the title compound (86KK25e) (0.103 g, 50%). [H MR (CD3OD + CDC13) δ 0.88 (t, J = 6.6 Hz, CH3), 1.34 - 1.11 (m, 18H), 1.63 (d, J = 11.3 Hz, 2 H), 1.88 - 1.99 (m, 4 H), 2.41 (t, J = 7.2 Hz, CH2), 2.86 (d, J = 11.9 Hz, 2 H), 3.91 (t, J = 6.8 Hz, CH2), 7.19 - 7.11 (m, 3 H); 13C NMR (CD3OD + CDCI3) δ 14.4, 23.7, 25.7, 29.9, 32.0, 33.0, 35.7, 36.6, 37.1, 41.4, 54.9, 56.8, 107.0, 110.0, 120.4, 132.0, 141.7, 148.9, 156.7; HPLC-MS (ammonium acetate) [M+H]+=373.3.
3.139 3-r3-(4-butylpiperidin-l-yl)propyn-6-chloro-3H-benzooxazol-2-one (86KK25f)
[0246] 3-(3-chloropropyl)-6-chloro-3H-benzooxazol-2-one (86KK21f) (0.138 g, 0.56 mmol) and 4-butylpiperidine (0.088 g, 0.62 mmol) were reacted according to GP16. Purified by prep. RP-HPLC to give the title compound (86KK25f) (0.103 g, 53%). 'HNMR (CD3OD) δ 0.89 (t, J = 6.9, CH3), 1.31 - 1.08 (m, 9 H), 1.62 (d, J = 11.9, 2 H), 1.84 - 1.98 (m, 4 H), 2.38 (t, J = 7.0 Hz, CH2), 2.83 (d, J = 11.9 Hz, 2 H), 3.89 (t, J = 6.7 Hz, CH2), 7.28 - 7.17 (m, 3 H); 13C NMR (CD3OD) δ 14.4, 23.9, 25.6, 30.1, 33.1, 36.8, 37.4, 41.9, 55.0, 56.8, 110.9, 111.5, 125.1, 128.7, 131.6, 144.3, 155.9; HPLC-MS (ammonium acetate) [M+H]+=351.2.
3.140 3-[3-(4-butylpiperidin-l-yl)propyll-5-methoxy-3H-benzooxazol-2-one (86KK22D
[0247] 3-(3-chloropropyl)-5-methoxy-3H-benzooxazol-2-one (86KK2H) (0.041 g,
0.17 mmol) and 4-butylpiperidine (0.027 g, 0.19 mmol) were reacted according to GP16. Purified by prep. RP-HPLC to give the title compound (86KK22i) (0.103 g, 36%). *H NMR (CD3OD + CDCI3) δ 0.88 (t, J = 6.9 Hz, CH3), 1.28 - 1.13 (m, 9 H), 1.65 (d, J = 12.1 Hz, 2 H), 1.98 - 1.89 (m, 4 H), 2.39 (t, J = 7.2 Hz, CH2), 2.86 (d, J = 11.9 Hz, 2 H), 3.81 (s, OCH3), 3.86 (t, J = 6.9 Hz, CH2), 6.67 - 6.65 (m, 1 H), 6.77 - 6.76 (m, 1 H), 7.11 - 7.09 (m, 1 H); 13C NMR (CD3OD + CDC13) δ 14.3, 23.7, 25.6, 29.8, 32.9, 36.5, 37.1, 41.4, 54.8, 56.4, 56.6, 96.9, 108.1, 110.9, 132.9, 137.7, 156.8, 158.1; HPLC-MS (ammonium acetate) [M+H]+=347.1.
3.141 3-[3-(4-butylpiperidin-l-yl)propyl1-5-fluoro-3H-benzooxazol-2-one (86KK22k)
[0248] 3-(3-chloropropyl)-5-fluoro-3H-benzooxazol-2-one (86KK21k) (0.039 g, 0.17 mmol) and 4-butylpiperidine (0.027 g, 0.19 mmol) were reacted according to GP16. Purified by prep. RP-HPLC to give the title compound (86KK22k) (0.032 g, 56%). !H NMR (CD3OD) δ 0.89 (t, J = 7.0 Hz, CH3), 1.29 - 1.09 (m, 9 H), 1.64 (, J = 11.9 Hz, 2 H), 1.99 - 1.86 (m, 4 H), 2.38 (t, J = 7.0 Hz, CH2), 2.84 (d, J = 11.7 Hz, CH2), 3.89 (t, J = 6.8 Hz, CH2), 6.88 - 6.83 (m, 1 H), 7.22 - 7.09 (m, 2 H); 13C NMR (CD3OD) δ 14.4, 23.9, 25.5, 30.1, 33.2, 36.8, 37.4, 41.9, 55.0, 56.8, 98.6 (J = 30.3 Hz), 109.4 (J = 25.2 Hz), 111.4 (J = 9.7 Hz), 133.7 (J = 13.2 Hz), 140.0 (J = 2.3 Hz), 156.7, 161.1 (J = 240.0 Hz); HPLC-MS (ammonium acetate) [M+H]+=335.1
3.142 3-r3-(4-butylpiperidin-l-yl)propyll-6-fluoro-3H-benzooxazol-2-one (97KK28)
[0249] 3-(3-chloropropyl)-6-fluoro-3H-benzooxazol-2-one (86KK21J) (0.090 g, 0.39 mmol) and 4-butylpiperidine (0.070 g, 0.50 mmol) were reacted according to GP16. Purified by flash CC (Si02; DCM/MeOH 20:1) and prep. RP-HPLC to give the title compound (97KK28) (0.065 g, 50%). Η NMR (CD3OD) δ 0.89 (t, J = 7.0, CH3), 1.29 - 1.09 (m, 9 H), 1.64 (d, J = 11.7, CH2), 1.99 - 1.86 (m, 4 H), 2.38 (t, J = 7.0 Hz, CH2), 2.84 (d, J = 11.9 Hz, 2 H), 3.90 (t, J = 6.9 Hz, CH2), 7.02 - 6.96 (m, 1 H), 7.21 - 7.10 (m, 2 H); 13C CD3OD) δ 14.4, 23.9, 25.6, 30.1, 33.2, 36.8,
37.4, 41.8, 55.0, 56.9, 99.9 (J = 29.4 Hz), 110.4 (J = 9.4 Hz), 111.4 (J = 24.2 Hz), 129.0 (J = 1.9 Hz), 144.1 (J = 13.6 Hz), 156.4, 160.2 (J = 240.0 Hz); HPLC-MS (ammonium acetate) [M+H]+=335.3
3.143 General procedure 17 (GP 17)
[0250] A 4 ml vial was charged with 3-(3-bromopropyl)-3H-benzooxazol-2-one (1 equiv), 4-butylpiperidine (1.4 equiv), and K2C03 (0.075 g, 0.54 mmol) in MeCN (1 ml) and shaken at 60 °C for 20 h. The reaction mixture was cooled to r.t., water was added (1 ml), and the product extracted into ethyl acetate (2 x 1 ml). The combined org. layer was added an acidic ion-exchange column. The column was washed with MeOH (2 column volumes) then the product was eluded of the column using 10% ammonium hydroxide in MeOH (2 column volumes). The product was purified by flash CC and/or by prep. RP-HPLC [conditions: stationary phase, Luna 15um C18; column, 250x21.2 mm; mobile phase, 20 ml/min, H20/MeCN, ammoniumacetate buffer (25nM)].
3.144 3-r3-(4-butylρiperidin-l-yl)propyll-6-methoxy-3H-benzooxazol-2-one (97KK02a) [0251] 3-(3-Bromopropyl)-6-methoxy-3H-benzooxazol-2-one (97KK01a) (0.093 g, 0.56 mmol) and 4-butylpiperidine (0.086 g, 0.61 mmol) were reacted according to GP17. Purified by prep. RP-ΗPLC to give the title compound (97KK02a) (0.114 g, 71%). !Η NMR (CD3OD) δ 0.89 (t, J = 6.1 Hz, CH3), 1.27 - 1.12 (m, 9 H), 1.64 (d, J = 11.7 Hz, 2 H), 1.99 - 1.88 (m, 4 H), 2.39 (t, J = 7.2 Hz, CH2), 2.86 (d, J = 11.5 Hz, 2 H), 3.78 (s, OCH3), 3.86 (t, J = 6.6 Hz, CH2), 7.10 - 6.78 (m, 3 H); 13C NMR (CD3OD) δ 14.4, 23.9, 25.7, 30.1, 33.1, 36.8, 37.4, 41.6, 55.0, 56.5, 56.9, 98.3, 126.0, 144.7, 156.7, 157.8; HPLC-MS (ammonium acetate) [M+H]+=347.3.
3.145 3-r3-(4-butylpiperidin-l-yl)propyl]-5.7-dibromo-3H-benzooxazol-2-one (97KK02b) [0252] 3-(3-Bromopropyl)-5,7-dibromo-3H-benzooxazol-2-one (97KK02b) (0.138 g,
0.47 mmol) and 4-butylpiperidine (0.069 g, 0.49 mmol) were reacted according to GP17. Purified by prep. RP-ΗPLC to give the title compound (97KK02b) (0.152 g, 78%). *Η NMR (CD3OD + CDC13) δ 0.80 (t, J = 6.6 Hz, CH3), 1.18 - 1.06 (m, 9 H), 1.61 (d, J = 12.1 Hz, 2 H), 1.95 - 1.89 (m, 4 H), 2.38 (t, J = 6.6 Hz, CH2), 2.81 (d, J = 11.7 Hz, 2 H), 3.81 (t, J = 6.6 Hz, CH2), 7.34 - 7.28 (m, 2 H); 13C NMR (CD3OD + CDC13) δ 14.3, 23.4, 24.8, 29.6, 32.4, 36.0, 36.7, 41.7, 54.4, 55.8, 103.5, 112.1, 117.6, 128.4, 134.0, 140.7, 154.5; HPLC-MS (ammonium acetate) [M+H]+=473.0.
3.146 3-[3-(4-butylpiperidin-l-yl)propyl1-7-methyl-3H-benzooxazol-2-one (97KK06a)
[0253] Crude 3-(3-bromopropyl)-7-methyl-3H-benzooxazol-2-one (97KK03a) (0.074 g) and 4-butylpiperidine (0.052 g, 0.37 mmol) were reacted according to GP17. Purified by prep. RP-HPLC to give the title compound (97KK06a) (0.056 g). !HNMR (CD3OD + CDC13) δ 0.87 (t, J = 6.1 Hz, CH3), 1.26 - 1.17 (m, 9 H), 1.68 (d, J = 12.1 Hz, 2 H), 2.10 - 1.97 (m, 4 H), 2.34 (s, CH3), 2.53 (t, J = 7.4 Hz, CH2), 2.96 (d, J = 11.3 Hz, 2 H), 3.88 (t, J = 6.8 Hz), 6.97 - 6.93 (m, 2 H), 7.11 - 7.08 (m, 1 H); 13C NMR (CD3OD + CDC13) δ 14.3, 14.4, 23.6, 23.8, 25.1, 29.7, 32.2, 36.0,
36.8, 41.2, 54.5, 56.2, 107.1, 121.2, 124.7, 125.0, 131.6, 142.1, 156.1; HPLC-MS (ammonium acetate) [M+H]+=331.3.
3.147 3-[3-(4-butylpiperidin-l-yl)propyl1-7-isopropyl-3H-benzooxazol-2-one (97KK06b) [0254] Crude 3-(3-bromoproρyl)-7-isopropyl-3H-benzooxazol-2-one (97KK03b)
(0.059 g) and 4-butylpiperidine (0.039 g, 0.28 mmol) were reacted according to GP17. Purified by prep. RP-ΗPLC. Purified by prep. RP-ΗPLC to give the title compound (97KK06b) (0.044 g). Η NMR (CD3OD) δ 0.88 (t, J = 6.3 Ηz, CΗ3), 1.32 - 1.07 (m, 15 H), 1.61 (d, J = 12.1 Hz, 2 H), 1.99 - 1.84 (m, 4 H), 2.39 (t, J = 7.0 Hz, CH2), 2.83 (d, J = 11.3 Hz, 2 H), 3.19 (sept, J = 6.8 Hz, CH), 3.89 (t, J = 6.7 Hz, CH2), 7.03 - 7.00 (m, 2 H), 7.17 - 7.13 (M, 1 H); 13C NMR (CD3OD) δ 14.4, 22.8,
23.9, 25.7, 29.9, 30.1, 33.2, 36.9, 37.4, 41.8, 55.0, 57.0, 107.7, 121.3, 125.2, 132.3, 132.3, 141.4, 156.5; HPLC-MS (ammonium acetate) [M+H]+=359.3. 3.148 3-[3-(4-butylpiperidin-l-yl)propyl]-5.7-diisopropyl-3H-benzooχazol-2-one (97KK07a) [0255] Crude 3-(3-bromopropyl)-5,7-diisopropyl-3H-benzooxazol-2-one (97KK03c)
(0.077 g) and 4-butylpiperidine (0.040 g, 0.28 mmol) were reacted according to GP17. Purified by prep. RP-HPLC to give the title compound (97KK07a) (0.056 g). 1H NMR (CD3OD) δ 0.88 (m, CH3), 1.32 - 1.16 (m, 21 H), 1.69 (d, J = 12.1, 2 H), 2.17 - 2.01 (m, 4 H), 2.60 (t, J = 7.2, CH2), 3.03 - 2.92 (m, 3 H), 3.15 (sept, J = 6.9 Hz, CH), 3.90 (t, J = 6.7 Hz, CH2), 6.88 (s, 1 H), 6.92 (s, 1 H); 13C NMR (CD3OD) δ 14.4, 22.8, 23.9, 24.8, 25.3, 30.0, 30.3, 32.5, 35.8, 36.3, 37.1, 41.3, 54.7, 56.5, 105.6, 119.5, 132.0, 132.3, 139.7, 146.9, 156.8; HPLC-MS (ammonium acetate) [M+H]+=401.4.
3.149 3-[3-(4-butylpiperidin-l -yl)propyl]-4,6-dimethoxy-3H-benzooxazol-2-one (97KK07c) [0256] 3-(3-Bromopropyl)-4,6-dimethoxy-3H-benzooxazol-2-one (97KK05b) (0.033 g, 0.10 mmol) and 4-butylpiperidine (0.024 g, 0.17 mmol) were reacted according to GPl 7. Purified by prep. RP-ΗPLC to give the title compound (97KK07c) (0.023 g, 61%). lR NMR (CD3OD) δ 0.89 (m, CΗ3), 1.27 - 1.13 (m, 9 H), 1.66 (d, J = 11.9 Hz, 2 H), 2.03 - 1.95 (m, 4 H), 2.47 (t, J = 6.8 Hz, CH2), 2.94 (d, J = 10.6 Hz, 2 H), 3.78 (s, OCH3), 3.90 (s, OCH3), 3.96 (t, J = 6.8 Hz, CH2), 6.54 - 6.46 (m, 2 H); 13C NMR (CD3OD) δ 14.4, 23.8, 24.1, 29.9, 30.2, 35.0, 36.3, 53.8, 53.9, 54.1, 56.5, 115.3, 125.0, 129.6, 130.6, 131.1, 159.3, 161.1; HPLC-MS (ammonium acetate) [M+H]+=377.3.
3.150 3-r3-(4-Butylpiperidin-l-yl)propyll7-fluoro-3H-benzooxazol-2-one ('97KK13)
[0257] 3-(3-bromopropyl)-7-fluoro-3H-benzooxazol-2-one (97KK12a) (0.100 g, 0.36 mmol) and 4-butylpiperidine (0.095 g, 0.67 mmol) were reacted according to GP17. Purified by flash CC (Si02; DCM/MeOH 10:1) and prep. RP-HPLC to give the title compound (97KK13) (0.078 g, 65%). 1H NMR (CD3OD) δ 0.88 (t, J = 6.9 Hz, CH3), 1.29 - 1.07 (m, 9 H), 1.61 (d, J = 11.9 Hz, 2 H), 1.99 - 1.84 (m, 4 H), 2.39 (t, J = 7.0 Hz, CH2), 2.83 (d, J = 11.7 Hz, 2 H), 3.91 (t, J = 6.8 Hz, CH2), 6.97 - 6.92 (m, 1 H), 7.06 - 7.03 (m, 1 H), 7.22 - 7.17 (m, 1 H); 13C NMR (CD3OD) δ 14.4, 23.9, 25.5, 30.0, 33.1, 36.8, 37.4, 42.3, 55.0, 56.9, 106.3 (J = 3.9 Hz), 111.0 (J = 17.1 Hz), 125.8 (J = 6.8 Hz), 130.7 (J = 14.2 Hz), 135.3 (J = 4.8 Hz), 147.1 (J = 247.4), 155.6; HPLC-MS (ammonium acetate) [M+H]+=335.3.
3.151 3 -r3 -(4-Butylpiρeridin- 1 -y propyl] — 5 ,7-dichloro-6-methyl-3H-benzooxazol-2-one (97KK16)
[0258] Crude 3 -(3 -bromopropyl)-5 ,7-dichloro-6-methyl-3H-benzooxazol-2-one
(97KK12b) (0.051 g) and 4-butylpiperidine (0.041 g, 0.29 mmol) were reacted according to GP17. Purified by prep. RP-HPLC to give the title compound (97KK16) (0.016 g). ]H NMR (CD3OD + CDCI3) δ 0.88 (t, J = 6.6 Hz, CH3), 1.29 - 1.07 (m, 9 H), 1.63 (d, J = 12.1 Hz, 2 H), 1.97 - 1.87 (m, 4 H), 2.38 (t, J = 7.2 Hz, CH2), 2.44 (s, CH3), 2.83 (d, J = 11.7 Hz, 2 H), 3.87 (t, J = 6.7 Hz, CH2), 7.27 (s, IH); 13C NMR (CD3OD + CDC13) δ 14.4, 16.7, 23.8, 25.2, 29.9, 32.9, 36.5, 37.2, 42.0, 54.8, 56.4, 109.5, 117.0, 129.0, 130.8, 131.7, 139.5, 155.2; HPLC-MS (ammonium acetate) [M+H]+=399.2.
3.152 General procedure 18 (GP 18)
[0259] A 4 ml vial was charged with 3H-benzooxazol-2-one (1 equiv), 3-(4- butylpiperidin-l-yl)propan-l-ol (1.2 equiv), diethyl azodicarboxylate (1.2 equiv), and triphenylphosphine (1.2 equiv) in THF (4 ml) and shaken at r.t. for 20 h. The reaction mixture was added water (1 ml), and the product extracted into EtOAc (2 x 1 ml). The combined org. layer was added an acidic ion-exchange column. The column was washed with MeOH (2 column volumes) then the product was eluded of the column using 10% ammonium hydroxide in MeOH (2 column volumes). The product was purified by flash CC and/or by prep. RP-HPLC [conditions: stationary phase, Luna 15um C18; column, 250x21.2 mm; mobile phase, 20 ml/min, H20/MeCN, ammoniumacetate buffer (25nM)].
3.153 3-(4-Butylpiperidin-l-yl)propan-l-ol C92LH52)
[0260] A vial was charged with 4-butylpiperidine (0.706 g, 5.0 mmol), 3- bromopropan-1-ol (0.694 g, 5.0 mmol), and K2C03 (0.967 g, 7.0 mmol) in MeCN ( 4 ml) and was shaken at 50° for 72 h. The reaction mixture was added water and the product was extracted into EtOAc. The combined org. layer was dried over Na2S04 and concentrated in vacuo. The material was used for the next reaction step without further purification.
3.154 3-f3 -(4-butylpiρeridin- 1 -vnpropyl1-5.7-dichloro-6-ethyl-3H-benzooxazol-2-one (97KK14) [0261] 5,7-Dichloro-6-ethyl-3H-benzooxazol-2-one (97KK10) (0.257 g, 1.11 mmol),
3-(4-butylpiperidin-lyl)propan-l-ol (0.272 g, 1.36 mmol), diethyl azodicarboxylate (0.232 g, 1.33 mmol), and PPh3 (0.355 g, 1.35 mmol) in THF (4 ml) were reacted according to GPl 8. Purified by flash CC (Si02; DCM/MeOH 20:1) and prep. RP-HPLC to give the title compound (97KK14) (0.058 g, 13%). Η NMR (CD3OD + CDC13) δ 0.87 (t, J = 6.6 Hz, CH3), 1.28 - 1.04 (m, 12 H), 1.61 (d, J = 11.9 Hz, 2 H, 1.95 - 1.85 (m, 4 H), 2.38 (t, J = 7.0 Hz, CH2), 2.81 (d, J = 11.7 Hz, 2 H), 2.93 (q, J = 7.4 Hz, CH2), 3.87 (t, J = 6.6 Hz, CH2), 7.23 (s, 1 H); 13C NMR (CD3OD + CDC13) δ 13.2, 14.4, 23.6, 24.8, 25.1, 29.8, 32.8, 36.4, 37.1, 42.0, 54.7, 56.3, 109.6, 116.6, 130.2, 131.6, 134.5, 139.4, 155.1.
3.155 5-Bromo-3-r3-(4-butylpiperidin-l-yl)propyη-7-fluoro-3H-benzooxazol-2-one f97KK15-a^ [0262] 5-Bromo-7-fiuoro-3H-benzooxazol-2-one (97KK09b) (0.049 g, 0.21 mmol), 3-
(4-butylpiperidin-lyl)propan-l-ol (0.066 g, 0.33 mmol), diethyl azodicarboxylate (0.044 g, 0.25 mmol), and PPh3 (0.071 g, 0.27 mmol) in THF (2 ml) were reacted according to GPl 8. Purified by flash CC (Si02; DCM/MeOH 20:1) and prep. RP-HPLC to give the title compound (97KK15-a) (0.019 g, 22%). *H NMR (CD3OD + CDC13) δ 0.80 (t, J = 6.8 Hz, CH3), 1.23 - 1.04 (m, 9 H), 1.58 (d J = 13.3 Hz, 2 H), 1.90 - 1.81 (m, 4 H), 2.30 (t, J = 7.0 Hz, CH2), 2.76 (d, J = 11.7 Hz, 2 H), 3.81 (t, J = 6.7 Hz, CH2), 7.20 - 7.06 (m, 2 H); HPLC-MS (ammonium acetate) [M+H]+=413.2.
3.156 3-r3-(Butylpiperidin-l-vDpropyll-6.7-difluoro-3H-benzooxazol-2-one C97KK15-b [0263] 6,7-Difluoro-3H-benzooxazol-2-one (97KK11) (0.136 g, 0.79 mmol), 3-(4- butylpiperidin-lyl)propan-l-ol (0.196 g, 0.98 mmol), diethyl azodicarboxylate (0.165 g, 0.95 mmol), and PPh3 (0.389 g, 1.48 mmol) in THF (2 ml) was reacted according to GP18. Purified by flash CC (Si02; DCM/MeOH 20:1) and prep. RP-HPLC to give the title compound (97KK15-b) (0.063 g, 23%). Η NMR ^DsOD) δ 0.89 (m, CH3), 1.31 - 1.05 (m, 9 H), 1.64 (d, J - 12.5 Hz, 2 H), 2.00 - 1.87 (m, 4 H), 2.42 (t, J = 7.2, CH2), 2.86 (d, J = 11.7 Hz, 2 H), 3.91 (t, J = 6.6 Hz, CH2), 7.03 - 6.99 (m, 1 H), 7.17 - 7.10 (m, 1 H); 13C NMR (CD3OD) δ 14.4, 23.9, 25.3, 30.0, 33.0, 36.7, 37.3, 42.2, 55.0, 56.8, 105.0 (J = 4.6 Hz, J = 7.7 Hz), 112.7 (J = 20.4 Hz), 130.7, 131.8 (J = 4.6 Hz, J = 10.8 Hz), 136.8 (J = 18.5 Hz, J = 251.4 Hz), 148.3 (J = 10.0, J = 240.6 Hz), 155.6; HPLC-MS (ammonium acetate) [M+H]+=353.3.
3.157 3-f3-(Butylpiperidin-l-yl)propyll-4,5.7-trichloro-3H-benzooxazol-2-one (97KK29) [0264] 4,5,7-Trichloro-3H-benzooxazol-2-one (97KK26) (0.342 g, 1.43 mmol), 3-(4- butylpiρeridin-lyl)propan-l-ol (0.280 g, 1.40 mmol), diethyl azodicarboxylate (0.299 g, 1.72 mmol), and PPh3 (0.516 g, 1.97 mmol) in THF (5 ml) was reacted according to GP18. Purified by flash CC (Si02; DCM MeOH 20:1) and prep. RP-HPLC to give the title compound (97KK29) (0.085 g, 14%). 'H NMR (CD3OD + CDC13) δ 0.88 (t, J = 6.7 Hz, CH3), 1.29 - 0.90 (m, 9 H), 1.65 (d, J = 13.5 Hz, 2 H), 2.11 - 1.89 (m, 4 H), 2.62 (t, J = 7.0 Hz, CH2), 2.96 (d, J = 11.9 Hz, 2 H), 4.23 (t, J = 6.8 Hz, CH2), 7.40 (s, 1 H); 13C NMR (CD3OD + CDC13) δ 14.3, 23.8, 26.8, 29.8, 32.4, 36.1, 37.0, 43.4, 54.7, 56.5, 113.6, 115.4, 124.4, 130.1, 131.3, 140.0, 155.1; HPLC-MS (ammonium acetate) [M+H]+=419.1.
3.158 3-r3-.4-butylpiperidin-l-vnpropyll-4-methoxy-3H-benzooxazol-2-one .92LH60-lA) [0265] A 4 ml vial was charged with 4-methoxy-3H-benzooxazol-2-one (92LH58)
(0.345 g, 0.73 mmol), 3-(4-butylpiperidin-l-yl)propan-l-ol (0.175 g, 0.88 mmol), diethyl azodicarboxylate (0.152 g, 0.88 mmol), and triphenylphosphine (0.230 g, 0.88 mmol) in THF (4 ml) and shaken at r.t. for 20 h. The reaction mixture was added was added an acidic ion-exchange column. The column was washed with MeOH (2 column volumes) then the product was eluded of the column using 10% ammonium hydroxide in MeOH (2 column volumes). The product was purified by flash CC (SiO2; EtOAc) and by prep. RP-HPLC [conditions: stationary phase, Luna 15um C18; column, 250x21.2 mm; mobile phase, 20 ml/min, H 0/MeCN, ammoniumacetate buffer (25nM)] to give the title compound (92LH60-1A) (0.135 g, 53%). Η NMR (CD3OD) δ 0.88 (t J = 6.8 Hz, CH3), 1.28 - 1.06 (m, 9 H), 1.60 (d, J = 10.9 Hz, 2 H), 1.99 - 1.82 (m, 4 H), 2.38 (t, J = 7.0 Hz, CH2), 2.84 (d, J = 11.9 Hz, 2 H), 3.92 (s, OCH3), 3.98 (t, J = 6.8 Hz, CH2), 6.86 - 6.81 (m, 2 H), 7.07 - 7.03 (m, 1 H); 13C NMR (CD3OD) δ 13.2, 23.7, 27.2, 29.8, 32.9, 36.6, 37.1, 43.5, 54.8, 56.5, 56.8, 103.8, 108.3, 120.1, 123.8, 144.6, 146.3, 156.0; HPLC-MS (ammonium acetate) [M+H]+=347.
3.159 3-F3-(4-butylpiperidin-l -yl)propyll-7-nitro-3H-benzooxazol-2-one (92LH60-2A)
[0266] A 4 ml vial was charged with 7-nitro-3H-benzooxazol-2-one (92LH59) (0.090 g, 0.5 mmol), 3-(4-butylpiperidin-l-yl)propan-l-ol (0.120 g, 0.60 mmol), diethyl azodicarboxylate (0.153 g, 0.60 mmol), and triphenylphosphine (0.230 g, 0.60 mmol) in THF (4 ml) and shaken at r.t. for 20 h. The reaction mixture was added was added an acidic ion-exchange column. The column was washed with MeOH (2 column volumes) then the product was eluded of the column using 10% ammonium hydroxide in MeOH (2 column volumes). The product was purified by flash CC (S1O2; EtOAc) and by prep. RP-HPLC [conditions: stationary phase, Luna 15um C18; column, 250x21.2 mm; mobile phase, 20 ml/min, H2θ/MeCN, ammoniumacetate buffer (25nM)] to give the title compound (92LH60-2A (0.067 g, 37%). XHNMR (CD3OD) δ 0.88 (t, J = 6.6 Hz, CH3), 1.60 - 0.98 (m, 9 H), 1.81 (d, J = 12.7 Hz, 2 H), 2.01 - 1.84 (m, 4 H), 2.41 (t, J = 7.0 Hz, CH2), 2.80 (d, J = 11.7 Hz, 2 H), 4.00 (t, J = 6.8 Hz, CH2), 7.42 - 7.38 (m, 1 H), 7.62 - 7.59 (m, 1 H), 7.90 - 7.88 (m, 1 H); HPLC-MS (ammonium acetate) [M+H]+=362.
3.160 3-r3-r4-butylpiperidin-l-yl)propyπ-5.7-diiodo-3H-benzooxazol-2-one (92LH66)
[0267] A 4 ml vial was charged with 5,7-diiodo-3H-benzooxazol-2-one (92LH49) (0.166 g, 0.40 mmol), 3-(4-butylpiperidin-l-yl)propan-l-ol (0.096 g, 0.48 mmol), diethyl azodicarboxylate (0.084 g, 0.48 mmol), and triphenylphosphine (0.126 g, 0.48 mmol) in THF (4 ml) and shaken at r.t. for 20 h. The reaction mixture was added was added an acidic ion-exchange column. The column was washed with MeOH (2 column volumes) then the product was eluded of the column using 10%) ammonium hydroxide in MeOH (2 column volumes). The product was purified prep. RP-HPLC [conditions: stationary phase, Luna 15um C18; column, 250x21.2 mm; mobile phase, 20 ml/min, H20/MeCN, ammoniumacetate buffer (25nM)] to give the title compound (92LH66) (0.068 g, 30%). Η NMR (CD3OD) δ 0.80 (t, J = 7.0 Hz, CH3), 1.20 - 1.12 (m. 9 H), 1.53 (d, J = 13.1 Hz, 2 H), 1.91 - 1.80 (m, 4 H), 2.33 (t, J = 7.0 Hz, CH2), 2.76 (d, J = 11.7 Hz, 2 H), 3.78 (t, J = 6.5 Hz, CH2), 7.68 - 7.47 (m, 2 H); 13C NMR (CD3OD) δ 14.4, 23.9, 25.0, 30.1, 33.1, 36.7, 37.4, 42.2, 55.0, 56.6, 74.6, 87.8, 118.9, 133.9, 139.6, 145.6, 154.7; HPLC- MS (ammonium acetate) [M+H]+=569.
3.161 3 -[3 -(4-butylpiperidin- 1 -vDpropyl] -4-methyl-7-isopropyl-3H-benzooxazol-2-one (92LH75) [0268] A 4 ml vial was charged with 4-methyl-7-isopropyl-3H-benzooxazol-2-one
(92LH71) (0.100 g, 0.52 mmol), 3 -(4-butylpiperidin- l-yl)propan-l-ol (0.124 g, 0.62 mmol), diethyl azodicarboxylate (0.109 g, 0.62 mmol), and triphenylphosphine (0.164 g, 0.62 mmol) in THF (4 ml) and shaken at r.t. for 20 h. The reaction mixture was added was added an acidic ion-exchange column. The column was washed with MeOH (2 column volumes) then the product was eluded of the column using 10% ammonium hydroxide in MeOH (2 column volumes). The product was purified by prep. RP-HPLC [conditions: stationary phase, Luna 15um C18; column, 250x21.2 mm; mobile phase, 20 ml/min, H20/MeCN, ammoniumacetate buffer (25nM)] to give the title compound (92LH75) (0.100 g, 52%). Η NMR (CD3OD) δ 0.90 (m, CH3), 1.33 - 1.21 (m, 15 H), 1.76 (d, J = 13.5 Hz, 2 H), 2.08 (quint, 7.8 Hz, CH2), 2.40- 2.34 (m, 2 H), 2.53 (s, CH3), 2.82 - 2.78 (m, 2 H), 3.19 - 3.14 (m, 3 H), 4.08 (t, J = 6.9 Hz, CH2), 6.94 - 6.90 (m, 2 H); 13C NMR (CD3OD) δ 14.4, 17.4, 22.7, 23.8, 27.0, 29.4, 29.9, 31.9, 35.8, 36.9, 42.4, 54.5, 56.1, 119.0, 121.1, 128.2, 129.6, 130.0, 141.6, 157.0; HPLC-MS (ammonium acetate) [M+H]+=373.
3.162 3- 3-(4-butylpiperidin-l-yl)propyll-7-methyl-4-isopropyl-3H-benzooxazol-2-one (92LH77) [0269] A 4 ml vial was charged with 7-methyl-4-isopropyl-3H-benzooxazol-2-one
(92LH76) (0.066 g, 0.35 mmol), 3 -(4-butylpiperidin- l-yl)propan-l-ol (0.084 g, 0.42 mmol), diethyl azodicarboxylate (0.073 g, 0.42 mmol), and triphenylphosphine (0.110 g, 0.42 mmol) in THF (4 ml) and shaken at r.t. for 20 h. The reaction mixture was added was added an acidic ion-exchange column. The column was washed with MeOH (2 column volumes) then the product was eluded of the column using 10% ammonium hydroxide in MeOH (2 column volumes). The product was purified by prep. RP-HPLC [conditions: stationary phase, Luna 15um C18; column, 250x21.2 mm; mobile phase, 20 ml/min, H20 MeCN, ammoniumacetate buffer (25nM)] to give the title compound (92LH77) (0.035 g, 27%). Η NMR (CD3OD) δ 0.90 (t, J = 6.3 Hz, CH3), 1.33 - 1.13 (m, 15 H), 1.68 (d, J = 12.7 Hz, 2 H), 2.11 - 1.94 (m, 4 H), 2.30 (s, CH3), 2.58 (t, J = 7.2 Hz, CH2), 2.98 (d, J = 11.5 Hz, 2 H), 3.36 - 3.31 (m, 1 H), 4.07 (t, J = 7.0 Hz, CH2), 7.10 - 6.93 (m, 2 H); 13C NMR (CD3OD) δ 14.2, 14.4, 23.9, 24.4, 26.9, 28.1, 30.0, 32.7, 36.4, 37.2, 43.5, 55.0, 56.7, 118.8, 122.4, 125.5, 127.8, 130.6, 142.6, 157.3; HPLC-MS (ammonium acetate) [M+H]+=373.
3.163 General procedure 19 (GP 19) [0270] A 4 ml vial was charged with 3-chloroalkyl-3H-benzothiazol-2-one (1 equiv), piperidine (1 equiv), KI (1.3 equiv), and K2Cθ3 (1.3 equiv) in MeCN (2 ml) and shaken at 50 °C for 48 h. The reaction mixture was added water, the product extracted into EtOAc, and the combined org. layer was concentrated. The product was purified by flash CC (Si02; EtOAC, MeOH/EtOAc 1:4).
3.164 3-r5-(4-Butylpiperidin-l-yl)pentyl)-3H-benzothiazol-2-one (107LH03-n
[0271] 3-(5-Chloropentyl)-3H-benzothiazol-2-one (107LΗ01) (0.203 g, 0.9 mmol), 4- butylpiperidine (0.127 g, 0.9 mmol), KI (0.200 g, 1.2 mmol), and K2C03 (0.166 g, 1.2 mmol) in MeCN (2 ml) were reacted according to GP19. Purified by flash CC (Si02; EtOAc, MeOH/EtOAc 1:4) to give the title compound (107LH03-1) (0.173 g, 53%). Η NMR (CD3OD) δ 0.88 (m, CH3), 1.38 - 1.19 (m, 11H), 1.76 - 1.50 (m, 6H), 1.94 - 1.89 (m, 2 H), 2.28 (t, J = 7.4 Hz, CH2), 2.88 (d, J = 10.8 Hz, 2 H), 3.96 (t, J = 7.0 Hz, CH2), 7.23 - 7.14 (m, 2 H), 7.36 - 7.32 (m, 1 H), 7.48 - 7.46 (m, 1 H); 13C NMR (CD3OD) δ 14.5, 23.9, 25.7, 27.0, 28.5, 30.1, 32.9, 36.7, 37.3, 43.5, 54.9, 59.8, 112.3, 123.5, 123.7, 124.3, 127.7, 138.4, 171.4; HPLC-MS (ammonium acetate) [M+H]+=361.3.
3.165 3-15 -( 4-Propyloxypiperidin- 1 -vDpentylV3H-benzothiazol-2-one ( 107LH03 -2)
[0272] 3-(5-Chloropentyl)-3H-benzothiazol-2-one (107LH01) (0.203 g, 0.9 mmol), 4- propyloxypiperidine (0.129 g, 0.9 mmol), KI (0.200 g, 1.2 mmol), and K2C03 (0.166 g, 1.2 mmol) in MeCN (2 ml) were reacted according to GP19. Purified by flash CC (Si02; EtOAc, MeOH/EtOAc 1:4) to give the title compound (107LH03-2) (0.153 g, 47%). JH NMR (CD3OD) δ 0.90 (t, J = 7.4 Hz, CH3), 1.61 - 1.30(m, 9 H), 1.76 - 1.69 (m, 2 H), 1.90 - 1.84 (m, 2 H), 2.23 - 2.18 (m, 2 H), 2.35 - 2.31 (m, 2 H), 2.76 - 2.74 (m, 2 H), 3.39 - 3.29 (m, 2 H), 3.95 (t, J = 7.2 Hz, CH2), 7.22 - 7.14 (m, 2 H), 7.36 - 7.32 (m, 1 H), 7.48 - 7.46 (m, 1 H); 13C NMR (CD3OD) δ 11.0, 24.2, 25.6, 27.0, 28.4, 31.6, 43.5, 51.9, 59.2, 70.6, 112.3, 123.5, 123.7, 124.4, 127.7, 138.4, 171.5; HPLC-MS (ammonium acetate) [M+H]+=363.3.
3.166 3 -r6-(4-Butylpiperidin- 1 -yl)hexylV3H-benzothiazol-2-one ( 107LH04- 1 ^
[0273] 3-(6-Chlorohexyl)-3H-benzothiazol-2-one (107LH02) (0.243 g, 0.9 mmol), 4- butylpiperidine (0.127 g, 0.9 mmol), KI (0.200 g, 1.2 mmol), and K2C03 (0.166 g, 1.2 mmol) in MeCN (2 ml) were reacted according to GP19. Purified by flash CC (Si02; EtOAc, MeOH/EtOAc 1:4) to give the title compound (107LH04-1) (0.186 g, 55%). *H NMR (CD3OD) δ 0.88 (m, CH3), 1.47 - 1.19 (m, 15 H), 1.72 - 1.63 (m, 4 H), 1.94 - 1.89 (m, 2 H), 2.28 (t, J = 7.4 Hz, CH2), 2.88 (d, J = 11.0 Hz, 2 H), 3.94 (t, J = 7.0 Hz, CH2), 7.21 - 7.15 (m, 2 H), 7.35 - 7.31 (m, 1 H), 7.47 - 7.45 (m, 1 H); 13C NMR (CD3OD) δ 14.5, 23.9, 27.2, 27.5, 28.3, 28.5, 30.1, 32.9, 36.7, 37.3, 43.6, 54.9, 59.9, 112.3, 123.5, 123.7, 124.3, 127.7, 138.4, 171.4; HPLC-MS (ammonium acetate) [M+H]+=375.3.
3.167 3-r6-.4-Propyloxypiperidin-l-yl)hexyl)-3H-benzothiazol-2-one (107LH04-2>
[0274] 3-(6-Chlorohexyl)-3H-benzothiazol-2-one (107LΗ02) (0.243 g, 0.9 mmol), 4- propyloxypiperidine (0.129 g, 0.9 mmol), KI (0.200 g, 1.2 mmol), and K2C03 (0.166 g, 1.2 mmol) in MeCN (2 ml) were reacted according to GP19. Purified by flash CC (Si02; EtOAc, MeOH/EtOAc 1:4) to give the title compound (107LH04-1) (0.159 g, 47%). Η NMR (CD3OD) δ 0.90 (t, J = 7.4 Hz, CH3), 1.89 - 1.34 (m, 15 H), 2.32 - 2.17 (m, 4 H), 2.73 (br. s, 2 H), 3.39 - 3.30 (m, 2 H), 3.94 (t, J = 6.7 Hz, CH2), 7.22 - 7.14 (m, 2 H), 7.35 - 7.32 (m, 1 H), 7.48 - 7.46 (m, 1 H); 13C NMR (CD3OD) δ 11.1, 24.3, 27.3, 27.5, 28.2, 28.5, 31.7, 43.5, 51.9, 59.4, 70.6, 112.3, 123.5, 123.7, 124.3, 127.7, 138.4, 171.4; HPLC-MS (ammonium acetate) [M+H]+=377.3.
3.168 General Procedure 20 (GP20
[0275] A 7 ml vial was charged with l-(3-chloropropyl)-l,3-dihydrobenzoimidazol-2- one (210 mg, 1.0 mmol), amine (0.5 mmol), Nal (150 mg, 1.0 mmol), sodium carbonate (106 mg, 1.0 mmol) and MeCN (2 ml) and shaken at 60 °C for 18 h. The reaction was cooled to r.t. and water (1 ml) was added. The product was extracted into ethyl acetate (2 x 1 ml) and the organic layer loaded onto a Varian SCX ion exchange column. The column was washed with MeOH (2 column volumes) then the product was eluted off the column using 10%> ammonium hydroxide in MeOH (2 column volumes). The solute was concentrated in vacuo, dissolved up in acetone, dried (K2CO3) and concentrated in vacuo before being purified further.
3.169 1 - { 3 -r4-(2-Hydroxyethyl)piperidin- 1 -vfjpropyl} -1.3 -dihydrobenzoimidazol-2-one) (45NK- 55}
[0276] The reaction was carried out according to the GP20 using 2-piperidin-4- ylethanol (65 mg, 0.5 mmol). The product was purified using an Isco CombiFlash Sq 16x (4.1g silica column, eluting DCM (5 min), 0-20% MeOH in DCM (20 min), 20% MeOH in DCM (15 min)). MeOH (2 ml) and HC1 in ether (2 M, 0.2ml) were added, the solution concentrated to give the title compound (45NK-55) as the hydrochloride salt (4 mg). lR NMR (CD3OD) δ 1.44 (m, 2H), 1.52 (q, 2H), 1.74 (m, IH), 1.95 (br. d, 2H), 2.17 (m, 2H), 2.86 (br. t, 2H), 3.08 (m, 2H), 3.45 (br. d, 2H), 3.61 (t, 2H), 4.01 (t, 2H), 7.14 (m, 3H), 7.19 (m, IH); LC-MS [ + H]+ 304.2.
3.170 l-[3-(3.5-Dimethylpiperidin-l-yDpropyl]- 3-dihydrobenzoimidazol-2-one (45NK-56^ [0277] The reaction was carried out according to the GP20 using 3,5- dimethylpiperidine (57 mg, 0.5 mmol). MeOH (2 ml) and HC1 in ether (2 M, 0.2ml) were added, the solution concentrated and the product recrystallised from MeOH-ether to give the title compound (45NK-56) as the hydrochloride salt (17 mg). JH NMR (CD3OD) δ 0.95 (d, IH), 0.97 (d, 4H), 1.21 (d, IH), 1.41 (dt, 0.67H), 1.67 (br. d, 0.67H), 1.83-1.97 (m, 2H), 2.11 (m, 0.33H), 2.22 (m, 2H), 2.47 (m, 2H), 3.00 (dd, 09.33H), 3.17 (m, 2H), 3.36-3.45 (m, 2H), 3.96-4.08 (m, 2H), 7.16 (m, 3H), 7.21 (m, IH); LC-MS [M+ H]+ 288.3 (2 peaks).
3.171 1 -[3 -(4-Methylpiperidin- 1 -vDpropyll- 1 ,3-dihydrobenzoimidazol-2-one (45NK-58)
[0278] The reaction was carried out according to the GP20 using 4-methylpiperidine (50 mg, 0.5 mmol). The product was purified using an Isco CombiFlash Sq 16x (4.1g silica column, eluting DCM (5 min), 0-15% MeOH in DCM (20 min), 15% MeOH in DCM (15 min)). MeOH (2 ml) and HCl in ether (2 M, 0.2ml) were added, the solution concentrated to give the title compound (45NK-58) as the hydrochloride salt (24 mg). !H NMR (CDC13) δ 0.93 (d, 3H), 1.54 (m, IH), 1.62- 1.75 (m, 4H), 2.28 (tt, 2H), 2.53 (br. t, 2H), 2.94 (dd, 2H), 3.31 (br. d, 2H), 3.94 (t, 2H), 6.99 (m, 3H), 7.09 (m, IH), 10.2 (br. s, IH); LC-MS [ + H]+ 274.2.
3.172 1 - [3 -(4-(Hydroxymethyl)piperidin- 1 -vDpropyl]- 1.3 -dihydrobenzoimidazol-2-one (45NK- 60}
[0279] The reaction was carried out according to the GP20 using piperidin-4-ylMeOH
(58 mg, 0.5 mmol). The product was purified using an Isco CombiFlash Sq 16x (4.1g silica column, eluting DCM (5 min), 0-15% MeOH in DCM (20 min), 15% MeOH in DCM (15 min)). MeOH (2 ml) and HCl in ether (2 M, 0.2ml) were added, the solution concentrated to give the title compound (45NK-60) as the hydrochloride salt (28 mg). lR NMR (CD3OD) δ 1.46 (dq, 2H), 1.69 (m, IH), 1.92 (br. d, 2H), 2.16 (tt, 2H), 2.76 (br. t, 2H), 3.01 (dd, 2H), 3.40 (m, 2H), 3.43 (d, 2H), 4.00 (t, 2H), 7.08 (m, 3H), 7.20 (m, IH); LC-MS [M+ H]+ 290.2.
3.173 1 - (3 -[4-( 3 -Methylbutylidene)piperidin- 1 -yl]propyl> - 1 ,3 -dihydrobenzoimidazol-2-one .45NK70)
[0280] The reaction was carried out according to the GP20 using 4-(3- methylbutylidene)piperidine hydrochloride (95 mg, 0.5 mmol). The product was purified using an Isco CombiFlash Sq 16x (4.1g silica column, eluting DCM (5 min), 0-15% MeOH in DCM (20 min), 15% MeOH in DCM (15 min)). MeOH (2 ml) and HCl in ether (2 M, 0.2ml) were added, the solution concentrated to give the title compound (45NK70) as the hydrochloride salt (10 mg). !H NMR (CD3OD) δ 0.86 (d, 6H), 1.55 (sept, IH), 1.86 (t, 2H), 1.96 (tt, 2H), 2.18 (t, 2H), 2.22 (t, 2H), 2.40 (m, 6H), 3.93 (t, 2H), 5.15 (t, IH), 7.06 (m, 3H), 7.16 (m, IH); 13C NMR (CD3OD) δ 22.7, 26.6, 28.8, 30.1, 36.6, 37.2, 39.9, 55.7, 56.6, 109.3, 110.4, 122.4, 122.7, 123.0, 129.6, 131.6, 137.1, 156.9; LC-MS [ + H]+ 328. 3.174 l-[3-f4-Pentylpiperidin-l -yHpropyl]-! .3-dihvdrobenzoimidazol-2-one C45NK7 D
[0281] The reaction was carried out according to the GP20 using 4-pentylpiperidine hydrochloride trifluoroacetate (199 mg, 0.5 mmol). The product was purified using an Isco CombiFlash Sq 16x (4.1g silica column, eluting DCM (5 min), 0-15% MeOH in DCM (20 min), 15% MeOH in DCM (15 min)). MeOH (2 ml) and HCl in ether (2 M, 0.2ml) were added, the solution concentrated to give the title compound (45NK71) as the hydrochloride salt (4 mg). *H NMR (CD3OD) δ 0.88 (t, 3H), 1.14-1.35 (m, 11H), 1.66 (br. d, 2H), 1.95 (m, 4H), 2.42 (dd, 2H), 2.90 (br. d, 2H), 3.92 (t, 2H), 7.06 (m, 3H), 7.18 (m, IH); LC-MS [M+ H]+ 330.3.
3.175 l-[3-(4-Butylpiperidin-l-yl)propyl1-3-methyl-1.3-dihydrobenzoimidazol-2-one C45NK110 [0282] l-(3-Chloro-propyl)-3-methyl-l,3-dihydro-benzoimidazol-2-one (450 mg, 2.0 mmol), 4-butyl-piperidine (282 mg, 2.0 mmol), Nal (300 mg, 2.0 mmol) and sodium carbonate (212 mg, 2.0 mmol) were shaken in MeCN (5 ml) at 80°C for 18 h. The reaction was colled to r.t., water (5 ml) was added and the product extracted with ethyl acetate (2x20 ml). The organic layer was dried (K2CO3), filtered and concentrated in vacuo before being purified by using an Isco CombiFlash Sq 16x (10 g silica column, eluting 0-15% MeOH in DCM (33 min) then 15% MeOH in DCM (13 min)) to give the title compound (45NK110) (50 mg). The hydrochloride salt was formed by addition of HCl (4M in dioxane) and recrystallised from MeOH-Et20 to give a white precipitate which was filtered and dried. H NMR (CD3OD) δ 0.91 (t, 3H), 1.31 (m, 6H), 1.44 (m, 2H), 1.54 (m, IH), 1.95 (br. s, 2H), 2.22 (m, 2H), 2.92 (br. t, 2H), 3.15 ( , 2H), 3.43 (s, 3H), 3.55 (m, 2H), 4.04 (t, 2H), 7.17 (m, 3H), 7.23 (m, IH); m.p. 157.7-158.4°C.
3.176 General Procedure 21 (GP21)
[0283] The amine (0.10 mmol) in DCM (0.3 ml) and iodide (0.12 mmol) in DMF (0.2 ml) were added to a reaction vessel and DCM (1 ml) was added. The reactions were shaken at r.t. for 72 h then isocyanate resin (ca. 50 mg, 1.1 mmol/g) was added and the reactions were shaken at r.t. for 24 h. The reactions were filtered, washing with MeOH (1 ml) onto a SCX ion exchange column which had been prewashed with MeOH (2 column volumes). The column was washed with MeOH (2 column volumes) then the product was eluted off the column using 5% aqueous NH3 in MeOH (1 column volume) and concentrated in vacuo. The product was purified by the general prep. LC-MS procedure and the desired fractions were concentrated in vacuo to give the desired product.
3.177 1 -(4-r4-Cvclohexylmethyl-piperidin- 1 -yl]butyl)- 1.3 -dihydrobenzimidazol-2-one t56NK118B-cpd2 [0284] 4-(l-Cyclohexylmethyl)piperidine (18 mg, 0.10 mmol) and l-(4-iodobutyl)- l,3-dihydrobenzoimidazol-2-one (38 mg, 0.12 mmol) were used according to general GP21 to give the trifluoroacetate salt of the title compound (56NK118-cpd2) (1.5 mg). HPLC-MS (ammonium acetate) [M+H]+=370.5.
3.178 1 -(3 -[4-Cyclohexylmethyl-piperidin- 1 -yl]propyl)- 1.3 -dihydrobenzimidazol-2-one (56NK138-A1)
[0285] 4-(l-Cyclohexylmethyl)piperidine (18 mg, 0.10 mmol) and l-(3-iodopropyl)- l,3-dihydrobenzoimidazol-2-one (36 mg, 0.12 mmol) were used according to GP21 to give the trifluoroacetate salt of the title compound (56NK138-A1) (3.1 mg). HPLC-MS (ammonium acetate) [M+H]+=356.5.
3.179 1 -(3 -[4-(2-Ethoxyethyl)piperidin- 1 -yllpropylV 1.3 -dihvdrobenzimidazol-2-one ,56NK 138- A2)
[0286] 4-(2-Ethoxyethyl)piperidine (16 mg, 0.10 mmol) and l-(3-iodopropyl)-l,3- dihydrobenzoimidazol-2-one (36 mg, 0.12 mmol) were used according to GP21 to give the trifluoroacetate salt of the title compound (56NK138-A2) (3.7 mg). HPLC-MS (ammonium acetate) [M+H]+=332.4.
3.180 1 -(3-[4-Cyclohexylmethyl-piperidin- 1 -yl]propyl)-3 -methyl- 1 ,3-dihydrobenzimidazol-2-one (56NK138-B1)
[0287] 4-(l-Cyclohexylmethyl)piperidine (18 mg, 0.10 mmol) and l-(3-iodopropyl)-3- methyl-l,3-dihydrobenzoimidazol-2-one (38 mg, 0.12 mmol) were used according to GP21 to give the trifluoroacetate salt of the title compound (56NK138-B1) (1.3 mg). HPLC-MS (ammonium acetate) [M+H]+=370.5.
3.181 l-f3-r4-(2-Ethoxyethyl)piperidin-l-yl1propyl)-3-methyl-1.3-dihydrobenzimidazol-2-one (56NK138-B2)
[0288] 4-(2-Ethoxyethyl)piperidine (16 mg, 0.10 mmol) and l-(3-iodopropyl)-3- methyl-l,3-dihydrobenzoimidazol-2-one (38 mg, 0.12 mmol) were used according to GP21 to give the trifluoroacetate salt of the title compound (56NK138-B2) (7.3 mg). HPLC-MS (ammonium acetate) [M+H]+=346.5.
3.182 3-r3-r4-Cvclohexylmethyl-piperidin-l-yllpropyl)-3H-benzothiazol-2-one ('56NK138-Cn [0289] 4-(l-Cyclohexylmethyl)piperidine (18 mg, 0.10 mmol) and l-(3-iodopropyl)-
3H-benzothiazol-2-one (38 mg, 0.12 mmol) were used according to GP21 to give the trifluoroacetate salt of the title compound (56NK138-C1) (2.2 mg). HPLC-MS (ammonium acetate) [M+H]+=373.4.
3.183 3-f 3 -r4-(2-Ethoxyethyl)piperidin- 1 -yllpropyl)-3H-benzothiazol-2-one (56NK138-C2 [0290] 4-(2-Ethoxyethyl)piperidine (16 mg, 0.10 mmol) and l-(3-iodopropyl)-3H- benzothiazol-2-one (38 mg, 0.12 mmol) were used according to GP21 to give the trifluoroacetate salt of the title compound (56NK138-C2) (2.5 mg). HPLC-MS (ammonium acetate) [M+H]+=349.4.
3.184 l-(3-[4-Allyloxy-piperidin-l-yl]propyl)-1.3-dihvdrobenzimidazol-2-one (56NK136-A4) [0291] 4-(l-Cyclohexylmethyl)piperidine (18 mg, 0.10 mmol) and l-(3-iodopropyl)- l,3-dihydrobenzoimidazol-2-one (36 mg, 0.12 mmol) were used according to GP21 to give the trifluoroacetate salt of the title compound (56NK136-A4) (10.8 mg). ΗNMR (CDC13) δ 8.17 (br. s, IH), 7.03-7.26 (m, 4H), 5.93 (ap. ddd, J=17.2, 10.4, 5.5Hz, IH), 5.26 (ap. ddd, J=17.2, 3.2, 1.6Hz, IH), 5.15 (ap. ddd, J=10.4, 2.8, 1.4Hz, IH), 3.99 (ap. dt, J=5.5, 1.7Hz, 2H), 3.93 (t, J= 6.8Hz, 2H), 3.35 (m, IH), 2.73 (m, 2H), 2.39 (t, J=7.1Hz, 2H), 2.10 (m, 2H), 1.95 (tt, J=7.1, 6.8, 2H), 1.90 (m, 2H), 1.63 (m, 2H); HPLC-MS (ammonium acetate) [M+H]+=316.40.
3.185 l-(3-[4-Allyloxy-piperidin-l-yl]propyl)-3-methyl-1.3-dihydrobenzimidazol-2-one (56NK136-B4)
[0292] 4-(2-Ethoxyethyl)piperidine (16 mg, 0.10 mmol) and l-(3-iodopropyl)-3- methyl-l,3-dihydrobenzoimidazol-2-one (38 mg, 0.12 mmol) were used according to GP21 to give the trifluoroacetate salt of the title compound (56NK136-B4) (8.3 mg). !HNMR (CDC13) δ 7.07 (m, 3H), 6.97 (m, IH), 5.93 (ap. ddd, J=17.2, 10.4, 5.5Hz, IH), 5.27 (ap. ddd, J=17.2, 3.2, 1.7Hz, IH), 5.15 (ap. ddd, J=10.4, 3.0, 1.8Hz, IH), 3.99 (ap. dt, J=5.5, 1.7 Hz, 2H), 3.94 (t, J= 6.9Hz, 2H), 3.42 (s, 3H), 3.36 (m, IH), 2.72 (m, 2H), 2.39 (m, 2H), 2.10 (m, 2H), 1.92 (m, 4H), 1.61 (m, 2H); HPLC-MS (ammonium acetate) [M+H]+=330.4.
3.186 General Procedure 22 ( GP22)
[0293] The amine (0.10 mmol) in DCM (0.3 ml) and iodide (0.12 mmol) in DMF (0.2 ml) were added to a reaction vessel and DCM (1 ml) was added. The reactions were shaken at r.t. for 72 h then isocyanate resin (ca. 50 mg, 1.1 mmol/g) was added and the reactions were shaken at r.t. for 24 h. The reactions were filtered, washing with MeOH (1 ml) onto a SCX ion exchange column which had been prewashed with MeOH (2 column volumes). The column was washed with MeOH (2 column volumes) then the product was eluted off the column using 5% aqueous NH3 in MeOH (1 column volume) and concentrated in vacuo. The product was purified by the general prep. LC-MS procedure and the desired fractions were made pH 12 by addition of sodium hydroxide (2M). The product was extracted with EtOAc (3x5 ml), and the organic layer washed with brine (5 ml), dried (K2C03) and concentrated in vacuo to give the desired compound.
3.187 l-(3-r4-Methyl-piperidin-l-yl1propyl)-3-methyl-l .3-dihydrobenzimidazol-2-one (56NK125-A)
[0294] 4-Methylpiperidine (10 mg, 0.10 mmol) and 1 -(3 -iodopropyl)-3 -methyl- 1,3- dihydrobenzoimidazol-2-one (38 mg, 0.12 mmol) were used according to GP22 to give the title compound (56NK125-A) (8.4 mg). Η NMR (CDC13) δ 7.07 (m, 3H), 6.96 (m, IH), 3.94 (t, J=7.0 Hz, 2H), 3.41 (s, 3H), 2.84 (m, 2H), 2.37 (m, 2H), 1.93 (m, 4H), 1.61 (m, 2H), 1.34 (m, IH), 1.24 (m, 2H), 0.92 (d, J=6.2Hz, 3H); HPLC-MS (ammonium acetate) [M+H]+=288.4.
3.188 l-r2-r4-Butylpiperidin-l-yl)ethyll-l,3-dihvdrobenzoimidazol-2-one (56NK117-A) [0295] 4-Butylpiperidine (14 mg, 0.10 mmol) and l-(2-iodoethyl)-l,3- dihydrobenzoimidazol-2-one (35 mg, 0.12 mmol) were used according to GP22 to give the title compound (56NK117-A) (7.6 mg). HPLC-MS (ammonium acetate) [M+H]+=302.4.
3.189 l-r4-('4-Butylpiperidin-l-yl)butyll-1.3-dihvdrobenzoimidazol-2-one (56NK118-At [0296] 4-Butylpiperidine (14 mg, 0.10 mmol) and l-(4-iodobutyl)-l,3- dihydrobenzoimidazol-2-one (38 mg, 0.12 mmol) were used according to GP22 to give the title compound (56NK118-A) (11.6 mg). *H NMR (CDC13) δ 9.02 (br. s, IH), 7.06 (m, 3H), 7.01 (m, IH), 3.90 (t, J=7.0Hz, 2H), 2.89 (m, 2H), 2.37 (m, 2H), 1.89 (m, 2H), 1.79 (m, 2H), 1.64 (m, 4H), 1.23 (m, 9H), 0.88 (m, 3H); HPLC-MS (ammonium acetate) [M+H]+=330.4.
3.190 3-r4-(4-Butylpiperidin-l-vnbutyll-3H-benzooxazole-2-thione (56NK139CD
[0297] 3-(4-Chlorobutyl)-3H-benzooxazole-2-thione (68 mg, 0.28 mmol) and Nal (210 mg, 1.4 mmol) in acetone (10ml) were heated to 50°C for 72h then cooled to r.t. Aqueous sodium thiosulphate solution (10 ml) was added and the product was extracted into EtOAc (2x20 ml). The organic layer was dried (K2C03), filtered and concentrated in vacuo. DMF (0.2 ml), DCM (1 ml) and 4-butylpiperidine (14 mg, 0.1 mmol) in acetonitile (0.2 ml) were added and the reaction was shaken at r.t. for 72 h then isocyanate resin (ca. 50 mg, 1.1 mmol/g) was added and the reactions were shaken at r.t. for 24 h. The reactions were filtered, washing with MeOH (1 ml) onto a SCX ion exchange column which had been prewashed with MeOH (2 column volumes). The column was washed with MeOH (2 column volumes) then the product was eluted off the column using 5%> aqueous NH3 in MeOH (1 column volume) and concentrated in vacuo. The product was purified by preparative LC/MS (method TJ1) and the desired fractions were concentrated in vacuo to give the trifluoroacetate salt of the title compound (56NK139C1) (0.4 mg). HPLC-MS (ammonium acetate) [M+H]+=347.4. 3.191 1 -( 3-r4-Cvclohexylpiperidin- 1 -yllpropylV 1.3-dihvdrobenzimidazol-2-one (75NK58-A2) [0298] 4-Cyclohexylpiperidine (33 mg, 0.20 mmol) in DCM (0.5 ml) and MeCN (0.5 ml) was added to l-(3-iodopropyl)-l,3-dihydrobenzoimidazol-2-one (76 mg, 0.24 mmol), K2CO3 (66 mg, 0.48 mmol) and Nal (72 mg, 0.48 mmol). The reaction was stirred at r.t. for 36 h then aqueous sodium thiosulphate solution (5 ml) was added. The product was extracted into EtOAc (2x10 ml), and the organic layer was dried (K2C03), filtered and concentrated in vacuo. MeOH (1 ml) was added and the compound was loaded onto a SCX ion exchange column which had been prewashed with MeOH (2 column volumes). The column was washed with MeOH (2 column volumes) then the product was eluted off the column using 5%> aqueous NH in MeOH (1 column volume) and concentrated in vacuo. The product was purified by preparative LC/MS (method TJ1) and the desired fractions were made pH 12 by addition of sodium hydroxide (2M). The product was extracted with EtOAc (3x5 ml), and the organic layer washed with brine (5 ml), dried (K2CO3) and concentrated in vacuo to give the title compound (75NK58-A2) (12.1 mg). *H NMR (CDCI3) δ 9.25 (br. s, IH), 7.07 (m, 4H), 3.93 (t, J=7.0Hz, 2H), 2.93 (m, 2H), 2.40 (m, 2H), 1.98 (pent, J=7.0Hz, 2H), 1.86 (m, 2H), 1.69 (m, 7H), 1.32-0.87 (m, 9H); HPLC-MS (ammonium acetate) [M+H]+=342.3.
3.192 l-r3-r4-Cvclohexylpiperidin-l-vnpropyl)-3H-benzothiazol-2-one T75NK58-B2)
[0299] 4-Cyclohexylpiperidine (33 mg, 0.20 mmol) in DCM (0.5 ml) and MeCN (0.5 ml) was added to l-(3-iodopropyl)-3H-benzothiazol-2-one (77 mg, 0.24 mmol), K2C03 (66 mg, 0.48 mmol) and Nal (72 mg, 0.48 mmol). The reaction was stirred at r.t. for 36 h then aqueous sodium thiosulphate solution (5 ml) was added. The product was extracted into EtOAc (2x10 ml), and the organic layer was dried (K2CO3), filtered and concentrated in vacuo. MeOH (1 ml) was added and the compound was loaded onto a SCX ion exchange column which had been prewashed with MeOH (2 column volumes). The column was washed with MeOH (2 column volumes) then the product was eluted off the column using 5% aqueous NH3 in MeOH (1 column volume) and concentrated in vacuo. The product was purified by preparative LC/MS (method TJ1) and the desired fractions were made pH 12 by addition of sodium hydroxide (2M). The product was extracted with EtOAc (3x5 ml), and the organic layer washed with brine (5 ml), dried (K2C03) and concentrated in vacuo to give the title compound (75NK58-B2) (9.1 mg). HPLC-MS (ammonium acetate) [M+H]+=359.2.
3.193 l- -(4-Butylpiperidin-l-yl)propyl)-lH-indol-2.3-dione (85LM03c)
[0300] A 50 ml flask, charged with 4-butylpiperidine (0.042 g, 0.30 mmol), l-(3- iodopropyl)-lH-indol-2,3-dione (85LM05) (0.113 g, 0.36 mmol) and K2C03 (0.062 g, 0.45 mmol) in CH3CN (20 ml), was stirred at 50°C for 24 hours. Water (10 ml) and EtOAc (10 ml) were added and the phases were separated. The water phase was re-extracted with EtOAc (10ml). The combined organic phases were dried (Na S04) and evaporated to dryness. The crude product was purified by column chromatography (Si02; EtOAc/n-heptane 1:1+ 1% Et3N) to give the title compound (85LM03c) (0.012 g, 10%). !H NMR (CDC13) δ 0.95 (t, 3H), 1.10-1.30 (m, 8H), 1.60 (d, 2H), 1.75-1.80 (m, IH), 1.85-1.95 (m, 4H), 2.40 (t, 2H), 2.80 (d, 2H), 3.80 (t, 2H), 7.0 (d, IH), 7.10 (t, IH), 7.55-7.65 (m, 2H); HPLC-MS (ammonium acetate) [M+H]+=329.3.
3.194 1 -(3 -(4-Butylpiperidin- 1 -vDpropylV 1.3 -dihvdro-indol-2-one (85LM 12)
[0301] A mixture of compound l-(3-(4-Butyl-piperidin-l-yl)-propyl)-lH-indol-2,3- dione (85LM03c) (0.030 g, 0.09 mmol) and 10% Pd/C catalyst (0.016 g) in acetic acid (1.4 ml) containing 70%> perchloric acid (0.014 ml) was hydrogenated at 50°C for 20 hours. After removal of the catalyst (filtration of the solution through celite and wash with ethanol) the solution was evaporated. Water (10 ml) and EtOAc (10 ml) were added to the residue followed by addition of sodium hydroxide (1-2 drops) until pH 7. The EtOAc phase was separated, dried (Na2S04) and evaporated to dryness. The crude product was purified by column chromatography (Si02; EtOAc/n- heptane 1:3 + 1% Et3N) to give the title compound (85LM12) (0.001 g, 4%). !H NMR (CDC13) δ 0.95 (t, 3H), 1.10-1.30 (m, 8H), 1.60 (d, 2H), 1.75-1.80 (m, IH), 1.85-1.95 (m, 4H), 2.40 (t, 2H), 2.80 (d, 2H), 3.48 (s, 2H), 3.80 (t, 2H), 6.90-6.95 (m, IH), 7.00-7.05 (m, IH), 7.20-7.30 (m, 2H); HPLC-MS (ammonium acetate) [M+H]+=314.3.
3.195 3-(3-(4-Butylpiperidin-l-yl)propyl)-lH-indole (85LM18)
[0302] A 100 ml flask, charged with 4-butylpiperidine (1.7 g, 12.0 mmol), crude toluene-4-sulfonic acid 3-(lH-indol-3-yl)-propyl ester (85LM17) (4.0 g) and K2C03 (2.0 g, 14.4 mmol) in CH3CN (20 ml), was stirred at 50°C for 24 hours. Water (20 ml) and EtOAc (20 ml) were added and the phases were separated. The aqueous phase was re-extracted with EtOAc (20ml). The combined organic phases were dried (Na2SU4) and evaporated to dryness. The crude product was purified by column chromatography (Si02; EtOAc/n-heptane 1:3) to give the title compound (85LM18) (0.8 g, 10% -3 steps). ^ NMR ^DCls) δ 0.95 (t, 3H), 1.18-1.38 (m, 8H), 1.65 (d, 3H), 1.83-1.98 (m, 4H), 2.40 (t, 2H), 2.78 (t, 2H), 2.90 (d, 2H), 6.98 (s, IH), 7.10 (t, IH), 7.20 (t, IH), 7.35 (d, IH), 7.62 (d, IH); HPLC-MS (ammunium acetate) [M+H]+=299.3.
3.196 3-(3-(4-Butylpiperidin-l-yl)propyl)-L3-dihvdro-indol-2-one (85LM23)
[0303] 3-(3-(4-Butylpiperidin-l-yl)propyl)-lH-indole (85LM18) (0.156 g, 0.52) was dissolved in DMSO (1 ml) in a 10 ml flask and stirred at room temperature. Concentrated hydrochloric acid (0.04 ml, 0.52 mmol) was added slowly and stirring was continued for 24 hours. Water (10 ml) was added and then aqueous sodium bicarbonate (10-20 ml) until pΗ 7 followed by extraction with EtOAc (2x20 ml). The combined organic phases were dried (Na2Sθ4) and evaporated to dryness. The crude product was purified by column chromatography (Si02; EtOAc/n- heptane 1:10) and prep. RP-HPLC (conditions: stationary phase, Luna 15um C18; column, 250x21.2 mm; mobile phase, 20 ml/min, H20/CH3CN, ammoniumacetate buffer (25nM)) to give the title compound (85LM23) (0.002 g, 1%). Η NMR (CDC13) δ 0.95 (t, 3H), 1.10-1.30 (m, 8H), 1.50-1.70 (m, 5H), 1.80-1.90 (m, 2H), 1.90-2.00 (m, 2H), 2.30 (m, 2H), 2.85 (m, 2H), 3.45 (m, 2H), 6.80 (d, IH), 7.00 (t, IH), 7.20-7.30 (m, 2H); HPLC-MS (ammonium acetate) [M+H]+=315.3.
3.197 General Procedure 23 (GP23)
[0304] A 7 ml sealed vial, charged with 4-propoxy-piperidine (1 equiv), chloroalkylheterocycle (1 equiv), Nal (2 equiv) and K2C03 (equiv) in MeCN (4 ml), was stirred at 50 °C for 24 hours. The mixture was poured into water (20 ml) followed by extraction with EtOAc (2x20 ml). The combined organic phases were dried (Na2S04) and evaporated to dryness. The crude product was purified by column chromatography (Si0 ; MeOH/DCM 1:20).
3.198 3-(3-(4-Propoxypiperidine-l-yl)-propyl)-3H-benzooxazol-2-one (85LM37).
[0305] 3-(3-Chloropropyl)-3H-benzooxazol-2-one (62KK30) (0.200 G, 0.95 mmol),
4-propoxypiperidine (0.138 g, 0.95 mmol), Nal (0.285 g, 1.90 mmol), and K2C03 (0.262 g, 1.90 mmol) were reacted according to GP23 to give the title compound (85LM37) (0.21 lg, 70%>). !H NMR (CDC13) δ 0.95 (t, 3H), 1.50-1.65 (m, 4H), 1.80-1.90 (m, 2H), 1.95-2.00 (m, 2H), 2.00-2.10 (m, 2H), 2.40 (t, 2H), 2.65-2.75 (m, 2H), 3.20-3.30 (m, IH), 3.40 (t, 2H), 3.90 (t, 2H), 7.05-7.15 (m, 2H), 7.15-7.25 (m, 2H); HPLC-MS (ammonium acetate) [M+H]+=319.3.
3.199 l-.3-,4-Butylpiperidine-l-yl')propyn-1.3-dihvdro-benzimidazol-2-one ('85LM35y
[0306] l-(3-chloropropyl)-l,3-dihydro-benzimidazol-2-one (0.200 G, 0.95 mmol), 4- propoxypiperidine (0.138 g, 0.95 mmol), Nal (0.285 g, 1.90 mmol), and K2C03 (0.262 g, 1.90 mmol) were reacted according to GP23 to give the title compound (85LM35) (0.183 g, 60%>). H NMR (CD3OD) δ 0.95 (t, 3H), 1.50-1.65 (m, 2H), 1.75-1.85 (m, 2H), 1.95-2.05 (m, 2H), 2.15 (m, 2H), 2.85-3.00 (m, 4H), 3.10-3.20 (m, 2H), 3.40 (t, 2H), 3.55 (m, IH), 4.00 (t, 2H), 7.05-7.15 (m, 3H), 7.20 (d, IH); HPLC-MS (ammonium acetate) [M+H]+=318.3.
3.200 3-(3-f4-Butyl-piperidin-l-yl)-2-hvdroxy-propylV3H-benzothiazol-2-one (85LM15). [0307] A 50 ml flask, charged with 4-butylpiperidine (0.152 g, 1.1 mmol), crude 3-(3- bromo-2-hydroxypropyl)-3H-benzothiazol-2-one (85LM04) (0.308 g) and K2C03 (0.295 g, 2.1 mmol) in MeCN (10 ml), was stirred at 50 °C for 24 hours. Water (10 ml) and EtOAc (10 ml) were added and the phases were separated. The aqueous phase was re-extracted with EtOAc (10ml). The combined organic phases were dried (Na2Sθ4) and evaporated to dryness. The crude product was purified by column cliromatography (Si02; EtOAc/n-heptane 1:3) to give the title compound (85LM15) (0.261 g, 28% -2 steps). *H NMR (CDC13) δ 0.90-1.0 (m, 6H), 1.15-1.30 (m, 9H), 1.60- 1.70 (m, 2H), 1.90 (t, IH), 2.25 (t, IH), 2.40 (m, IH), 2.05 (dd, IH), 2.75 (d, IH), 2.90 (d, IH), 3.90 (dd, IH), 4.00-4.15 (m, 2H), 7.10-7.20 (m, IH), 7.25-4.05 (m, 3H); HPLC-MS (ammonium acetate) [M+H]+=349.1.
3.201 General Procedure 24 f GP24)
[0308] A 100 ml flask, charged with piperidine (1 equiv), 3-(3-chloro-2- methylpropyl)-3H-benzothiazol-2-one (85LM13) (1.2 equiv), Nal (2 equiv) and K2C03 (2 equiv) in MeCN (30 ml), was stirred at 100 °C for 5 days. Water (20 ml) and EtOAc (20 ml) were added and the phases were separated. The aqueous phase was re-extracted with EtOAc (20ml). The combined organic phases were dried (Na2Sθ4) and evaporated to dryness. The crude product was purified by column chromatography (Si02; EtOAc/n-heptane 1:3).
3.202 3-(3-r4-Butyl-piperidin-l-yl)-2-methyl-propyl)-3Η-benzothiazol-2-one ( 85LM14Y
[0309] 4-Butylpiperidine (0.471 g, 3.3 mmol), 3-(3-chloro-2-methylpropyl)-3H- benzothiazol-2-one (0.964 g, 4.0 mmol), Nal (1.0 g, 6.7 mmol), and K2C03 (0.93 g, 6.7 mmol) were reacted according to GP24 to give the title compound (85LM14) (0.344 g, 25%). !H NMR (CDC13) δ 0.90-1.0 (m, 6H), 1.15-1.30 (m, 9H), 1.55-1.65 (m, 2H), 1.80 (t, IH), 1.95 (t, IH), 2.15-2.30 (m, 3H), 2.70 (d, IH), 2.90 (d, IH), 3.80 (dd, IH), 4.05 (dd, IH), 7.10-7.20 (m, 2H), 7.30 (t, IH), 7.40 (d, IH); HPLC-MS (ammonium acetate) [M+H]+=347.3.
3.203 3-(3-(4-Propoxy-piperidin-l-yl)-2-methyl-propyl)-3H-benzothiazol-2-one (85LM49B). [0310] 4-Propxypiperidine (79KS66) (0.150 g, 0.62 mmol), 3-(3-chloro-2- methylpropyl)-3H-benzothiazol-2-one (85LM13) (0.179 g, 0.74 mmol), Nal (0.185 g, 1.2 mmol), and K2C03 (0.172 g, 1.2 mmol) were reacted according to GP24 to give the title compound (85LM49b) (0.049 g, 23%). 1HNMR (CDC13) δ 0.90-1.0 (m, 6Η), 1.45-1.60 (m, 4H), 1.80-1.90 (m, 2H), 2.00 (t, IH), 2.10-2.30 (m, 4H), 2.60 (m, IH), 2.80 (m, IH), 3.20 (m, IH), 3.40 (t, 2H), 3.80 (dd, IH), 4.00 (dd, IH), 7.10-7.20 (m, 2H), 7.30 (d, IH), 7.40 (d, IH); HPLC-MS (ammonium acetate ) [M+H]+=349.2.
3.204 General Procedure 25 rGP25
[0311] A 100 ml flask, charged with 4-butyl-piperidine (1 equiv), toluene-4-sulfonic acid ester (1 equiv) and K2C03 (1 equiv) in MeCN (20 ml), was stirred at 40°C for 48 hours. Water (20 ml) and EtOAc (20 ml) were added and the phases were separated. The aqueous phase was re- extracted with EtOAc (20ml). The combined organic phases were dried (Na2Sθ4) and evaporated to dryness. The crude product was purified by CC (Si02; MeOH/DCM 1:50).
3.205 3-(3-(4-Butyl-piperidin-l-yl)-(S)-3-hydroxy-2-methyl-propyl)-3H-benzothiazol-2-one (85LM74-62S).
[0312] Toluene-4-sulfonic acid (R)-2-methyl-3-(2-oxobenzothiazol-3-yl)-propyl ester (85LM73-61) (0.900 g, 2.4 mmol), 4-butylpiperidine (0-336 g, 2.4 mmol), and K2C03 (0.30 g, 2.4 mmol) were reacted according to GP25 to give the title compound (85LM74-62S) (0.450 g, 24%). Η NMR (CDCl3) δ 0.90-1.0 (m, 6H), 1.15-1.30 (m, 9H), 1.55-1.65 (m, 2H), 1.80 (t, IH), 1.95 (t, IH), 2.15-2.30 (m, 3H), 2.70 (d, IH), 2.90 (d, IH), 3.80 (dd, IH), 4.05 (dd, IH), 7.10-7.20 (m, 2H), 7.30 (t, IH), 7.40 (d, IH); HPLC-MS (ammonium acetate) [M+H]+=347.3.
3.206 3-(3-(4-Butylpiperidin-l-yl)-(R)-3-hydroxy-2-methylpropyl)-3H-benzothiazol-2-one (85LM91-78R).
[0313] Toluene-4-sulfonic acid (S)-2-methyl-3-(2-oxo-benzothiazol-3-yl)-propyl ester (85LM90-77) (0.900 g, 2.4 mmol), 4-butylpiperidine (0-336 g, 2.4 mmol), and K2C03 (0.30 g, 2.4 mmol) were reacted according to GP25 to give the title compound (85LM91-78R) (0.450 g, 24%). 'H N R (CDC13) δ 0.90-1.0 (m, 6H), 1.15-1.30 (m, 9H), 1.55-1.65 (m, 2H), 1.80 (t, IH), 1.95 (t, IH), 2.15-2.30 (m, 3H), 2.70 (d, IH), 2.90 (d, IH), 3.80 (dd, IH), 4.05 (dd, IH), 7.10-7.20 (m, 2H), 7.30 (t, IH), 7.40 (d, IH); HPLC-MS (ammonium acetate) [M+H]+=347.3.
3.207 General Procedure 26 (GP26)
[0314] A mixture of 3-(3-Iodopropyl)-3H-benzothiazol-2-one (61KS80) (1.2 equiv), an amine (1.0 equiv) and K2C03 (2.0 equiv) in MeCN/DCM (1:2, 3 mL) was shaken at 40 °C for 15 h. The mixture was cooled to room temperature before adding resin bound isocyanate (ArgoNaut Technologies Inc., PS-isocyanate, 3 equiv) and was then left standing for 18 h. Thereafter filtration through cotton wool was performed and subsequently purified by ionexchange (Varian BondElut®- SCX, ϊ ). Elution with 2.5 % NH4OH in MeOH and concentration gave the title compounds.
3.208 3-r3-G-Pent-l-ynyl-8-aza-bicvclor3.2.11oct-2-en-8-vnpropyll-3H-benzothiazol-2-one (79KS38-5).
[0315] 3-Pent-l-ynyl-8-azabicyclo[3.2.1]oct-2-ene (79KS36-5) (0.033 g, 0.188 mmol), 3-(3-Iodopropyl)-3H-benzothiazol-2-one (61KS80) (0.072 g, 0.226 mmol), and K2C03 (0.052 g, 0.376 mmol) were reacted according to GP26 to give the title compound (79KS38-5) (0.018 g, 26%). JH NMR (CDCI3) δ 0.98 (t, 3H, J=7.5Hz, -C^O CEb), 1.57 (sixt, 2H, J=7.5Hz, - CR2 __2CΑ_), 1.59 (ddd, IH, J=6.8Hz, 8.3Hz, J=13.9Hz), 1.71 (d, IH, J=18.0Hz), 1.85 (td, IH, J=3.0Hz, J=9.0Hz), 1.89 - 2.02 (m, 3H), 2.11 (m, IH), 2.26 (t, 2H, J=7.2Hz, -CH2CH2Ctt-N(fπHn bicyclo[3.2.1]-oct-2-en-8-yl system)), 2.53 (m, IH, J=18.0Hz), 2.56 - 2.68 (m, 2H), 3.31 (dd, IH, J=4.5Hz, 8.1Hz), 3.35 (t, IH, J=5.4Hz), 4.04 (t, 2H, J=6.8Hz, N(from Ar)-CH2CH2CH2-), 6.02 (d, IH, J=5.6Hz, H2 (from bicyclo[3.2.1]-oct-2-en-8-yl system), 7.01 - 7.44 (m, 4H, Ar); 13C NMR (CDCI3): δ 13.7, 21.5, 22.4, 26.7, 29.8, 33.8, 35.4, 41.3, 45.5, 55.6, 57.0, 80.7, 89.6, 111.1, 118.5, 122.7, 123.0, 123.1, 126.4, 135.3, 137.6, 170.2. HPLC-MS (ammonium acetate): [M+H]+= 367.31
3.209 3- 3-(3-Hex-vnyl-8-aza-bicvclor3.2. oct-2-en-8-yl)propyll-3H-benzothiazol-2-one (79KS38-6V
[0316] 3-Hex-l-ynyl-8-azabicyclo[3.2.1]oct-2-ene (79KS36-6) (0.049 g, 0.259 mmol), 3-(3-Iodopropyl)-3H-benzothiazol-2-one (61KS80) (0.099 g, 0.311 mmol) and K2C03 (0.072 g, 0.518 mmol) were reacted according to GP26 to give the title compound (79KS38-6) (0.053 g, 54 %). 1H NMR (CDCI3) δ 0.90 (t, 3H, J=7.0Hz, -CH3), 1.34 - 1.52 (m, 4H, 1.55 (ddd, IH, J=6.6Hz, 9.0Hz, 12.1Hz), 1.66 (d, IH, J=17.6Hz), 1.85 (td, IH, J=2.6Hz, 10.8Hz), 1.86 - 1.97 (m, 3H), 2.06 (m, IH), 2.26 (t, 2H, J=7.2Hz, -CH2CH2CH2-N (from bicyclo[3.2.1]-oct-2-en-8- yl system), 2.49 (d, IH, J=17.6Hz), 2.56 (m, 2H), 3.25 (dd, IH, J=4.6Hz, 6.9Hz), 3.28 (t, IH, J=5.8Hz), 4.02 (t, 2Hz, J=5.8Hz, N(from Ar)-CH2CH2CH2- ), 6.01 (d, IH, J=6.8Hz, H2(from bicyclo[3.2.1]-oct-2-en-8-yl system); 13C NMR (CDCI3) δ 13.8, 19.2, 22.2, 26.8, 29.3, 31.1, 33.9, 35.4, 41.3, 45.6, 55.5, 56.9, 80.7, 89.4, 111.1, 118.4, 122.7, 123.0, 123.1, 126.4, 135.7, 137.7, 170.1; HPLC-MS (ammonium acetate): [M+H]+= 381.32
3.210 3-r3-(3-Hept-l-vnyl-8-aza-bicvclor3.2.11oct-2-en-8-vnpropyll-3H-benzothiazol-2-one f79KS38-7).
[0317] 3-Hept-l-ynyl-8-azabicyclo[3.2.1]oct-2-ene (79KS36-7) (0.051 g, 0.250 mmol), 3-(3-Iodopropyl)-3H-benzothiazol-2-one (61KS80) (0.096 g, 0.300 mmol) and K2C03 (0.069 g, 0.500 mmol) were reacted according to GP26 to give the title compound (79KS38-7) (0.057 g, 58%). !H NMR (CDCI3) δ 0.90 (t, 3H, J=7.1Hz, -CH2CH2CH2CH3), 1.24 - 1.40 (m, 4H), 1.44 - 1.54 (m, 2H), 1.59 (ddd, IH, J=5.5Hz, 9.1Hz, 13.1Hz), 1.72 (d, IH, J=18.0Hz), 1.84 (td, IH, J=2.8Hz, 8.3Hz), 1.90 - 2.06 (m, 3H), 2.06 - 2.18 (m, IH), 2.28 (t, 2H, J=6.9Hz, -CH2CH2CHr N(from bicyclo[3.2.1]-oct-2-en-8-yl system), 2.52 (d, IH, J=18.0Hz), 2.64 (m, 2H), 3.26 - 3.42 (m, 2H), 4.04 (t, 2H, J=6.9Hz, N (from Ar)-CH2CH2CH2-), 6.02 (d, IH, J=5.9Hz), 7.06-7.44 (m, 4H, Ar); 13C NMR (CDC13) δ 14.1, 19.5, 22.4, 26.6, 28.7, 29.8, 31.3, 33.8, 35.3, 41.2, 45.5, 55.6, 57.0, 80.5 and 90.0 (sp C's), 111.1, 118.6, 122.6, 123.3, 126.4, 137.6 (Ar), 170.2 (C=0); HPLC-MS (ammonium acetate): [M+H]+= 395.34
3.211 3-{3-[3-.4-Hvdroxy-but-1 -ynviy8-aza-bicvclor3.2.11oct-2-en-8-yllproPyl)-3H- benzothiazol-2-one (79KS38-2Y [0318] 4-(8-Azabicyclo[3.2.1]oct-2-en-3-yl)-but-3-yn-l-ol (79KS36-2) (0.018 g, 0.102 mmol), 3-(3-Iodopropyl)-3H-benzothiazol-2-one (61KS80) (0.039 g, 0.122 mmol) and K2C03 (0.028 g, 0.204 mmol) were reacted according to GP26 to give the title compound (79KS38-2) ( 0.022 g, 59%). Η NMR (CDC13) δ 1.56 (ddd, IH, J=5.9Hz, 9.3Hz, 13.2Hz), 1.67 (d, IH, J=17.6Hz), 1.83 (td, IH, J=2.3Hz, 9.1Hz), , 1.87 (m, 6H), 2.02 - 2.15 (m, IH), 2.51 (m, IH, 17.6Hz), 2.54 - 2.64 (m, 4H), 3.27 (dd, IH, J=4.7Hz, 7.1Hz), 3.31 (t, IH, J=5.7Hz), 3.71 (t, 2H, J=6.3Hz, -CH2CH20H), 4.04 (t, 2H, J=7.0Hz, N(from Ar)-CH2CH2CH2-), 6.08 (d, IH, J=5.6Hz, H2 (from bicyclo[3.2.1]-oct-2-en-8-yl system)), 7.10 - 7.44 (m, 4H, Ar); 13C NMR (CDC13) δ 24.0, 26.8, 29.9, 33.8, 35.3, 41.3, 45.7, 55.5, 57.0, 61.3, 82.7, 85.4, 111.1, 117.9, 122.7, 123.0, 123.1, 126.4, 136.9, 137.7, 170.2. HPLC-MS (ammonium acetate): [M+H]+= 369.28
3.212 3-(3-r3-r5-Hvdroxy-pent-l-vnyl)-8-aza-bicvclor3.2.noct-2-en-8-yllpropyl>-3H- benzothiazol-2-one (79KS38-3).
[0319] 5-(8-Azabicyclo[3.2.1]oct-2-en-3-yl)-pent-4-yn-l-ol (79KS36-3) (0.045 g, 0.235 mmol), 3-(3-Iodoproρyl)-3H-benzothiazol-2-one (61KS80) (0.090 g, 0.282 mmol) and K2C03 (0.065 g, 0.470 mmol) were reacted according to GP26 to give the title compound (79KS38- 3) (0.059 g, 66%). *H NMR (CDC13): δ 1.57 (ddd, IH, J=6.2Hz, 9.4Hz, 13.4Hz), 1.68 (d, IH, J=17.9Hz), 1.72 - 2.00 (m, 6H), 2.03 - 2.16 (m, IH), 2.42 (t, 2H, J=6.9Hz), 2.50 (d, IH, 17.9Hz), 2.54 - 2.63 (m, 2H), 3.28 (td, IH, J=4.8Hz, 6.9Hz), 3.74 (t, 2H, J=6.0Hz, -CH2CH2CH2θH), 4.40 (t, 2H, J=7.2Hz, N (from Ar)-CH2CH2CH2-), 6.04 (d, IH, J=4.5Hz), 7.10 - 7.44 (m, 4H, Ar); 13C NMR (CDC13) δ 16.2, 26.8, 29.9, 31.6, 33.8, 35.3, 41.3, 45.6, 55.5, 57.0, 62.0, 81.3, 88.5, 111.1, 118.2, 122.7, 123.0, 123.1, 126.4, 136.0, 137.6, 170.2; HPLC-MS (ammonium acetate): [M+H]+= 383.30
3.213 3-r3-(3-Propyl-8-aza-bicvclor3.2.11oct-8-yl)-propyll-3H-benzothiazol-2-one (79KS83-2') [0320] 8-tgrtButyloxycarbonyl-3-propyl-8-aza-bicyclo[3.2.1]octane (79KS75) (0.012 g, 0.0474 mmol) was dissolved in DCM (2 mL) followed by the addition of TFA (0.5 mL) under stirring. The mixture was left stirring until complete conversion of the starting material had occurred before it was concentrated in vacuo, basified (2M NaOH), extracted (EtOAc) and concentrated once again. The resultant oil was reacted with 3-(3-Iodopropyl)-3H-benzothiazol-2- one (61KS80) (0.018 g, 0.0569 mmol) and K2C03 (0.013 g, 0.0948 mmol) in accordance with GP26 to give the title compound (79KS83-2) (0.011 g, 67 %). !H NMR (CDC13) δ 0.86 (t, 3H, 7.2Hz, -CH2CH2CH3), 1.10 - 1.20 (m, 2H), 1.20 - 1.42 (m, 4H), 1.42 - 1.50 (m, 2H), 1.50 - 1.66 (m, 3H), 1.80 - 1.98 (m, 4H), 2.38 - 2.50 (m, 2H), 3.05 - 3.15 (m, 2H), 4.05 (t, 2H, J=6.6Hz, N(from Ar)-CI CH2CH2), 7.10 - 7.44 (m, 4H, Ar); 13C NMR (CDC13) δ 14.5, 20.2, 26.8, 27.9, 37.8, 39.4, 41.2, 49.0, 59.8, 111.4, 122.7, 122.9, 123.1, 126.4, 137.7; HPLC-MS (ammonium acetate): [M+H]+= 377.16 3.214 3-[3-G-Butyl-8-aza-bicvclo[3.2.11oct-8-ylVpropyll-3H-benzothiazol-2-one 79KS96-2 [0321] 8-tgrt-Butyloxycarbonyl-3-butyl-8-aza-bicyclo[3.2.1]octane (79KS92) (0.045 g, 0.168 mmol), 3-(3-Iodopropyl)-3H-benzothiazol-2-one (61KS80) (0.064 g, 0.202 mmol) and K2C03 (0.046 g, 0.336 mmol) were reacted according to GP26 to give the title compound (79KS96- 2) (0.019 g, 32%). !H NMR (CDC13) δ 0.87 (t, 3H, J=7.2Hz, -CH2CH2CH2CH3), 1.12 - 1.64 (m, 13H), 1.80 - 1.98 (m, 4H), 2.43 (t, 2H, J=6.4Hz), 3.18 (br s, 2H), 4.05 (t, 2H, J=6.3Hz, N(from Ar)- CH2CH2CH2), 7.10 - 7.43 (m, 4H, Ar); 13C NMR (CDC13) δ 14.3 (-CH2CH2CH2CH3) , 23.1, 26.8, 28.2, 29.4, 36.8, 37.9, 41.2, 49.0, 59.7, 111.4, 122.7, 122.9, 123.1, 126.4, 137.7, 170.2 (C=0); HPLC-MS (ammonium acetate): [M+H]+= 359.27
3.215 3-r3-(3-Pentyl-8-aza-bicvclor3.2. lloct-8-yl)-propyl1-3H-benzothiazol-2-one (79KS97- oxalate)
[0322] 3-Pentyl-8-aza-bicyclo[3.2.1]octane (79KS95) (0.118 g, 0.651 mmol), 3-(3-
Iodopropyl)-3H-benzothiazol-2-one (61KS80) (0.064 g, 0.781 mmol) and K2C03 (0.046 g, 1.30 mmol) were reacted according to GP26 to give (79KS97) (0.161 g, 66%). The oxalate salt was prepared by dissolving the product in Et20 and a minimum of MeOH followed by the addition of a solution of oxalic acid (l.leq of obtained product) in Et20. Filtration gave the title compound (79KS97-oxalate). NMR of the free base was recorded. !H NMR (CDC13); δ 0.88 (t, 3H, J=6.9Hz, - CH2CH2CH2CH2CH3), 1.17 - 1.38 (m, 8H), 1.38 - 1.48 (m, 2H), 1.56 - 1.75 (m, 3H), 1.86 - 2.00 (m, 4H), 2.08 - 2.22 (m, 2H), 2.43 (t, 2H, J=6.7Hz), 3.18 (br s, 2H), 4.07 (t, 2H, J=6.9Hz, N(from Ar)- CH2CH2CH2), 7.12 - 7.43 (m, 4H, Ar); 13C NMR (CDC13) δ 14.3 (-CH2CH2CH2CH2CH3), 22.9, 26.9, 27.3, 28.3, 28.5, 32.2, 35.7, 38.6, 41.2, 48.9, 58.9, 111.3, 122.7, 123.0 123.1, 126.4, 137.7, 170.2(C=O); HPLC-MS (ammonium acetate): [M+H]+= 373.28
3.216 3-r3-(3-Hexyl-8-aza-bicvclo[3.2. noct-8-ylVpropyn-3H-benzothiazol-2-one C79KS83-8) [0323] 8-tgrtButyloxycarbonyl-3-hexyl-8-aza-bicyclo[3.2.1]octane (79KS81) (0.031 g,
0.105 mmol), 3-(3-Iodopropyl)-3H-benzothiazol-2-one (61KS80) (0.040 g, 0.126 mmol) and K2CO3 (0.029 g, 0.210 mmol) were reacted according to GP26 to give the title compound (79KS83- 8) (0.035 g, 86%). Η NMR (CDC13) δ 0.82 - 0.94 (t, 3H, J=6.8Hz, -CH2CH2CH2CH2CH2CH3), 1.10 - 1.37 (m, 12H), 1.40 - 1.62 (m, 5H), 1.80 - 1.95 (m, 4H), 2.40 (t, 2H, 6.2Hz), 3.18 (br s, 2H), 4.04 (t, 2H, J=6.8Hz, N(from Ar)-CI .CH2CH2), 7.08 - 7.44 (m, 4H, Ar); 13C NMR (CDC13) δ 14.3 (-CH2CH2CH2CH2CH2CH3), 22.9, 26.8, 27.0, 27.1, 28.3, 29.7, 32.1, 37.2, 38.1, 41.3, 49.0, 59.7, 111.3, 122.7, 122.9, 123.1, 126.4, 137.8, 170.2(0=0); HPLC-MS (ammonium acetate): [M+H]+= 387.27
3.217 3-r3-G-Butylidene-8-aza-bicvclor3.2.noct-8-yl)-propyl1-3H-benzothiazo1-2-one C61KS91- B [0324] To a slurry of butylphosphonium bromide (1.70 g, 4.26 mmol) in dry THF (10 mL) was added BuLi (2.66mL, 1.6M sol., 4.26 mmol) at 0°C under stirring. The mixture was allowed to reach room temperature and stirred for another 2 h before dropwise addition of a solution of N-Boc-nortropinone (0.960 g, 4.26 mmol) in dry THF (5 mL) at 0 °C. The reaction mixture was slowly heated to room temperature and thereafter left stirring overnight. The resultant heterogeneous mixture was filtered and concentration in vacuo followed by column chromatography in DCM to yield the bicyclic amine 32HS95 (0.032 g, 3%). This was then dissolved in DCM/TFA (1:1, 2 mL) and concentrated. To the resultant syrup was added 2M NaOH (5 mL) and the mixture was extracted (DCM). The combined organic phase was dried (Na2S04), filtered and concentrated. This product was reacted with 3-(3-Iodopropyl)-3H-benzothiazol-2-one (61KS80) (0.046 g, 0.145 mmol) and K2C03 (0.033 g, 0.242 mmol) according to GP26 to give the title compound (61KS91-1) (0.025 g, 58%). !H NMR (CDC13) δ 0.88 (t, 3H, J=7.2Hz, =CHCH2CH2CH3), 1.35 (sixt, 2H, J=7.2Hz, ^HC^CH^C^), 1.43 (t, IH, J=8.6Hz), 1.55 (t, IH, J=8.6Hz), 1.76 - 1.92 (m, 5H), 1.97 (quint, 2H, J=7.2Hz), 2.22 (d, IH, J=14.4Hz), 2.27 (d, IH, J=14.4Hz), 2.50 - 2.64 (m, 3H), 3.24 - 3.35 (m, 2H), 4.01 (t, 2H, 7.0Hz, N(from Ar)-CH2CH2CH2), 5.22 (t, IH, J=7.4Hz), 7.20 - 7.42 (m, 4H, Ar); HPLC-MS (ammonium acetate): [M+H]+= 357.40
3.218 3-r3-('4-Methoxymethyl-piperidine-l-vn-propyll-3H-benzothiazol-2-onef61KS89- oxalate) [0325] To a solution of l-tgrtButyloxycarbonyl-4-methoxymethyl-piperidine
(61KS83) (0.088 g, 0.385 mmol) in DCM (2 mL) was added TFA (2 mL) under stirring. After complete conversion of the starting material the mixture was basified (2M NaOH) and extracted with DCM. After drying (Na2S0 ) of the combined organic phase, filtering and concentration, the crude product was reacted with 3-(3-Iodopropyl)-3H-benzothiazol-2-one (61KS80) (0.147 g, 0.462 mmol) and K2C03 (0.106 g, 0.770 mmol) to give the title compound (61KS89) (0.086 g, 67%). The oxalate salt was prepared by dissolving the product in Et20 and a minimum of MeOH followed by the addition of a solution of oxalic acid (l.leq of obtained product) in Et20. Filtration gave the title compound (61KS89-oxalate). NMR of the free base was recorded. ]H NMR (CDC13) δ 1.23 (dq, 2H, J=3.9Hz, 12.1Hz), 1.48 - 1.63 (m, IH), 1.64 - 1.73 (m, 2H), 1.83 - 1.95 (m, 4H), 2.35 (t, 2H, J=6.9Hz), 2.84 (m, 2H, J=l 1.8Hz), 3.19 (d, 2H, J=7.2Hz, -CHzOCHs), 3.30 (s, 3H, -CH2OCH3), 3.97 (t, 2H, J=7.2Hz, N(from Ar)-CH2CH2CH2), 7.07 - 7.40 (m, 4H, Ar); 13C NMR (CDC13): δ 25.3, 29.5, 36.4, 41.3, 53.7, 55.7, 59.0, 78.2 (-CH2OCH3) , 111.0, 122.7, 123.0, 123.1, 126.4, 137.6, 170.1 (C=0); HPLC-MS (ammonium acetate): [M+H]+= 321.36
3.219 3-r3-(4-Ethoxymethyl-piperidine-l-ylVpropyll-3H-benzothiazol-2-one f61KS91-3-oxalate') [0326] To a solution of l-tgrtButyloxycarbonyl-4-ethoxymethyl-piperidine (61KS90)
(0.071 g, 0.292 mmol) in DCM (2 mL) was added TFA (2 mL) under stirring. After complete, conversion of the starting material the mixture was basified (2M NaOH) and extracted with DCM. After drying (Na2S0 ) of the combined organic phase, filtering and concentration, the crude product was reacted with 3-(3-Iodopropyl)-3H-benzothiazol-2-one (61KS80) (0.112 g, 0.350 mmol) and K2CO3 (0.067 g, 0.484 mmol) according to GP26 to give the title compound (61KS91-3) (0.048 g, 49%). The oxalate salt was prepared by dissolving the product in Et2O and a minimum of MeOH followed by the addition of a solution of oxalic acid (l.leq of obtained product) in Et20. Filtration gave the title compound (61KS91-3-oxalate). NMR of the free base was recorded. Η NMR (CDC13) δ 1.16 (t, 3H, J=7.0Hz, -CH2OCH2CH3), 1.41 (dq, 2H, J=4.2Hz, 12.6Hz), 1.56 - 1.70 (m, IH), 1.74 - 1.82 (m, 2H), 2.05 (quint, 2H, J=7.0Hz, N(from Ar)-CH2CH2CH2), 2.13 (td, 2H, J=2.8Hz, 11.8Hz), 2.57 (t, 2H, J=7.0Hz, N(from Ar)-CH2CH2CH^), 3.04 (m, 2H, J=11.2Hz), 3.22 (d, 2H, J=6.2Hz, -CH2θCH2CH3), 3.43 (q, 2H, J=7.0Hz, -CH2OCHbCH3), 4.00 (t, 2H, J=7.0Hz, N(from Ar)-CH2CH2CH2), 7.10 - 7.40 (m, 4H, Ar); HPLC-MS (ammonium acetate): [M+H]+= 335.39
3.220 3-(3-r4-("2-Methoxyethvn-piperidine-l-yll-propyU-3H-benzothiazol-2-one C61KS91-2- oxalate)
[0327] To a solution of l-tgrtButyloxycarbonyl-4-(2-methoxyethyl)-piperidine (61KS86) (0.100 g, 0.410 mmol) in DCM (2 mL) was added TFA (2 mL) under stirring. After complete conversion of the starting material the mixture was basified (2M NaOH) and extracted with DCM. After drying (Na2S0 ) of the combined organic phase, filtering and concentration, the crude product was reacted with 3-(3-Iodopropyl)-3H-benzothiazol-2-one (61KS80) (0.157 g, 0.492 mmol) and K2C03 (0.113 g, 0.820 mmol) according to GP26 to give the title compound (0.089 g, 65%). The oxalate salt was prepared by dissolving the product in Et2O and a minimum of MeOH followed by the addition of a solution of oxalic acid (l.leq of obtained product) in Et20. Filtration gave the title compound (61KS91-2-oxalate). NMR of the free base was recorded. *H NMR (CDCI3) δ 1.23 (dq, 2H, J=12.1Hz), 1.31 - 1.43 (m, IH), 1.49 (q, 2H, J=6.3Hz, -C__ CR2OCH_), 1.62 - 1.70 (m, 2H), 1.85 - 1.96 (m, 4H), 2.37 (t, 2H, J=7.3Hz, N(from Ar)-CH2CH2CH2), 2.80 - 2.88 (m, 2H, J=12.0Hz), 3.30 (s, 3H, -CEbCHaOCHj), 3.38 (t, 2H, J=6.3Hz, -CH2CH2θCH3), 3.98 (t, 2H, J=7.3Hz, N(from Ar)-CH2CH2CH2), 7.08 - 7.40 (m, 4H, Ar); HPLC-MS (ammonium acetate): [M+H]+= 335.39
3.221 General Method 27 (GP27
[0328] To a solution of a Boc-protected amine (l.Oeq) in DCM (2 mL) was added TFA (2 mL) followed by concentration in vacuo. The remaining syrup was dissolved in MeCN (3 mL) followed by addition of 3-(3-Chloropropyl)-3H-benzothiazol-2-one (61KS67) (0.046 g, 0.204 mmol, 1.3 equiv), Nal (0.031 g, 0.204 mmol, 1.3 equiv) and Na2C03 (0.083 g, 0.7.85 mmol, 5 eq). The reaction mixture was shaken at 80 °C for 18 h. Excess cyclohexyl isocyanate (4.0 equiv) was added and shaking at 80 °C was continued for another 30min before the reaction mixture was put on an ionexchange column (Varian BondElut®-SCX, Fi4) and eluted with 2.5% NH-jOH in MeOH. Evaporation of the solvent gave the desired product. This was taken up in Et20 and a solution of oxalic acid (1.1 equiv) in Et20 was added. The white precipitate was filtered off and dried. NMR spectra of the free bases were recorded.
3.222 3- (3 -f4-(Prop-2-ene- 1 -oxyVpiperidin- 1 -vf|-propyl} -3H-benzothiazol-2-one (61KS69- oxalate).
[0329] l-tgrt-Butyloxycarbonyl-4-(prop-2-ene-l-oxy)-piperidine (104KS20) (0.038 g,
0.157 mmol) was reacted according to GP27 to give the title compound (61KS69-oxalate) (0.040 g, 77%). 1HNMR (CDC13) δ 1.54 - 1.65 (m, 2H), 1.80 - 1.94 (m, 5H), 2.06 (td, J=2.0Hz, 11Hz), 2.36 (t, 2H, 7.0Hz), 2.66 - 2.75 (m, 2H), 3.34 (sept, IH, J=4.3Hz), 3.96 - 4.04 (m, 4H), 5.14 (ddt, IH, J=1.5Hz, J=l lHz, -OCH2CH=CHcHt), 5.26 (ddt, IH, J=1.8Hz, 17.6Hz, -OCH2CH=CHcHt), 5.91 (ddt, IH, J=5.5Hz, 11Hz, 17.6Hz, -OCH2CH=CHcHt), 7.10 - 7.42 (m, 4H, Ar); 13C NMR (CDCI3) δ
25.4, 31.7, 41.2, 51.5, 55.2, 69.0 and 74.8 (C4 and -OCH2CH=CHcHt), 111.0, 116.7, 122.8, 123.0, 123.1, 126.4, 135.6, 137.6 (Ar), 170.2 (C=0). HPLC-MS (ammonium acetate): [M+H]+= 333.35
3.223 3-r3-f4-Propoxy-piperidin-l-yl)-propyn-3H-benzothiazol-2-one (61KS70-l-oxalate) [0330] l-tgrt-Butyloxycarbonyl-4-propoxy-piperidine (104KS21) (0.049 g, 0.200 mmol) was reacted according to GP27 to give the title compound (61KS70-l-oxalate) (0.056 g, 80%). 'H NMR (CDC13) δ 0.90 (t, 3H, J=7.1Hz, -OCH2CH2CH3), 1.50 - 1.63 (m, 4H), 1.82 - 1.95 (m, 4H), 2.06 (td, 2H, J=2.4Hz, 10.8Hz), 2.35 (t, 2H, J=6.8Hz), 2.70 (dt, 2H, J=4.8Hz, 8.0Hz), 3.26 (sept, IH, J=4.3Hz), 3.37 (t, 2H, J=6.8Hz), 3.99 (t, 2H, J=7.0Hz), 7.09 - 7.42 (m, 4H, Ar); 13C NMR (CDCI3) δ 10.9 (-OCH2CH2CH3), 23.5, 25.3, 31.4, 41.1, 51.4, 55.2, 69.8 and 74.9 (-OCH2CH2CH3 and C4), 111.1, 122.8, 122.9, 123.2, 126.5, 137.5 (Ar), 170.3 (C=0). HPLC-MS (ammonium acetate): [M+H]+= 335.37
3.224 3-[3-(4-Isobutoxy-piperidin-l-yl)-propyl]-3H-benzothiazol-2-one (61KS70-2-oxalate') [0331] l-tgrt-Butyloxycarbonyl-4-(isobutoxy)-piperidine (61KS66) (0.051 g, 0.200 mmol) was reacted according to GP27 to give the title compound (61KS70-2-oxalate) (0.059 g, 85%). !H NMR (CDCI3) δ 0.89 (d, 6H, J=6.6Hz, -0CH2CH(CH3)3), 1.52 - 1.63 (m, 2H), 1.81 (nonet, IH, J=6.9Hz, -0CH2CH(CH3)3), 1.82 - 1.89 (m, 2H), 1.90 (quint, 2H, 7.0Hz, N(from Ar)- CH2CH2CH2-), 2.65 (td, 2H, J=2.3Hz, 10.9Hz), 2.35 (t, 2H, J=7.0Hz, N(from Ar)-CH2CH2CH2-), 2.68 (m, 2H), 3.17 (d, 2H, J=6.9Hz, -0CH2CH(CH3)3), 3.20 - 3.28 (m, IH), 3.99 (t, 2H, J=7.0Hz, N(from Ar)-CH2CH2CH2-), 7.10 - 7.42 (m, 4H, Ar); 13C NMR (CDC13) δ 19.7 (-0CH2CH(CH3)3),
25.5, 29.0, 31.7, 41.2, 51.5, 55.3, 75.1 and 75.2 (C4 and -OCH2CH(CH3)3), 111.0, 122.7, 123.0, 123.1, 126.4, 137.7 (Ar), 170.1 (C=0); HPLC-MS (ammonium acetate): [M+H]+= 349.1 3.225 3-[3-f4-Cvclobutylmethoxy-piperidin-l-ylVpropyn-3H-benzothiazol-2-one C61KS70-3- oxalate)
[0332] l-tgrt-Butyloxycarbonyl-4-(cyclobutylmethoxy)-piperidine (61KS51) (0.054 g,
0.200 mmol) was reacted according to GP27 to give the title compound (61KS70-3 -oxalate) (0.044 g, 61%). Η NMR (CDC13) δ 1.53 - 1.64 (m, 2H), 1.64 - 1.75 (m, 2H), 1.78 - 1.97 (m, 5H), 1.98 - 2.20 (m, 3H), 2.39 (t, 2H, J=6.9Hz), 2.52 (sept, IH, J=7.4Hz, -OCH2CH(CH2CH2CH2)), 2.67 - 2.76 (m, 2H), 3.22 - 3.30 (m, IH), 3.39 (d, 2H, J=7.4Hz, -OCEbCH(CH2CH2CH2), 3.99 (t, 2H, J=6.9Hz), 7.09 - 7.41 (m, 4H, Ar); 13C NMR (CDC13) δ 18.8 (-OCH2CH(CH2CH2CH2)), 25.3 (- OCH2CH(CH2CH2CH2)), 31.4, 34.2, 35.6, 41.2, 51.4, 55.2, 72.8 and 74.9 (-OCH2CH(CH2CH2CH2) and C4), 111.1, 122.7, 122.9, 123.2, 126.4, 137.6 (Ar), 170.2 (C=0).

Claims

CLAIMSWhat is claimed is:
1. A compound of Formula I
or a pharmaceutically acceptable salt or prodrug thereof, wherein
X is selected from the group consisting of C, O, N and S
Z is selected from the group consisting of CH and N
Y is selected from the group consisting of =0, =N and =S or tautomers thereof;
SPU is a spacer unit providing a distance J between Z and N wherein
-SPU- is a biradical selected from the group consisting of -(CR6R7)n-A- and -C3_g- cycloalkyl- wherein n is in the range 1 to 5, such as 1, 2, 3, 4, or 5 and A is absent or an optionally substituted -C3.s-cycloalkyl;
N together with R1 and R2 form a heterocyclic ring wherein said heterocyclic ring is selected from the group consisting of perhydroazocine, perhydroazepine, piperidine, pyrrolidine, azetidine, aziridine and 8-azabicyclo[3.2.1]octane and wherein the heterocyclic ring is substituted with one or more substituents R4 selected from the group consisting of halogen, Cι_g-alkyl, C3.8-cycloalkyl, Ci-g-alkoxy, -g- alkylcarbonyl, -g-alkylidene, C2-s-alkenyl, C2-s-alkynyl, Cι-6-alkyloxyimino, and Cι.6- alkyloxyamino each of which may be optionally substituted with a substituent R5 and wherein at least one of said substituents R4 is R4 selected from the group consisting of Cι.8-alkyl, C3.8-cycloalkyl, Cι.8-alkoxy, Cι.s-alkylcarbonyl, -g-alkylidene, each of which may be optionally substituted with a substituent R5;
R5 is selected from the group consisting of hydrogen, halogen, hydroxy, Cι„g-alkyl, -g- alkoxy, C3.8-cycloalkyl, C3.g-heterocyclyl, -g-alkylcarbonyl, -g-alkylidene, C2.8-alkenyl and C -s- alkynyl;
Rxmay be absent or selected from the group consisting of hydrogen, optionally substituted Ci-g-alkyl, optionally substituted C3.g-cycloalkyl, optionally substituted C2.s-alkenyl, optionally substituted C2.s-alkynyl, CH2-N(R5)(R5), CH2-OR5, CH2-SR5, CH2-0-C(=0)R5, CH2-0-C(=S)R5; R3 may be present 0-4 times and selected from the group consisting of halogen, hydroxy, optionally substituted Cι„g-alkyl, Cι.g-alkoxy, optionally substituted Cι.8-alkylidene, optionally substituted C2.g-alkenyl, optionally substituted C2_8-alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3.g-cycloalkyl, optionally substituted C .8- heterocyclyl, and optionally substituted Cι.8-alkylcarbonyl; each R6 and each R7 is optionally and independently selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted -g-alkyl, -g-alkoxy, optionally substituted Ci-s-alkylidene, optionally substituted C2.8-alkenyl, optionally substituted C2.8-alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3_8-cycloalkyl, optionally substituted C .g-heterocyclyl, and optionally substituted -s-alkylcarbonyl.
2. The compound of claim 1, wherein Z is N.
3. The compound of claim 2, wherein X is selected from the group consisting of N, S, and O.
4. The compound of claim 3, wherein -Y is =0.
5. The compound of claim 1, wherein N(R*)R2 is selected from the group consisting of a piperidine with at least one substituent R4 in the 2-position, a piperidine with at least one substituent R4 in the 3 -position, a piperidine with at least one substituent R4 in the 4-position.
6. The compound of claim 5, wherein N(R*)R2 is selected from the group consisting of a piperidine with at least one substituent R4 in the 4-position.
7. The compound of any one of claims 1 -6, wherein N(R!)R2 is
wherein R4 is selected from the group consisting of hydrogen, halogen, Cι.g-alkyl, C3.8- cycloalkyl, Cι_g-alkoxy, Cι_8-alkylcarbonyl, Cj-s-alkylidene, C2.8-alkenyl, and C2_8-alkynyl each of which may be optionally substituted with a substituent R5 and wherein R4 is selected from the group consisting of Cι.8-alkyl, Cι_g-alkoxy, C3.8- cycloalkyl, Cι_8-alkylidene, C2-8-alkenyl, and C2.s-alkynyl each of which may be optionally substituted with a substituent R5; and
R5 is selected from the group consisting of hydrogen, halogen, hydroxy, Cι.8-alkyl, C3.8- cycloalkyl, Cι_8-alkylidene, C2.s-alkenyl and C2.8-alkynyl.
8. The compound of claim 7, wherein R4 is hydrogen.
9. The compound of any one of claims 1-8, wherein R4 is selected from the group consisting of C^-alkyl, Cι.8-alkoxy, C3.8-cycloalkyl, Cι_8-alkylidene, each of which may be optionally substituted with a substituent R5.
10. The compound of any one of claims 1-9, wherein R4 is selected from the group consisting of C3.8-alkyl, C3.8-alkoxy, and C3.8-alkylidene, each of which may be optionally substituted with a substituent R5 wherein R5 is selected from the group consisting of hydrogen, halogen, hydroxy and Cι.s-alkyl.
11. The compound of any one of claims 1-10, wherein R4 is selected from the group consisting of an optionally substituted butyl, an optionally substituted pentyl, an optionally substituted propyloxy, and 3-(Cι.8-alkyl)-butylidene.
12. The compound of any one of claims 1-11 for use in the treatment or prevention of a mental disease or disorder in a human.
13. The compound of any one of claims 1-11 for use in the treatment or prevention of a disease or disorder associated with increased intraocular pressure in a human.
14. The compound of Claim 1, wherein
X is selected from the group consisting of O, N and S;
Z is N;
Y is =0 or tautomers thereof;
SPU is a spacer unit providing a distance d between Z and N wherein -SPU- is -(CR6R7)n- A-, n is 3, and A is absent;
N together with R1 and R2 form a piperidine ring substituted with one or more substituents R4 selected from the group consisting of hydroxy, halogen, Ci-s-alkyl, C3.8-cycloalkyl, Cι.s-alkoxy, Cι.8-alkylcarbonyl, Ci-s-alkylidene, C2.s-alkenyl, C2.s-alkynyl, Cμ6-alkyloxyimino, and C^- alkyloxyamino each of which may be optionally substituted with a substituent R5 and wherein at least one of said substituents R4 is R4 selected from the group consisting of Cι.8-alkyl, C3.8-cycloalkyl, Cμ8-alkoxy, Cι.8-alkylidenec, each of which may be optionally substituted with a substituent R5;
R5 is selected from the group consisting of hydrogen, halogen, hydroxy, Cι.8-alkyl, Cι.8- alkoxy, C3-s-cycloalkyl, C3.8-heterocyclyl, Cι.8-alkylcarbonyl, Cι_8-alkylidene, C .8-alkenyl and C2.8- alkynyl;
Rx may be absent or selected from the group consisting of hydrogen, optionally substituted Cι.8-alkyl
R3 may be present 0-4 times and selected from the group consisting of halogen, hydroxy, optionally substituted Cι.8-alkyl, Cι.8-alkoxy, optionally substituted Cι.8-alkylidene, optionally substituted C2.8-alkenyl, optionally substituted C2.8-alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3.8-cycloalkyl, optionally substituted C3.8- heterocyclyl, and optionally substituted Cι.8-alkylcarbonyl; and each R6 and each R7 is optionally and independently selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted Cι-8-alkyl, C3.8-cycloalkyl.
15. A pharmaceutical composition comprising a compound according to claim 1, together with pharmaceutically acceptable carriers or excipients.
16. A method of increasing an activity of a cholinergic receptor comprising contacting the cholinergic receptor or a system containing the cholinergic receptor with an effective amount of at least one compound of Formula I
or a pharmaceutically acceptable salt or prodrug thereof, wherein
X is selected from the group consisting of C, O, N and S
Z is selected from the group consisting of CH andN
Y is selected from the group consisting of =0, =N and =S or tautomers thereof, such as Y- alkylated tautomers;
SPU is a spacer unit providing a distance d between Z and N wherein
-SPU- is a biradical selected from the group consisting of -(CR6R7)n-A- and -C3.8- cycloalkyl- wherein n is in the range 1 to 5, such as 1, 2, 3, 4, or 5 and A is absent or an optionally substituted -C3.8-cycloalkyl;
N together with R1 and R2 form a heterocyclic ring wherein said heterocyclic ring is selected from the group consisting of perhydroazocine, perhydroazepine, piperidine, pyrrolidine, azetidine, aziridine and 8-azabicyclo[3.2.1]octane and wherein the heterocyclic ring is substituted with one or more substituents R4 selected from the group consisting of hydroxy, halogen, -s-alkyl, C3.8-cycloalkyl, Cι_8- alkoxy, Cι.8-alkylcarbonyl, Cι.8-alkylidene, C2.8-alkenyl, C2-8-alkynyl, Cι.6-alkyloxyimino, and Cι-6-alkyloxyamino each of which may be optionally substituted with a substituent R5 and wherein at least one of said substituents R4 is R4 selected from the group consisting of -s-alkyl, C3.g-cycloalkyl, C^-alkoxy, Cι.8-alkylcarbonyl, Cι.8-alkylidenec
Cι-8-alkyloxyimino, and Cι-8-alkyloxyamino each of which may be optionally substituted with a substituent R5;
R is selected from the group consisting of hydrogen, halogen, hydroxy, Cι.8-alkyl, Cι_8- alkoxy, C3_8-cycloalkyl, C3.8-heterocyclyl, Cι.8-alkylcarbonyl, Cι.8-alkylidene, C2.8-alkenyl and C2.8- alkynyl;
R may be absent or selected from the group consisting of hydrogen, optionally substituted -s-alkyl, optionally substituted C3.8-cycloalkyl, optionally substituted C2.8-alkenyl, optionally substituted C2.8-alkynyl, optionally substituted aryl, optionally substituted heteroaryl CH2- N(R5)(R5), CH2-OR5, CH2-SR5, CH2-0-C(=0)R5, CH2-0-C(=S)R5; R3 may be present 0-4 times and selected from the group consisting of halogen, hydroxy, optionally substituted Cι.8-alkyl, Cι.s-alkoxy, optionally substituted Cι.8-alkylidene, optionally substituted C2.8-alkenyl, optionally substituted C2.8-alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3.8-cycloalkyl, optionally substituted C3.g- heterocyclyl, and optionally substituted Cι_8-alkylcarbonyl; each R6 and each R7 is optionally and independently selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted Cι_8-alkyl, Cι.8-alkoxy, optionally substituted Cμ8-alkylidene, optionally substituted C2-8-alkenyl, optionally substituted C2.8-alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3.s-cycloalkyl, optionally substituted C3.8-heterocyclyl, and optionally substituted Cι.8-alkylcarbonyl.
17. The method of claim 16, wherein the compound is a cholinergic agonist.
18. The method of claim 17, wherein the compound is selective for the one or both of the Mi and M4 receptor subtypes.
19. The method of any one of claims 16-18, wherein the compound further acts as a D2 antagonist or D2 inverse agonist.
20. A method of treating or preventing a mental disorder in a mammal, such as a human, comprising the administration of an effective amount of a compound of any of claims 1-11.
21. The method of claim 20, wherein the mental disorder is selected from the group consisting of cognitive impairment, forgetfulness, confusion, memory loss, attentional deficits, deficits in visual perception, depression, sleep disorders, and psychosis.
22. A method of treating or preventing pain in a mammal, such as a human, comprising the administration of an effective amount of a compound of any of claims 1-11.
23. A method of treating or preventing increased intraocular pressure in a mammal, such as a human, comprising the administration of an effective amount of a compound of any of claims 1-11.
24. The method of claim 20, wherein the mental disorder is selected from the group consisting of neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Down Syndrome, Pick disease, dementia, clinical depression, age-related cognitive decline, attention-deficit disorder, and sudden infant death syndrome.
25. Use of a compound according to any one of claims 1-11, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the preparation of a medicament for the prophylactic or curative treatment of psychosis or alleviation of symptoms of psychosis.
26. A use according to claim 25, wherein the medicament acts, at least in part, as an Mi agonist or as Mi and t agonist.
27. A use according to claim 26, wherein the anti-psychotic further acts as a D2 antagonist.
28. A use according to claim 26, wherein the medicament is selective for the Mi or Mj, or both the Mi and Mt muscarinic receptor subtypes.
29. A method of modulating or preventing the progression or formation of amyloid plaques in an individual susceptible to or affected by Alzheimer's Disease by administering an effective amount of a compound of Formula I, said effective amount sufficient to modulate amyloid precursor protein processing.
EP02763824A 2001-10-02 2002-09-30 Benzimidazolidinone derivatives as muscarinic agents Expired - Lifetime EP1432420B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32675401P 2001-10-02 2001-10-02
US326754P 2001-10-02
PCT/US2002/031308 WO2003028650A2 (en) 2001-10-02 2002-09-30 Benzimidazolidinone derivatives as muscarinic agents

Publications (3)

Publication Number Publication Date
EP1432420A2 true EP1432420A2 (en) 2004-06-30
EP1432420A4 EP1432420A4 (en) 2005-11-09
EP1432420B1 EP1432420B1 (en) 2011-07-13

Family

ID=23273560

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02763824A Expired - Lifetime EP1432420B1 (en) 2001-10-02 2002-09-30 Benzimidazolidinone derivatives as muscarinic agents

Country Status (17)

Country Link
US (6) US7087593B2 (en)
EP (1) EP1432420B1 (en)
JP (1) JP4347047B2 (en)
KR (2) KR100809569B1 (en)
CN (1) CN1561212A (en)
AR (1) AR036716A1 (en)
AT (1) ATE516030T1 (en)
AU (1) AU2002327810B2 (en)
BR (1) BR0213611A (en)
CA (1) CA2457647A1 (en)
MX (1) MXPA04003103A (en)
NO (1) NO20041317L (en)
NZ (1) NZ531550A (en)
RU (1) RU2288919C2 (en)
TW (1) TWI310034B (en)
WO (1) WO2003028650A2 (en)
ZA (1) ZA200402609B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2288919C2 (en) 2001-10-02 2006-12-10 Акадиа Фармасьютикалз, Инк. Derivatives of benzimidazolidinone as agents for muscarinic receptors
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
DE60322212D1 (en) 2002-05-07 2008-08-28 Neurosearch As NEW AZACYCLIC ETHINYL DERIVATIVES
JP2006521399A (en) * 2003-03-28 2006-09-21 アカディア ファーマシューティカルズ，インコーポレーテッド Muscarinic M1 receptor agonist for pain management
US7157471B2 (en) * 2003-08-25 2007-01-02 Boehringer Ingelheim International Gmbh Haloalkyl- and piperidine-substituted benzimidazole-derivatives
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007036715A2 (en) * 2005-09-30 2007-04-05 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
EP1960389B1 (en) * 2005-09-30 2012-08-15 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
EP1937670A1 (en) * 2005-09-30 2008-07-02 Glaxo Group Limited Benzimidazolones which have activity at m1 receptor
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
CA2634999A1 (en) * 2005-12-27 2007-07-05 University Of Toledo Muscarinic agonists and methods of use thereof
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
GB0607949D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
TW200813018A (en) * 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AR063275A1 (en) * 2006-10-12 2009-01-14 Epix Delaware Inc CARBOXAMIDE COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES MEDIATED BY THE ACTIVATION OF CCR2.
EP2194983A1 (en) * 2007-09-20 2010-06-16 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
JP2010539217A (en) * 2007-09-20 2010-12-16 グラクソ グループ リミテッド Compounds having activity at the M1 receptor and their use as medicaments
GB0718415D0 (en) * 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
AU2008335135A1 (en) 2007-12-11 2009-06-18 Cytopathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
US20110294835A1 (en) 2008-05-15 2011-12-01 The Board Of Trustees Of The University Of Illinois Muscarinic Agonists as Cognitive Enhancers
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
TW201105667A (en) * 2009-05-08 2011-02-16 Cytopathfinder Inc Dihydronaphthyridinyl and related compounds for use in treating ophthalmological disorders
MX337662B (en) 2010-10-06 2016-03-14 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors.
WO2012149524A1 (en) 2011-04-29 2012-11-01 The University Of Toledo Muscarinic agonists as enhancers of working memory and cognitive flexibility
JP6393524B2 (en) * 2014-06-05 2018-09-19 ロート製薬株式会社 Moisturizer
WO2016022644A1 (en) * 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
HUE055763T2 (en) 2015-07-20 2021-12-28 Acadia Pharm Inc Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US20190117636A1 (en) * 2016-03-29 2019-04-25 Acadia Pharmaceuticals Inc. 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
US11464768B2 (en) 2016-12-20 2022-10-11 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US20230183214A1 (en) * 2020-05-06 2023-06-15 Merck Sharp & Dohme Llc Il4i1 inhibitors and methods of use
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024662A1 (en) * 2000-09-19 2002-03-28 Boehringer Ingelheim Pharma Gmbh & Ko. Kg New benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH407121A (en) 1962-03-30 1966-02-15 Geigy Ag J R Process for the preparation of new piperidine derivatives
US4371388A (en) * 1980-01-25 1983-02-01 Monsanto Company 3-Substituted aminoalkyl-2-benzothiazolinones as plant growth regulants
US4254127A (en) * 1980-04-03 1981-03-03 Janssen Pharmaceutica, N.V. 1,3-Dihydro-1-[(1-piperidinyl)alkyl]-2H-benzimidazol-2-one derivatives
US4943580A (en) * 1987-03-09 1990-07-24 Janssen Pharmaceutica N.V. Anti-histaminic benzimidazole, imidazopyridine and purine derivatives
US4861889A (en) * 1988-03-14 1989-08-29 Hoechst-Roussel Pharmaceuticals, Inc. 3-(2,3,4,5,6-pentafluorophenoxy)-8-azabicyclo[3.2.1]octanes
US5707798A (en) 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors
JP3916092B2 (en) 1993-09-17 2007-05-16 杏林製薬株式会社 Imidazolidinone derivatives and their acid addition salts and therapeutic agents for senile dementia
JP3916093B2 (en) 1993-09-17 2007-05-16 杏林製薬株式会社 Optically active imidazolidinone derivative and method for producing the same
EP0786997A4 (en) * 1994-10-27 1998-03-11 Merck & Co Inc Muscarine antagonists
JP3884477B2 (en) * 1995-03-22 2007-02-21 大正製薬株式会社 Thiazole derivative
AU7528696A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine antagonists
AU7478396A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine agonists
US5756508A (en) 1995-10-31 1998-05-26 Merck & Co., Inc. Muscarine antagonists
WO1997016187A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
US5718912A (en) 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
WO1999032481A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
US6569956B1 (en) 1999-12-22 2003-05-27 Basf Corporation Hyperbranched polyol macromolecule, method of making same, and coating composition including same
KR100879647B1 (en) 2000-03-06 2009-01-20 아카디아 파마슈티칼스 인코포레이티드 Azacyclic compounds for use in the treatment of serotonin related diseases
KR20030005306A (en) 2000-04-28 2003-01-17 아카디아 파마슈티칼스 인코포레이티드 Muscarinic agonists
US6586435B2 (en) * 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
RU2288919C2 (en) * 2001-10-02 2006-12-10 Акадиа Фармасьютикалз, Инк. Derivatives of benzimidazolidinone as agents for muscarinic receptors
US6951849B2 (en) * 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024662A1 (en) * 2000-09-19 2002-03-28 Boehringer Ingelheim Pharma Gmbh & Ko. Kg New benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
H. ITANI ET AL.: "novel potent antagonists of human neuropeptide Y Y5 receptors." BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, no. 5, 2002, pages 799-802, XP002344642 us *
RAJENDRA S. VARMA: "synthesis a. antibacterial activity of certain 3-substituted benzoxazolinones." JOURNAL OF PHARMACEUTICAL SCIENCES., vol. 57, no. 1, 1968, pages 39-44, XP002344641 USAMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON. *
See also references of WO03028650A2 *

Also Published As

Publication number Publication date
ZA200402609B (en) 2005-05-09
EP1432420B1 (en) 2011-07-13
ATE516030T1 (en) 2011-07-15
BR0213611A (en) 2005-12-20
NZ531550A (en) 2006-12-22
US20080070948A1 (en) 2008-03-20
US20060205785A1 (en) 2006-09-14
WO2003028650A3 (en) 2003-06-19
NO20041317L (en) 2004-06-29
US20100216840A1 (en) 2010-08-26
WO2003028650A2 (en) 2003-04-10
US20030100545A1 (en) 2003-05-29
US7273857B2 (en) 2007-09-25
KR20040047877A (en) 2004-06-05
US20060258707A1 (en) 2006-11-16
TWI310034B (en) 2009-05-21
RU2004113451A (en) 2005-09-10
US7087593B2 (en) 2006-08-08
AU2002327810B2 (en) 2006-11-02
CA2457647A1 (en) 2003-04-10
CN1561212A (en) 2005-01-05
MXPA04003103A (en) 2004-07-27
JP4347047B2 (en) 2009-10-21
RU2288919C2 (en) 2006-12-10
US20080009520A1 (en) 2008-01-10
JP2005510473A (en) 2005-04-21
AR036716A1 (en) 2004-09-29
EP1432420A4 (en) 2005-11-09
KR20060130271A (en) 2006-12-18
KR100809569B1 (en) 2008-03-04

Similar Documents

Publication Publication Date Title
US7273857B2 (en) Benzimidazolidinone derivatives as muscarinic agents
US7291611B2 (en) Benzimidazolidinone derivatives as muscarinic agents
AU2002327810A1 (en) Benzimidazolidinone derivatives as muscarinic agents
WO2004089942A2 (en) Benzimidazolidinone derivatives as muscarinic agents
US7576078B2 (en) Tetrahydroquinoline analogues as muscarinic agonists
US8680115B2 (en) Tetrahydroquinoline analogues as muscarinic agonists
JP2010519193A (en) Heterocyclic derivatives as M3 muscarinic receptors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040415

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 25/00 B

Ipc: 7C 07D 413/06 B

Ipc: 7A 61K 31/444 A

Ipc: 7C 07D 401/00 B

Ipc: 7A 61K 31/445 B

Ipc: 7C 07D 417/06 B

A4 Supplementary search report drawn up and despatched

Effective date: 20050922

17Q First examination report despatched

Effective date: 20070604

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TOLF, BO-RAGNAR

Inventor name: KELLY, NICHOLAS MICHAEL

Inventor name: KOCH, KRISTIAN NORUP

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60240515

Country of ref document: DE

Effective date: 20110901

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20110713

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20111005

Year of fee payment: 10

Ref country code: GB

Payment date: 20110926

Year of fee payment: 10

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 516030

Country of ref document: AT

Kind code of ref document: T

Effective date: 20110713

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110713

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110713

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111114

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110713

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110713

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111014

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110713

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110713

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110713

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110713

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110713

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110713

26N No opposition filed

Effective date: 20120416

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110713

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60240515

Country of ref document: DE

Effective date: 20120416

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111024

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20120930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111013

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20130531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130403

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120930

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60240515

Country of ref document: DE

Effective date: 20130403

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110713